var title_f35_31_36336="Gallbladder adenomyomatosis US";
var content_f35_31_36336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gallbladder adenomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of localized adenomyomatosis in the gallbladder fundus (arrow) producing a polypoid appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36336=[""].join("\n");
var outline_f35_31_36336=null;
var title_f35_31_36337="Hemochromatosis of liver CT";
var content_f35_31_36337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis of the liver as evaluated by CT scanning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 291px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEjAWoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzv4j+OfFlp8Q/FFtaeKNdgt4dUuo4ootQlVEUSsAqgNgADjArnP8AhYPjP/obvEP/AIMpv/iqPij/AMlM8Xf9he7/APRz1zNMDpv+Fg+M/wDobvEP/gym/wDiqP8AhYPjP/obvEP/AIMpv/iq5migDpv+Fg+M/wDobvEP/gym/wDiqP8AhYPjP/obvEP/AIMpv/iq5migDpv+Fg+M/wDobvEP/gym/wDiqP8AhYPjP/obvEP/AIMpv/iq5oA46UhNAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFUf8LB8Z/wDQ3eIf/BlN/wDFVzNFAHTf8LB8Z/8AQ3eIf/BlN/8AFV+iFfmTX6bUgPzw+KPHxM8Xf9he7/8ARz1zFdP8Uefib4t/7C93/wCjnrmKYBRRRQAUUUUAFFGDjpRQAUUUUAFFGPzpSCCQQQR2NACUV6l4K+EOqeIdOF5LHLCjYKqxCkjjqD0rR174Mvpdn58t46nBLLtBEfTkn05oA8coq/NpcyXUkELxTlVLbo2yCBnj68dKY2lX4jMn2Ocxg43BCRmgCnRVptPvVco1pcBwMkGNs/yoj069kZ1js7l2QZYLExK/XjigCrRWgmiao7xoNPug0n3N0ZXP51p2ngjxFdqGg012UnbneowcZ559KAOcortLf4eamFmbUZ7ayEOS4dskAEjPHXpSDwrpKWu+XXIjKDh1OEC8nuTyeOlAHGUV0WqWnhq1bbaX19dMCMlUUDp6mqmleHtU124ddB0y+vEDEKUiLY9iRxmgDK+Xy+p356Y4x9aQYyMnHrxXUXnhOTS7Nm18X+k3QztW4sn8t+OAHHc1zLoFVCHVtwzgdR9aAG4HZhQy7TjIP0pZI3ibbIrK3oRim0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+m1fmTX6bUMD88Pij/wAlM8W/9he7/wDRz1zFdN8Uf+SmeLv+wvd/+jnrmaACiiigAooooAM0UUUAFaWi6VJqk4VS0cK8vLsLfgAOregFU7S2mu51ht42eRuwGcD1Pt719M/sy+EtP1G1uNZltmkitJlS2Lr8plUfNIPfnH0oAk8BfBe0jsGuL61VzMoMZmGSo/vN6HPYdK84+OmnaJ4Y1K203Roov7R/1txL95x6c+p619B/HP4jR+BPDzR2bxtrd2NttGwztHdyPQfz4r4p1C8udRv57y9mee5ncvJI55Zj1NAHb6N8WPEWjWMUFhLH5i/fklG/d6DHQVR8S+PPFXiey8nWdSle1DEBFxGvIztIA5GOxrlFhJDBSu/HQ8E+oHvV6w0+71eUR21tczTkgAxoWBJPGeOO/PtSAsW+kobyNYblAAA7E/MMZOCMYyOK1LC28RQJENOuo3gVvkKyLt6HGQe2M102kfBrxDdoXugsKAcqHG5STgjHp396ueIPgzfWMP2i1vYZCrnejNt+gB7ZHSmByieJfE1i9yty8JZgQzSFflGMcYP0NX/C/i57YTxX3m3tzOxQi3JYyA9yAOcADFbnw++Ez6+UmvpTFYRsjiUJy45yoB61774W8I6NoQhNjawpKMBpioJYDjrjuOKBHjFs/i7Xnjk0vwzdrGABvumES7cYHXkev4Vs2/wy8e6qgN/r1hpeH3iO3BcgEeo/lmvdULEKGK7Sx4/u47fSnoGJ8sqFbjbuB6d80AeND4Ei5AbVPFGqT5BVWRFAOR3znvkVpWf7O3hKJVFzd6lcuPvt5ir+eBXrCOQz8MoLDgjnvnHt3qyJdybuu8Y4HJPcfSgZ57pfwQ8CabKr/wBkvdEqP+PqZnX8s4r0CwsINMjit9Ot4Le3UcRxgKqYHoO9WxuZl5AYn5lB7U25JZQE+bLgAcCkBQvEgvYJILuGO4gZTlZUyCO/B7Gvk346fDeDwzeLqegRt/Zcp/exgE+S/Xj/AGefwr6umuo7hiiDdIoOUUcY7AmuB+NlsP8AhXOrGRcSGE8Z2k46ce57e1MR8aLK6sWDHJG3J54pgoooGBwTwMD0oGCeTgetFFACkcdaSitXT9YFqipPp1hdxggnzYvmI9NwoAyqsWFpNf3cVtbJvlkYKorrBeeDdQiC3FjeWE55MkTZUewH19R0FQPBo+jahb3mla28skLBgRFyDn9R/nvQB0ll8D/Ft5AssK2eCpbDSkdO3SuH8TeGNZ8M3jW2tWE1swPDMp2N7huhr23T/inaNYmay1OOzu412JHPnY567iPrmsy9+N6a9aXmleJNLt7myl+VZFBJbngnPQfSgDwyit2bRxftcz6MpeKNuI85Zx1JX6ccVhlSpKsCpHBBHNACUUUUAFFFFABRRRQAV+m1fmTX6bUMD88Pij/yUzxb/wBhe7/9HPXMV03xR/5KZ4u/7C93/wCjnrmaACiiigAooooAKKK3PCempd3j3d3j7DZDzpsnG/HIUepOOnpmgBu99G0wKgKX94u4v0McXYD3br9Metdt8JPinr/gnTtQ03SobW4tpz54N0W2wNjBbg9Dgce1efTu2o6hLcXLmON3y74JEY/ugew4A9quYl1OWLTNGtrg2ruDHEBueR8Y3t+f0FAB4q8Raj4n1WbUNWunurqVstK/AA7BR0VfYVf8IeENX8Q3KR6bZGdTyXLbUweMFux9K9i8AfBe2toLe88UAzXIG/7IrBo8c9SOv0r1/T9Ogs7ZrWyghS32kRxKu3j6e1AjyPwl8DbO2Kvrt8bt1fBt0XERPbJ6ivVNF0yy04JbafbQ2z4MYKJgNg9D69zWjar8z+XIxbcM57gfXimTEG5wqs4PJCnH0yOx96AJrOE7P9HIeTbhxnnPJBHr9K8s+MGvS2MUUUO1WmBVOcFnBGE9j6GvU4MkLLcyEqcjeAQY+2D9D3r5x+KF55/xUsLSYNJBCQ8gYZDZHXH0oA9+8IQCx8OafEGQpHErICME5HNbOG3EYXAyzAYA9sf4VRiia20+FYyvkiIMMEMCMdFIqxYs81sjlQrBtoyOOmeKALFud8B37QXzHuI+7nk7hRFcMLoLKD2Ur+Hr3FNjhaNcq6qpOSWP3QR39u1UfP33ssMZEkoXfs6EjGcD+VAG9HKQ4KgDKFjn1xwRn3pFvCLpI/lMpOSo75HUelZwckCRDyEDLuJIOev41zerWuo3l9FMkk0cSggvEBuHX5jn8P8A9VAHosMwDFViblsH/P41Q1LUfs8gSPImdtoAHT0JrlfDVv4ikuPO1C5/0c/Kmw7mAx94nvnpXURWcVqiFRngkbhuOD9Ov40AR6dAkMCsQEkZTIzEZJOcf5xXmP7Rk11eeE2tNN3KW+aVnYKPLXruJ4Ge1ej69rllotlJdXkggjQE5c4G0D0r5e+PPxKi8VNbaVoswk0yMCSaUDmaTsM+g/n9KAPL4rCzE6R3epxRg/eaONpAv5da6y003wHb6JPd3ur393dBtsVvBHsduOpBGAPck1wNFAyWdoGuXaGN0gJ+VC+WA+uP6VLYWM9+7x2iiSUDKxA/O/8AujufaqtKjMjq6MVZTkEHBBoAHVkdkdSrqcEEYIPpSVrXutPqOnR21/BDJPEcpeBcTEc/K5/iHuefrWT0oAKB1oooAVjkkgYpKB155pTtIGM7u/pQB23wguoIfGVlBc79s8qgBcYJ56+1ex/G34VQarp0niDw1GP7RiAN1Egwsy9Mgf3v5181Ws0ltcwzwkiWNg6H3B4r7d+GfiWPxZ4Isr2cBN6mC7j6AMPlOe9Aj4edSjsjghlOCD2NJXqXxv8ABkmg69d3cMYW2MnUDaGRvusvr6HHtXltAwooooAKKKKACv02r8ya/Tahgfnh8Uf+SmeLv+wvd/8Ao565ium+KP8AyUzxd/2F7v8A9HPXM0AFFFFABRRRQBPY2k19eQ2tqheaVgqqPWuz12FLHSo9DtXgjhjUS3c+/wD1so/unvjHT6VV8OQpomg3Gv3KqbmQ+RZI6nqergj054/xrBhW91u7t7SCJp5pJGKIg+Z2Y5P40AWNFtdS1prTSLCAzJJchlRRjc5GMk/Tv2r6j+Gnw7t/B9slw5WXU5k2tMV3Kg/uAEZx6mm/Cr4c2fhGxF9IJDrE6Yd2A/dKf4R2z6nua9DOJI8OS69ckcqe/wD9egRFFtjUqYvunDBTxj2HWo5Z4EuBCJiSRlGY/Mn19qsSor5UMMtgseO/XPvWcNLi+1yvLvleTH7wHIDdMj0oARpgHxIwDAbFRepP06EdeKbIGsDFM4Y4OHKc4B6e5ANJbQpJqTktjyTgL0J45IrVYBiyygOA2Acc+oOP89KAALtHlvIMPkrLGMqSPUf5zXyl4sna7+NDiYGIxT7CFwMYBxj07cV9YOgSTyUUKGXcEBABHYn/ABFfKXxQ006F8XpJruKb7NcSLOpYZZgRg4I6kGgD6l0mQiztZUwhQAFVQ9D2x2z/AErQGHd4zCFfP7wPxnqQR2x/hWJ4XvYLrRIbiKXh41dzu6L3zjqcVzmofEjT7XVZLKzSS5MUjBpCOhA7jqcY6emDQB22ovHHpzKZG2Ljknvzx9Oc/SuO8L+H9Rj1KTWJrnyrYhozC7DcNx6kjjHUD0rR8J6rJ4ik+0sI3tFcAK2dp+Yev+cit3xNYS6ho88FowSRnDbCcFgG6ZHcds0ALZxo0IZ5WYFiQM4G7vkenFSZ/fERcNjjjop6MAeuOaxfAGg6jpsF19vdpIyQAjuMnqcnHf612E9uLgguVOCGVgMH6euM0AZ0UiW8h3L827CYJIYjsPQcfzqTUNds9N0+S6lcZBw2T0z/AEqHV7ZLGymv5Z0tVgBkkYnhR1PNfJ/jvx1q2uG9iuoJ7bT7iMpaQ4ZflB5bcfve/wCAoA1/j14/h1ryNN0i886JsvdlGyoIOFjB79MnHtXiZqy0TdCDge1R+S2elAyKipDEwHSmlGHY0ANopSCO1JQAU9sNGGz8wOMY7UylABzk44oASiiigAopyI0jBY1ZmPYDJq9HoupyQ+aljOY+uSuM96AKIIC8Z3ZyDXuX7MXiCSz8T3GiXs/+iarE0yHIz5qnHU9yAfyFeHSxSQvsmjeN/wC6wINdJ4L1AQappwVVS5tbgTQyDIPByRkdScflQB9OfHbQIrnQrK/8szNExs5TzzE/A5PQBsc18g3du9pdTW8uPMico2DkZBxX1P8AEf4i6Prnw11SEXaGWSLyjGzciXqBj1r5x8YhX1KG7SMRrdwJLtAwAcY4/IUAYNFFFABRRRQAV+m1fmTX6bUMD87/AIo/8lM8Xf8AYXu//Rz1zNdN8Uf+SmeLv+wvd/8Ao565mgAooooAKuaPZi/1GGB3WOInMkjdEQdSfwqnXrv7PvhZtZ8e2EEqSiKNPtl1jp5SkFUb2ZtuR3H40AQeKPB+tXOp2MV9Z/2fZtaF7W2J2nYvG7BHU9cE5+legfAn4fx6VajXdTH+nSgG2RlyUQ5+bHYn9K908faLDqsdg8y58uUqw2g7kKkkevUDpVALjCRLnAAXHIGOmaBCEzBjgOV5HAA470wtliACCWG75sc/hVedJ4GG6OR1ZtrBSfl98VYtXN2w8pssBt2kAtj3H9aALOzzPKCxMpOOc8H146GoixaAkgrJtbPZcjPTufaoYkkXCqQN+TtJAGOOnvnNWmR2CtESsmQpQcZ45IP9KAPP9A1i9n8Y3pmDSWbdNygeUwGOR3zz+VegJlIYyiqGbkLg/K3UEHrjtg1UtdJsre5knHyvIS0kjICGPYn/AB/Cp47iOOOZYijPGg+WMHbjnnOf0oAe8CO0ZgBDj5ZEJ5H+7689q8d/aO0V5dHg1lYWxZSqMqPmUHue4BI5969RbVJ7YsJ4JxGjYEiDcpBOQT/j0rmvipcj/hCb61MU7yXMJSN0G7AHOM4PX3zQBh+CNYNx4JLh1iKwmMl8kYIG04HUD8+Kwo/DWq6hqCpBBJKJFYxznCkrnq3qf6YqT4Jab5zXM9woEcQxE6gjcvXgdCAR0r3GFIfJMsCRkIoBzwcHofbjH8qAOf8AAug3Phy0iilZZEc7t5XKqT1C+g4/ya6/c0QkY5UIxJy24c/5zVO6cRxoAMSMSi5OVIPJJx2B7VYijdWXMvmRqAwypLAcjBI6/wBKAGXGHLFGEcZ+8U5Unrx6HjvUTTz4VhKgkcAKqry3PBz2B71KvKrJcSL5zHBBAGT6H2HrXK/EXUl0vwnf3plDCKL+BwBgjhR+Jz+FAHhvxw8dXt5q0ugWt062lrMWl2MNkrcYwf7vt61618I/Amm698N418RtJqUF3GpSOUbWtW6kxsOQc9we2K+Rru5e8uJJp23PJ1NfaH7OesDVPA20t89vL5ZHQAbRjA+lAzDvf2c9CluC9rrWpwxdkZY5CPx2g0tv+zl4eVgZ9Y1WRe4URLn/AMcNe4UUgPG7n9nnwjJbslvc6vDLjiQzq/5grj+VZyfs2+Hwv7zWtVZsjkCIDHpjb+te60UAeLD9nHwbk5u9aIP/AE3jH/tOqN7+zP4XlObbVtYh9maJ/wD2QV7vRQB4dZ/s0+D4sG6vtYuSDyDKiA/kn9a5v41/Cfwf4b8FK2i2b2t8JQwmaVnJUA53bj06V9K147+01bJN4LSRm2um8AlgoHHJPt9OaAPisAsQFBJPQCvQvCHglZkguNUjLvNhood3GMcbgOax/hhBb3PjOxiukLq27aAcfNtOPavoS5s4VhYRmSSRh8zR4VlAOQowPlHT3pgcIujaba4MUcWAhyVULu7Y2jHXpjnvWn9gUybpGIuTkohOBGCOv/1vpXQTW6osjsttFI4CIpQnYnOQq8Hk57571WmsokaT/V/MBl2HLH8eO3fimI5PUvDmjaqrJJ85ThpVYkjAwPmry3xFos3h7U8osjW+QYZHwCfqBXvDWxZFjhKqGiyUQgKB3BIHPFZutaFb6rps1tKNqON3my7Y1DY6gdaLAeIXttDLp41KW9iFzcOcWqqSTg8knoPXFT6hDJdeHLG/CALATbMR7ciqWoW76Zc3djPGjuGwGOcjB4I+orU0GWKbw9q2muHa4YedGuCQCuM4x34xSGc3V3RdKvtb1S307SbWS6vbhtkUMYyWP9B3JPAAyadoOj6hr+rW+m6PayXd9O22OKMcn1PsB1JPAr6DkudD/Z/8PNbW/kap8Q7+H95JjdHaKeg9QvfHVyMnAxgA8Y+I3gfUPAWswaZq09pNcS26XB+zybtmeqsOoIIP1HIrlKt6tqN5q+pXOoancyXN7cOZJZpDlmY/56dqqUAFfptX5k1+m1DA/O/4o/8AJTPF3/YXu/8A0c9czXTfFH/kpni7/sL3f/o565mgAooooA0/DemnVdZt7baWjLbpOcYQdfpX2j+z9o0Fr4NbV0WNrjVJWImHLGFGKIM+nDH/AIFXyv4N0qePwtquqQ7ftEy/Z7ccZPPPX/PFem/BDxjr8FvY+GXupBazAi2BQBoolJMhDY6HOAetAH0FrV79tuHSEFooSVBUj5j/ABHHfpis0BzlkSUFeoVcseMgGlZPKZSOVH3lGCAP0x+FAZfN3xbcqOQOn496BCEtg7EIDqOTyCe4I61EbeK4SQKY45AeHOVI45IIqVnjEpwqhmGflPJI54HWsu3Yxa5LHPEw84Ao2wkDHX/PNAGoFKxmM5dEXOWXIJ9z9eafEiRKjxKzAsQQHOUPY9elR3lxtQNtfOfmRc569h2NWLSYMUeIlVYbpCBlT6ggd/egCQsYgQVwgXGVYHcB7Hr9aVhbxeaN0YR1yzqApB4wCe59/eno4wGKYiD87mztJ79ORimOuZBuVPLcZ56L34HbPPWgDN0+5a+ad3t0tk6Isp2qecZUg9OOlWZIXvpDAxXaBmRiQ+R2wOxwTxV35A67UJZzhlyeOvrwKf5KpJGRCkIHDOuDz23dOM0AcXpWjweF9YaGCV4bTUJQVVn483/Z/ugjtjqK661VhMDasPmOBjBYEdyD0HNch8XYEu/A+pMZhJJbgyoqkghlPByPu4ODnPGBWJ8IfHMfiqyjttReNNVtVCSM0m0uwUYcDOSOOR680AepMsb+YskccmQEPy4P1A9OlRRSm2RlYwllYKGx04wATnIJ4FOhuMLtAUuSQxU8v6468d/wqUJ5sSsxic8/McKWTPb+VAEflMpYrG75BIGMlfm5614F+0d4sFvZx+H7ZcSTHzZn7sucjkdMenvXueoahFaW/mSb/MRDHCpYqGcDn6Hp1zXyD8ULfWNd8T3+pyWzbVfySnmKzLtzwADkjv360AcCrfNzX0L+y94rXTr+fS7iSNYbhxjdncMjGfTGe5r5+u7c20hRgwYcFWGCDWl4Y1ebR9Xtb62bEsThgD0I7g0hn6NUVzfw98Sw+K/CljqkCsvmoAysckEcGukoAKKKKACiiigAr55/a01eCPSrLTmnCyEM2wLknPTJ7dK991G9t9OsZ7u9mSG3hQu7u2AAPevgj4seMpPGXiq7vUDJaFz5SliSVHAJoAf8IbJrrxOZgDttozISBnB6Cvf0Luu6aTLSH5TNgAKOVAXqa8K+Csn/ABUU9uJMtNEAkBXKyEHue2Ote2JNdLlrqeBZVJ3oXJAxxwwA9qpCJjKwO4qzvJhVG0HgZyAD3P1xVGS2dy0t75rHaSsZfKLzx8qjrx71bRdzl9hnYdZUTAAz/DkZx/OkjY3EiMrXah1C5ZccZ5I9PqaAKLJGkbl5JVRlG8BcHj8u3alSLLGTaiL1Vd/z892HOP8A69TtcfvP3RLlT5YkzuPX8ufX+dPkhSN/kik35I25AOPUk/yoA8j+L+hMrJqiR4k+7MFYHA7E1z/w103UtS8T2NvpMT3M95vhdU52rjqxwdo4zmvcr/Qp/EtlLo9rC7TToVVRHjJP8TN6D16VX1W70v4CeD30/QBHqPjK+AS7vtuVg4zgZ6Adl7n5m7CkxlfUtR0H4BaFPpmitFqfj2+j/fXJUFbRDyB7AcEL1Y4ZsDAr5z1G+utSv573UJ5Li7ncySyyNuZ2PUk11zab/wAJl4lMzX7RPcQPcSXFxudpWXqMk/Mx44z2rldZsf7N1S5s97P5TbdzRlC3vg0AU6KKKACv02r8ya/Tahgfnf8AFH/kpni7/sL3f/o565mum+KP/JTPF3/YXu//AEc9czQAUDrRWv4RsV1HxJp9s/3GlBbjPA5P8qAPVdP0WKx0axsLuO3+WMOwIb/WnkZwcdTwfaux+BWiMLvWNZuIwFDf2fbiQg7UT7xB7ZauU17xBFZxXU8EcjYlwigbg4XgcYwOa9k+HekJpfg+wgeELMU86bK7G8x/mP6npQI6eeOWIKodQoIIJbLD6YFRzRorkBmUqDkp2pI4doKjcUI3Dy1HH156UIHCspmTheCv8NACbzKPlfeuf4QFbA9+9JGnmbI0RWdCShJx9ec5z+lLcMqxGbk4OSR8h/4DUVrdW00mLefch6qw289gcUASvJ5rmL5BIoJVGByD/WpLeKaGAeUqEo24kqenvgc1KjMziNUwpPBZslfUL6is/VNasdOvo7a8mS3JAC7n757de+OvFAGlA6SyblOyUYK7fUjtT5Q0YZy3zKBt3YI4HII9e3HPSoTmZEEPlCMSbtxwpU9ge/vUN0kr2jqvzOQ2/wCTdn+8c9QeOtAFuGcX9uQ8sLoo+dyM7WBxj8Rjk0yTULWygM15c2sESrgs7BRk9Dk8dhzXyP4s8a6jrHiKSLSLm8snWYxRtHMfnXod2OvIrmdfm1HUbkJeX97e3W8qyzZ2jHcc4oA9n+MPxOsNW0670DwtJLetMCLi4gQBABjoe4+mBXiGnXE+l63DdzSSW00L71eI/MD2xXZeHNFSwiMsgb7W8YTyWIKsp4DAd+/FQXGgx2khujbGOBGWO4hbMgAUjOAeSSOMdu1Az3v4TeMfEWvwmPUNMhubaEhEvzIkICEZClOpOO4/rXqDO6W4yYlAblWG5VAzxnuciuU8CT2B8OQPYJHFaYxEV+YLx93J5I7Z9q34JoRjyUYrGQSoIPuQAc5HPX60COE8f+GNS1QyXcmsXS7B8yJEAqlQeOOvUc9K8D1TVraC6urKFEK2q+czyxqshfHzbFGR39ea+o/FN1/xKLtZGeEGBvMwMFsjt2GSOo718q+I5of7b1M2unWMVo4TCRvlS2OcnH3j3HTP1oA4+/vxqcoa6/dhU2oyLnn39KoFvIV418mTeAd4GSPYHt711OgxWH2W+t78wSKiefHhigG0EHI65yRwfwFcjKoUja25exxigZ6Z8MPiBf8AgPVI2zI9jKoZohzkHHTPH5V9l+FfFGm+JtPhutNmWRZF3ADnj/PrX55W9xJLGtswZlzlMZO0k8nA6/Su0+HfjzUfBGtj7OyyQqx3xsWCsTgZIxngZ44pAfetFeL2Hx90FrCOa8inWVwNiIu7ee5GOR06Hmut0r4peG7+zjuBeCMMQCr8MpPbHU0Ad3Wbr2tWOhadPe6jN5cMSF2wCTgegFcB4++Mnh/wzE8MFzFc37AbI1fgEjq3oK8A1j4xXvix57S/V7eOVRFEY34YZ/jXHJPHHSgDqPir49ufH+jGy0iaWytT8zxSgKZRngd/6V4HrWj3Gkyotw0b+Zna0ZyOD3r0vSJQdLjtl+RRkMrASCPDc/N2BPf2qj4xt21a1jtYHSIghoopmwzHnJBJ6HPFMRj/AAhS4/4SwS25ZQkTBmC5POMAf417PCYyn2WRJZIy+5wrEpkH8O9cr4Q8PPoWjxwl4GuHctO0YJOR0UtnGAR2rqIo3xGJsR7mGXQAFx1IXjjtyDTQFxz9qiYeZtD8sEPCgcBQegx/jTrmFv8AVyzRiJBlVjOWbI9uw9aGFtZ/IlvIFC/KgLN8pPXHufWmiRxE8gt5UbOXcJk468jPHHYUAGYY1EckrR4+fbkLzjjp0/wruNC8EtrHhWO7FwIbuf54Dtwpj425789c+h6VyXhq1fX9dtLHqDJl0KfKkYGWJz1b/wCtXuGqavpfh+zQ31zDawooVE74HACqOT+ApMDgtT1Cy8D2p0nSEM+uToHnmVdzKPXnqeeB+J9/N7X4br4/nvLO4uLi1KMbh53+Y7mzjIPcnP610HxD8VWuvX0Q0+1niZFKGUY3yqe2BwMc9T3rpPgiqINYOcuVhyNo4A3jr3+tAHzFb+HpLW91WxuDBInh0SG9+0wlwq+YEyqAjJ3Edxwe9cTrt2b7VZ5zMswO1UdY9g2KoVQF7YUAd+nU9a+l/ih4OurH4leI9UsbuwtLLUdEkupI7tN8VwyNGHRwegzsbd2J+tfO3jKwNhqsRM9vOLm2iuQbeLy41Drnao9B0z3oGYVFFFABX6bV+ZNfptQwPzv+KP8AyUzxd/2F7v8A9HPXM103xR/5KZ4u/wCwvd/+jnrmaACu4+Eum3V7r81xaBN9vEcZXcQzcDA9etcPXuP7MNt5via1yBte6OfmIPyRlxx9aAJ/CfhzW28YXMGuWE9s3mohR49owAG3AYwQcmvfsRjG5nRgOjDKj8RV7xvCv9saVMyZAimDY6kApj+ZrLz5wVI1ldU5wCMH2ZqBErtG77Zlj359MH2wackmSBHJuHcqu1gPY0iozI5VMAYVtuOB9D1pgfqCwkbqoCAN+XegBbkGa1VImQqTjLYwc8d+4qro+iWVizPbOXLltyunTj149+eaxdB8SDVPGXijRWtGhGji1InWQ5k86IvgoRxjGOprqI2G0MpCLjlmBbJ9enHagAWErI/lIDub8Tkeg6fgafPpNhqA23kSzKTtWRQMj/Z96XzAzhVOckBlYEg8ccg59SOKjhuI3kaMKA4ABJP8Q78jrQBOiFY/Ki3KRlQAAc4rjviP4jj0rQ7xtxkuzEAjJJgAnjg9iScV1ckzQQsC7MFy3OWwOSD9PavnLxpPceLr2WKa5/0YPtihjbaAxB+U557AjJPNAHJWuiQzxJJZ+ZbhTuLSAlpyDkhSueQRnnHTjirklxpcs8MyzLFdJIBuljy7N6kk8nrg49K9r+Gfhezj8NKbyI7XBjdPLLFVGOB29ea0NT+FHhLVpElnspPMIdt8Uu0t7ZHcdOaAPIXgLxP5UkD5By7yBS4xjeM9TkZ49Knhh+0sB/pMkpTyzsfG4YyHwckMvPPOeld5qXwVR4yNC1uewYISBOolA54yx5x7+9dR4G8E/wBhRrLqV6lxduP3jCPbh8dU6np155xQBZ+HPhufQNFijv2aSQjlZOCwBzgDHB5rqHWzCOVjMaoT9442MR90DqARzmon1KKBZJp5ATjZIXbaGUcEoDznr71njxNpsdubi2uYXZl2KqggBhyR6k4HfpzQBzPj+2vZopIRJarHABLskkZsLg5xj73qRnHFfNni+N3v5vtFyxJVdxiAEWB0BIxz0xXpnxX8ebtQtrNJPsboCrMU+YDOMHHVTnIOeOeteX+MrO2WK31K3vobxZj86ovlqzL8pIGee3I9aAOXtmVLsBpGVdwxJ1K8/eroLnQ45LWSXfyASGDjaPQntz7evtXMSKQQSoUMMgA9q9M+G199p0a7hkHNsVLyHB/dk9wewx34GaBnnltBdo0zwl4pYU3nBKtt9R/OoLid7h98mN3c+p7mun8ex2K6/JLaM32djsEeegA+9kdjnODXNy2VxE8qtBL+7GWOwjAPQn0BpAQAkdCRUsV1PESYppELDBKsQTW7b6VAmhrfwmO7lY7mRlI8kD72Rn5qxGnQIyxworE8seePb0pgRzTSTsGlcs2AMn0qbTrx7C5E6IrNggbh0yMZHvUNvBLczJDAjSSucKqjJNdhB8P/ABBfQQuiR5wI/LllCsp5OAPTFAGFaaxLb3jPGGjt2/5ZFiwAxjAz69M+9eh/Dxhq7XGpXjeT5BxEMF9xOMjPX8Kg1rwvqY8OWWm6dbpOXYCR+jArweoyQD/Ot3wvo8vh3T4Yr0+XcKu/jjYx7H/69AjrEngTa1o0aEkjEgIwxHJXjGO+KsSypEkMI3C5c7iCBlSR2XGMnp1qGKd5oogt1EGYNlhkiI+iJ1P1pbdEtrmTannySdZDwX+vUnrTAI2e2J+1WrKsxAyrb2z15HbtU9xERI/mgSnIIV5c5I/vZx09BUFmksTPcFGikCkbC/zMM/wqMYB6YqR32gPOiR/OStunHGOnI5554zQBPY+JLnQUuJLJLeGWaPBkRDvPI4XuoPrg9OKzor64ubgtPLN51wctK43Me+SWPH48/Sqsl6kl9GpKRjgsI22sR6A9fbg1YRpJt48+MEEgLuG4DHQHv+dACkWx3Irjnr0Pc8mup+G2uad4d1i4k1G6iitriLy2cAhQwORkfTNcy0QEQjAMXy9GxyOvI7Vy3xAAj8Nmbz8mKRCdjAg/Ng8ZoA6j41/EG18XpLYeCrnzzb2c0NzKIc+YkhTdGuen+r5Ir5tvLy4vDCbqVpDDEsKZ/hReAPwr0zwxatpRMkDxrDcxtKzMMkjPTGMD8a8tlOZXI7sTSGNooooAK/TavzJr9NqGB+d/xR/5KZ4u/wCwvd/+jnrma6b4o/8AJTPF3/YXu/8A0c9czQAV7P8As5apFpPizSo7qMq15d7YXIODuVk69OvrXjFer6fM+mfDKw1uBhHd2kgNuwPKuJcg8+47UAfXniyIyy2gUAlVfqucZ2/lXOOsoIJ3kKf4SML9cdqxfAvjOfxtpj6xd272pYLGsSZbZgc/mcnp0Iro5Mou4R9Dkh8nn1+tAiBG80Zy0pB2g7BnPrUnzDcW+UDnIIXcfwOc0hcyAjdjHDcHH1+tIoRMGPYvGSFXDGgDlP8AhCR/wml94kttZ1m0ur94ZLqG2dDDIIlCorAoTggHPzdz0rsbVmKNmQlWAQKp459vw61HbzExsyhgiMTvV9yjjkEinpJ8uwuNwAIVcDg/7P8A+ugCRkJiO2KbBUhgmT17ZOMH3ryuSx8RWHipNjXs8IJCSMu5GHoQO3OM8YNdf4h8RWWixosrXDM5Plr5uI14+b8etWNC1q31Z4EgWUsYgWJQ7AvYA9zz0oAs3ep3CvJGLd1ZYd/mMRg7RgAZ789x2rwS+s9upvFPGoQSvlI5QzmQ4w/vgnkD1r6B1XP2F23MxbJETDrjnH096808N6N9p8UtMbcqhcuvy5OcfdBwAfrwR7UwPVdFiNtplvbfZwksKKjxq2dhAyWHtj1q1NOqymMxuqshJBjyVYnru/M9O1ROVkSPEyhs/wAC5GBnGc9eKV7ZkieSS4jWKUEtkEt6Z5PHTH40gEs7htrRBUZIm2lz97Hc+nPNZniLV4NJ0uS4WE3F9Ju8uHOUPqMdq0RLGIwiyId6ncEXdkj/AHjn+leAeMvGUHiHxnq2lW7xNaW6LDAynaJXX7zD057e1ADNW1S91S8nuZZYpZUJf7JIjfueMHnPzcdh0yfSsoG9MkTxSqskikeTDliCPfgAfzzUqQuuxmTdtDGM7wjbj6NjLdM496BLLB9oRJ2mtYnKvgDbuGfuAHnPvxxQBn+ILFdR0h/PH2kQxfu9p2mFsZUHJyR2rycBmwoyTnAA9a9bvGSz0fULicruWNihcnJbb8nB7ZzwOlcr8KtEk1fxPHKBEYrQeafObapb+EZPHXn8KBkdj8OPFV/HE0GkzGSVd8UJIEki4zkL1/PFafhvw14h8N+II/7Q07ULKVv3bRSW5w6nqTnjaK+o/B89p4e0K78QarLHKv3YTGTuYHr8p6Hp+RrlPG3jy411UtYGijtyVK26LvdiRkNnjp0xnvzQI+dviZolzouto04hRboGVYYjkRHPK/1/GsfW7qCa2sns5JFeWEC5QvkFwe/88V6v4qht/FNktjegx6kZMQ3EScNJ/tKvbtxnHXNeT+JdCuNAuYre6bc7KSw2ldrAkMvPXBHWgZ0mi2LweFoyHeX7USQq/Kg7Yz0JI4x6muR1qzSxv3ihYvCQGjYnOR/+vNEWrX8NkbSK7lW3znYD0+npVGgD2H4OeHrX+zJNXnbM8pMKIrfPtzglfTnHNelCIPKXnZo8Hc3Cl0BwNzYJ5yD05NcZ8I5El8Ex7XkWaKZ1bYwZsE9VUjrjA4rrZCkryLc2TQzO4XfGAGLfw5b+LHfHvTESyIpVY7fy4W8wLuilGFB5LEdCxz+VIroGeGOJZymcgt94E4IDD3z+VPkt1kVJyizr5IEce75WGeQ2Bw3pj1qaHaqSPbjy1AIQRvtdW7jn06cg0AYWrWrwQzTwyANGdjJCxDSdSBkDIA7rn3rIXWZrWDbJIViJACkMw3EdAeufUD866wSJGsURIiu1bKtIhCscdDjHP8+azm02GaQzeRFc3EeFLMmQSTz82ffk9e1AFaPUYRax5dHVv3cciJiQN6BRzgepptzfAqsMMfnyYwzSKxIJH8IPzZz3FMutITewAYzPJ87AZKjoAoGB+XSk077NbX8sDNtwNsYlGSB1z1z+IoAZpemF5t984MwIBLtub8c/dx6VpwxxkmGQq0ajKhVIU85545qRpFd3RQJWVf4XyUHp1+YmmD9yhjVDC3OMRruOT3wQfwoAsOwWJ2RymCPkhGQOOmMH+dcl45Mc/hSf5C4LAndEOeRzn2rpFlbI2ZIJ4cNjp2/+tWV4ntBqFgba5mYhnUnzF5wDnr+HagDFhgtVtbZJDIGjhJT5GCscdSCTn8c14tL/AK1+nU9K9hha9hub9XguYITF+4MpKrIncrnmvHWxk46UhiUUUUAFfptX5k1+m1DA/O/4o/8AJTPF3/YXu/8A0c9czXTfFH/kpni7/sL3f/o565mgAr0e1VLv4UR20LebN9o27Ochi+QAAcE456V5xXfaFokT+FLG8hFxJdSXaPtRsKcPgjB4zigD2z4BGW28KzwCOOKSK4KFN/I46nqMnrXpYyztuMigDG0uD075xXlfwVvQ3/CQW5WRXivB/rCCQpUelenSyyM4CYZAMtvycH2xQIaAwmKqRJbjJ+9kE/T/AOvT0VSxCq8KqNpCDCn14+nekWUjAQ8dCU4Prye1PQySDauH5JPLbvwJoAIlht2H2cssgYnBU4Oeef8AGnv5jxqoUCRuS7KOQOw9/eiFbhZVCttWMHIcAke+cnJ+lRxYYKpWQ8Y5bPPOfwoAxtQ8LWmosJb1D9oG5mBfZhSeRgHDVajutK0i2hiEuCqkQRhlVyB7DP8AOrd1Zma2EccpeHbwCc7xxnGOcc1hWnhiSG4drlFLjO1UVXKjPUcZB/GmBPOBrEZ81N8D52+YcCPGef8Ae9vSr2k2L6aGmYzTTMhVZlOCeem3/PtV1rdUQDzFl53YYgqvHoB1p/2j9yGjedmHIKn5iB2Yf56UgJWWRNvmb3/gwy4ZR1HH8/ao7l5RGmWeKMkcqp4OMbhgZAHc9K57XvF2maJayPql41uUBk2zOGduMcL65rwr4ifGC51SOWw8PNJBavxJO33nHoo/hFAHb/Gj4mwabpk2i6NcZ1K4XE0sRDNCPTdjqfavnTTdRmsL4XSYduQ6vyHB6g/561UJJJJJJPOTSUDPUdH8SadMwSxeS3mCbY1mkGM8Y+9/FnuPbitCO+sLISK19BbXoyyybwYmwRhSo5JOCM9M149T4G2TI+1G2nO1+h+tAHc+I7q+8Tajb6TpkzXCO+REXJCtnGcnovPT/wCtXf6PZxeC/Bt4r/LdoAZD5YLvIf8AlljPXjI9B60/wRo6Q6KtxNHE1/fptkE0R3RkYwQfYYAz+tcn8SFmvNUtotNiIsbWAMssabtzHgkY5OOvtmgR0cGr3uo6FpbzRRFvJZc28ZBV87svz97GPrgGnXMkwiLNDLZbVwUA2gKOd2ehbnDY9j2rnvh5qFjbarb6PfyLFpUlwhNzINyq3IZjznBzgele6N8JZmuUFleQXWlyE7D5pAVcDaSADk5zyM5zzQB5A01zFGQqRDz1whJGNoz8uMfM2TxjHel+NWhxwaDHdBzI8UqkkrkpuGCN3oT0HtXrfjbwTpPhrw5bXtxq1ta6iuxVjuceXPICuFReoPuM9ewrxL4wX7QWCWYut8t1N5sq9QQBwU9F6deePSgDyWiiigZ6j8G9WVWuNOmEchDebCkjYGcdu/UDpXrjTukUQmVFEQOJlPyoSc49SoOB9RzXzL4a1aTRdYt7yNnCqcSBCAzJ3AJ6V9HaRf2+pWVteWTr+9w4J/jGMgMcdcZ4NNCLtwEhadJ51zMB5TK4QSAfMU7DqM5qNY1kklnjZJEIwACQYzjkNngY7HkU4BJk3JHaXkTE7NmduQe4POPyqLd9o3SyHdJGSqpuAEJHbOOn0yelAEfmhrTECyyxRgKZePlOD8oBxx79KdBDJaWwWcSIThQsZUgcctlRnP8AhUL3ETMqzl4yqksUBAPtjkEH1PPPap0ESbfPWFlIyWxwAAeTkcDPvQBChtX8wl9ojBBkcFVbkdRgEnrWdPHazagzWsc1mJUJWSOQbnAPOFbj+dbbADb5IUMOEZBu5x/D/jVZ4hftuuwW2khvOkw2exC9MZ6YoArTvhEjaIMoB4YqhP4jv3qxMItohdo5cc/vPmIP8wfzoLC6VlcAso27iQSPTkcVHO6QKGlIQDkTIpbGeMUAVJ7pXDhBFGcYLD5T9GzwK6n4ZaVFrmu/ZbhENrbr50q79xkGQFGQSOv8jXNu7zjakkptzwxRCN3tg5Ar0/4JWtvbrq+zd55MY+Yk/JhsYJHTntQwMD9pOW3ittFt0ysvl3B2oduI8KO3avjmvoX9oHX4da8aeIrePy5ItIsUtA3UiRiWfH0JAP8Au189UhhRRRQAV+m1fmTX6bUMD87/AIo/8lM8Xf8AYXu//Rz1zNdN8Uf+SmeLv+wvd/8Ao565mgArtfCerNa+H5EJ3JBeRMUDbSVY4PTk8iuKqa1uJLeQMhONysVzw2DkUAfR3wsMtn401m3i+2RLdwJcKNo28cdPX3r1o+ZInyKihRjOSPz45NeL+AtQtpdb0S/scMsqPbOGkGMHGCc88MOnB5r2pc4HD8d4slvxzQIYuW2q0P7vHXGM/h+dP2bY1QgrgZDkEFfoB7Um6VH4RAep+cBifoKr31zciFhbQRNPt4aTqvuTQBdGyAHG0LyQ8jY3fQH8KU/vCcSxeWnLtJ1HsMdqbatPGoUOgl7k8ge4POabdIRKHiMbkNmVnYDjGBn364FAEoMYZmjIMhBVfJPHft/M1HuzIImlWRcBvLQkEc8lj+dMZkhj3KULEceWuQc9hjGa8k+KHxRttG8yw0uQXF43Enl/KE47t6jpigDtfF/jvRfDttvv7rFyQD5OCHwe2B0rxHxj8atX1OWaLRlWztmXyw5GZCM9d3GPpXl19eXOp3jTXMss80jH77Fjyegro9H8HS3Gf7Rc27MoaMZHzc8j60DOZvry5v7hp7yZ5pm6u5yTUFehN4X06Ff3kZllTcXVGIA5GAT+nFSz+FrCa0EvkOg5GYzgg9uvB54oA84orb8R6BNpEm5d8lsTgOwx/ke/FYlABWrp2kXVxp8moxIGt4ZVjY9fmPTis1F3NjvX0J+z14Th8S2l/p9/BnTEAkuWGQWcn5VBxjoOe+B70AWfh3pPirxbHLLp+nw2lnIvlteM+2MnAHTq5GOoFem+HPg1bWEjTX+s3knmoBLawBVhJ7/eBJH5V6nZ2sFlaRW1pEkNvCoSONBgKB0AFTUrgeUSfAjwm+cTaopPpOmB+BSuP8SfBPVtF0qR/CWpzXBjyRBG5t5SD1ClSAfpxmvoeigD4G1+91611kXGoXN9/aVn+6Rros8kBXgLh/ugf/Xrm/FOuTa9fRXNzBDFKsQR/KXAdu7H3Nfbvxb+HVr430kPAkUGsQcw3BXBkXvGx9D29D+NfEHiXTJtM1Ke3uYHt5omKPE4IKMDggg0AZFFaWiaYdRuQJJDBbKfnm2lsew9T7V31n4b0mFgVtlYKuUa5f75GQSRnBHQkDpTA8xVHZGZUYqv3iBwPrXVeAvFbeHb7bch5LJjkqpwUb+8P612kEMaTx2trbwvFGCwTlAW643egIwMg1lanoNpqMkouMQ3zdD935snIx6CgD1yC6We3W4sZfkk5jkYAA4GAMjrgk5708zq67IGCyB9lwgfknqcei/hXjPhvU7vwvqK2WoMk1iQfKeQHyxn9B7169HdWl7aRgyxyEEFnf5dqnB27v4l4wD16UxFi0kjd8fa1lcKwztBVR1wFHGMcZ/rTGiSC0h8yAvbElYyW2kHr16EdunHrUd0BxHdSRRqY2WM7SSydduR/h2qSNVhYAqwUHABk4wRwemScfhQBWaVYZo/LMyZG6MCIlDnsefUVIsTzpB58cFwwIbMv3dvqQ3epCJVR1O1xJjywHKAkf3e4+lNmVm2vD5scCtkoTuGe+C2QCDQAsltKyBniSMKSUO/B5+lVJDcxEiCOF0dc7VJyG9cn8z/ADq0iOhaRArIF+6SQxH+H0qMTxPcsscUUjAfN8oXnpwOtADABLCTIyJLH8u4Skj/AD9a4fxp411jw3el9Au57aV1MLTK24AY/h64Ndvc+RHblrt4IztPKL0Psf4a8i8axxT/AGWVyhLF5BGXHmPnhQAPwzQwMTUL65i8NpHOpEt7J5jOxyzgcliepJJzk9a5uuk8c3qzX1vZw8Q2cQjAwRg4GRj8q5ukMKKKKACv02r8ya/Tahgfnf8AFH/kpni7/sL3f/o565mum+KP/JTPF3/YXu//AEc9czQAUUUUAek/CgXDasun28ctzHNH9pjxEdqyL6k/w8delfT2mXouNPgmR44i68hBwGHUDHvkV4d+yn4is7Pxwmm3qqk9zayQW8pPBO4OF5PU4bFfRXiLSf7LmkurTctnOwLxqBiN8/TgN/P60CM5sbB843YySrdB+IqncBPKCxb9xwcv0989zT45Y23BeucDaSoPHfNSBXJADhQwxI4O44Pb0oAisLV4rZWLzur/ADYB7fTtUsoSCPuFHQ8bVHfJ/KpJYpGi+YF4xxuEmB9K8/8AjH4rj0Dw00VuyG6nTYp3kHJ9B1OKAOV+MPxIe0gbTtIEqTTLgzhgUAyMhfwr59d3mkLOzO7HJJ5Jp080lxK0kzl3bqTTFJVgVJBHIIoGd/4V02O3toC8KGSQb5WcZO3rgDt26V1ECJFO3lsyxZLK23Lj1GOg+vt3riPCerTXd+sNzIvm9nK9QOTnoD+PSuzEUW2SUwiIxuSgUlVb7vzZJzk569hQBevZXFqIlgaSaVAwUZ5YfxMxOO2eeaj/AHToWvUZpWZS8wVSD6ghfm3evGOOaZIZ4bc+VdSB5fmlVQpVdvTI/Lnp+NDPJIUkunuIpireSzAEHGD8vcEnnJ7GgRla9FZixvJZGTytrHlWO7IJHPQ9q8pHWuq8Wayjo9jZXLSwscyNtwMg5wPXnnNcqOtAy/pEQlu0VjhfUDP4V93/AAV0T+wfhxpMDxGOedWupgRgl3Of5YH0FfFPgzSp76SS5Rf3EBXc5bHzdQP0r9BtOMZ0+1ML+ZF5S7HzncMDBzSAsUUUUAFFFFABXyx+1l4dgstcsNYtxh9RjcTDH8cewBvxDfpX1PXzz+11IxsNAiKYiHnyb/fCDHt1zQB4p4KnWy8OySMyqGkbjBLMegPt0xxXWRWcbxNIzMswxLHGI1K8rjBPPoOc81wXgK82m6twmZFPnIVwWHY4Ht1rqtSgnXSprOEOlxODtifoGP8AEOuM+g65piMSTxh9i16EuwlgifypR5YVtv8AeXGRjOTj/GuiN3Za5E7R3CrJAgLTowYOX7ng7eT09vavHZYnhkaOZGR14KsMEfhV7Tr86VqMc9pK7IAA+BjcO45oGej6hYRSSSQ3eYigUYZhL5LdAQeuP9rmi01TVfDliqQ24nitTg5O8bCOPXnGfb+VTefHKlsVilEjIBmEYHIOM9gff3pl3FJsKvcCOF1KsjHa6ngEbe4ODzQI7Xw/4gtdWsnvNKvCu4hWtznJcc4Hp7dK1pnmMbRB1R2UZL4BK9TnJzjnt/WvCdP1e48HeJZDCubGQfPCvKyIR7969tsdSS70y1uFbdayoJFkB3uBjpz0P0pgSCJY40G6MKykh4vukZ5Hpu9Pyp0coEY2yTzFFKsGIBOenzHrTTKB5e5QUc7Tt5BwPUdD3/lVdmifAEDrMHyuSJAVJ/XPp1FAFuEKceUkkMjDaFYg7vXr0xUU22WVxJHHlWIVwxOcc8+nf3plwzsm1/NERHJOWUc9cg5/OnRRJLGggEfnAszYPP8An3oA5/xTetDarbW0zmS4Pk7G29D1PPoM9q8q8eyRwa9FFbN81tGo3bs4briu48Q69BDdtdz5mMYZIlU7skfebI6enNeTahdyX17NdTY8yVtxxSYEMsjyyPJIxZ3JZie5NNoooGFFFFABX6bV+ZNfptQwPzv+KP8AyUzxd/2F7v8A9HPXM103xR/5KZ4u/wCwvd/+jnrmaACiiigCW0uZrO6hubWR4p4XEkciHDIwOQQfUGvvD4ReOLX4keCvOuFRb+Nfs9/ADxux94egYcj05Havgquu+HXjHVfCGpvJpF29q9yAm8KGAOeNyngr6j06YNAH1wskdvqF7plxMPtdm3zR9dyHlH/4EP1BFXNyDlY1DkdAM4AHcDua+fPEvxd1W+8W6Zc3+mR2urWCtbzC3c+VOhwwO0n64yeA1e8eGtWtdf09Ly2MJyPmjDcxnuCKBC3cgdmafbIkS7ipPUY646V8mfFXxNN4g8TXI3EW8MjIiAjHHHb/AD1r6m8aTx2egXsokX5YyzFV5HuByPzr4ouJPNuJZMk72LZPXk0AR0UUUDJLeTyZ45OflYHg4P516Np2tW15ZoJZgxjXe0YBkbc3BwMZ6dTzivNaVWKnKkg+1AHe654ltbOUx2CLOwUL5m75SR1JHPr+lc7d+JtQuY5EZkUyrtdwvzMP6fhWHRQAVY0+0mvruO3t0ZndgOBnAz1pdPsp7+5WC2Tc56nso9SewrotJng8Ka5cC5DzDytquqFdxPpnnB6UAWf7Wfwvf22n2mUe2w08q/e8w9doPAOK+of2d/HqeIdBGi3sjNf2K/u3bOZYc/Ln/aHTHoBXxreXD317NcSP8zkt83U+1e6fsrof+ExkJkKubchBgENzlvfpj86APremPLGilnkRVUZJJAwK+cPij4s8aaN4k1e3lnuLOwuS0dsMDa0IPDKexPcjnmvMH12/Mgna9ufMB++ZDxx9eaQH29FLHMgaJ1dT3U5FPr478L/ELX9ClEtpfu8fVoZDvVxnpz/SvavDvxu0G4tAuuLNZXirltkZeNvYEdD9fzoA9ar5q/at1BLqGOCERSLa7Y3c8sjk5IXn025/KvQfit8U4PDfhqO40SWKTULk7IlkXIUEZL9ew59DXzD/AGvJ4nl1pp9peaEFzK2WLnOXHvuwaYHE6Pemw1KKcHChsNjrtzzjFep28/n2cjZhhDsSG3AkHAPJ9+vP6V48QQSDwRXR+E9dGnyfZrlXeB2whXkxE8EgHqD3FAGx4s0iJdKn1GSJmmdl2y7ug6YwOD9e1cRbwS3MyRQRtJK/CqoyTXqi3SCFGmQlCysAgyW5AwQMcevpVgJbWEjXGnwwpKI2CEQ7Ar/3c9x25FAGfpUt1F4dsYr+NoY1DKRKMrgDgkjoMeverUxQwokYIUkM8p6/Q5+vPFSWdy4twIzGDKxWWHbkxkc4GeoJzzUV1J9kgnuJhFHCyBluM5LegwfrjrQI4rxySdRh3MjNszlHLA89f8ir/wAPPFTaPdrZXe2TT52GQ7EeWc9QR0rmNWv5NSvXuJVVM8Ki9EHYCqdAz6aWd/IjYzPJAVB5XIYHou4dxnrVS4ECyFI870clZFPO30K9fyrkPhtr/wDaNk9tIxW7hAXYvCug7n09Ca7BoRKqIYHEa/MHZ/n25wSOcNj2xTESSTzGMCzliLDouCMjr+J9Qa2PAfh+58V6k1vNH5FrAf308Y3KFz9wZ/iPb0GTXOSK7z28UQX7ZPMI4YWUhncnAx69c19E6XBpXgXwmgv7m2s7aBfMubh22I0h5Y8+p6D0wKGB4Z+1P4f0vS9P0CezgS2iHmRSJCACUUDHufmKivmCvSfjp8RP+E/8V+dZB00i0Uw2qsMM4zkuw9yOnpivNqQwooooAKKKKACv02r8ya/Tahgfnf8AFH/kpni7/sL3f/o565mum+KP/JTPF3/YXu//AEc9czQAUUUUAFPRz5ZjYnYTnHv2NMooA1765uNThsrI2Ra9tUMZkQEvIg5AI74Hf0r0P4ZeLZrK0SG2m8u8hPzRk4V4x3Pqe1eY20rkxmAul5G2Y3Q8t7fUdqJZmnl+1xuFut2WCggk9d4/rQB7t8QPGd3feFJG+wzbHXJuACYlI4AOO+c47Cvn08mvo/8AZv8AiXpMCTeF/E/kQLdMPs0soHksenltngZ7Z47eldh8Q/2dND1rzLvwpMNGvTz5By1u5+nVPwyPagD5Aore8X+Eda8I6vNp2uWTwzxANuHzIynoysOCKwaACiirlrZbri2F8z2drM4BuHjYhV7tgcng9qAKiqzEBQSScADua0rbQtRmdc2N4IiRucW7kKPXpX1v8M4vhN4I0lLvTtf0a4unwHvbqdPOzjoFPKDvgAV1V/8AGfwBZQtI/iO2m28bIEeRj9AooA+KBqjWLeRpcJgKNgs/LMemT/geBUN8l9qUk11qF0klwAflZgWJHsOBXVfGjxH4Z8ReLvtvhDTDaWwGZpWUr9pkJzu2fwjt2zXD3V5Lcli+1QSWwihev07UASqPtFygEfzBQpAOSx/z2r7g+B3gePwj4SgkuFjfU7wedLIFwUU8qgPsP1r5l+AHgtPF3i2JbvzFsrdTM8kZwVdWBUfia+3Z54bWHzLiWOKIYG6Rgo54HJpAcv8AEbwmvi3S4bY+UHhcyIzDkHHQex6H/wCtXy/qXha5ttSnsruP7JNG5JBG3n2/nX2bXnvxR8AS+LJbO80y4htdQhzG7Sg7ZIz9M8jntyCaYHzJYaDdahfeTY20k0zNtTA3Y9eegAHevcPhz8G9PVF1DxK5vJVbEdqpKxrju3djntwOO9ej+B/B9j4U0mK1hxPcjJkuGTBYk5OB/CPaumoA+Yv2sdFFteaNf26BIHge32quFUqQQOPb+VeA+HLm/wBMvDqVkB5cR2SlgCNp65H9a+zf2i9Hm1f4aXRt1DSWkqXJXHLKudwHvg5/CvinT/La6a2nmeOGYgHa2B9TSAseKLVVvTfW2xrO7JdWjO5VbuufWsWu68OeEdXvbpINJ02bUmyzPCYiyccdRwCecGqfi3wXqWj3b50+7tgBua3uEKvHxk4z94e4zTAy9G8RXmmRiFD5kG7OwsePYeldBYeJ9PL/AL8PEjA7kYFh7jI9fXFcLRQB3Fx4i0yC2JtjLPPk7cAoQcg5z3Hb1rmdU1m81FSk7qsW4vsQYGT1NZtFABRRRQBNZXdxY3MdxaSvDOhyrocEV1lr8RNYgZHMdnJIi7QzRkfoCBXGgEnA5Jrb0uCKytJL67CNPjFvA4zuJ/i2+lAHUeGvHlx4e8S6Zq+pKNSmglM0luxK+XwQqDsME59sUz4pfE/V/iHNF/aC/ZrWJ8w2kLHy046n+83uenQCuSnsZY7Zry/mCSscpE/LyH1I9PrWcrFfmHXtQA3kHBooooAKKKKACiiigAr9Nq/Mmv02oYH53/FH/kpni7/sL3f/AKOeuZrpvij/AMlM8Xf9he7/APRz1zNABRRRQAUUUUAAODkVoIP7QYujLHfDHyjjzfp/te3es+gcHIoAsyESfu5Y/LuE+XPQsc9GHrnvXoHgf4yeMfBrpbpetf2UZCmzv8yBQOynO5fwOPauFef+0fKSfYtz937QxxvHbf7+/wCfrTbcQ7ntr8GFtx/fbSzIfQjuP5UAey/Fz4uaR8RPDNjb2eh3lpr8EodJtwby1I+dVZeWU8dQOg4ryzw/pd5qtxs8qFI9n+tnjwoHTjpk5qlaXtzo8kyRhRI6jDg8rxwVI9jXe6CRp2nJFNdOVijJkcLuG5v4ATxgdM/WgDmdU0l9L0SKR1jW4EpUOu0luTjjr0rnVlb7RF9s8yVIyAyMxztHYeldnr1ybW4idIHl1GYgTSH5mRScBY+y5/Om29tpLzTpqbxrvcKlvtZHVumSc5b655oAw5LSXXdVL6ZbeQJSNqyOOe2QcDitKbwibZJYru+UXaLkxxqXBOeOR+Hatfw8kmnKsOpStDuYQwqyKoAycEnvnFdJLqNrb2rXNzHHC8x2mVk3Pgk4AA5OcUAef+GfCo1dZxPceRIrhE75PuOoqj4q0WTRryJG2tG6DbIrZDEda7rRIhFrV7cx2rQuSOZmCqqk4JxnAJA70/4mabDeaTBdJKqTW67yHbLbD2OO/GRQI679kh9Ptdf1E3uo20c80CfZYGkCl23EN1/iHy8c8HNbH7TPjjzNatvDtukiQ2WJ5nLfLM7D5QB6KM8nua+dPDUZm17T4vM2KZ1Oc4wQc/0r03UtJ/4Se/We+LNP5jozA7ScDjHc9ufyoGeqfs2+Np7q8m8P39y8sUkXm2e9ixjZfvoPYjnHbafWvoKvkH9nC0lh+KdnDMrEwR3BzjjhCoP05r6+pAYni/xNp3hTRn1LVXYRBgiRoAXkY9FUevBP0Fea+HPjpZ6x4istMk0d7dLqZIUl+0hsMxwMjaP51yfxwv7jxd4obTrJxHp+j7o2Z/lDzEZcgn0wF/P1ryhfDEsd3AYL6RbghZlKqC0YzwfwxnPtTA+2tatUvNOmhkQuhU5UdTweBX52tp11qWuPbWUDPNI7EKOduTnnHTFfV2t/Hfw1p/gwwQ3N3f659mNu0awlCJduC7MeAM5PGTXknhHw+uh+Hmu75k8yVFkmO7aQrDATPfj9c0Add8H/AIn23gD/AIpjxg8aW4G9Lu3zKI2J6OAM7SOcjp3r3/SvEvhjxTD5Wnarpepo45hWVJD+KHn8xXxpq3g+x1Gc3unGSysQNzvcMS0pPQjP3cn19aw/DmlXIuS66jaLFGwJcDzMFc554IIFAH0B+038PvDdt4VbxDZwW2l38MioRCgRbjPAXaOM8da+UK7bxXrd7NN9nfUU1SKPGxXLzDHTuSB+lc9qM1xqCNcGxhhhjIiLRR7Qh9Cf8aAMqiunn8PyLpELJZK105BDx3GcDHdT/jVa1tbLSdesf+Ehs7mXT/leaGOVQ7r1IBHAoA2vAPwt8VeOI/P0WwC2IJX7Zct5cWR1APVvwBr23w/+zroGgWE2p+Ptb8+GFS0iQN5EKD3c/M34YqDVv2ktL07TILDwX4eaKOKMRxm7xHFCAOAEQkn8xXiXjr4ieJvHE6f23qLPAh/d28Q8qIe+0dT7nJpAZmq3Gm23iK6uvDySx2qzk2cbtvZUz8pJPfHarU+qefAbzVlgnkcny4Eyjof72R0HFc5KqR7PKlLP1OBgA+x71KLW5njNzIr+UTzNJwpPpk9TxTAhmbzGaQkbnYnbkkj8TUeTx7UUUAFFFFABRRRQAUUUUAFfptX5k1+m1DA/O/4o/wDJTPF3/YXu/wD0c9czXTfFH/kpni7/ALC93/6OeuZoAKKKKACiiigAooooAKvQyxXcSwXbFZhhYZieFH91v9n37VRooA0IpjaZt763E1u3I/vAZ6o3v68g10OiXcoRk0q4iuIBjFrdsqupPA2k8H+XtXN2t+UjSC6jFzaqSRGxwVz12t1H8varQ0qO+Z20acS7VDeRMQk30A6N+H5UAdGmoWiTTJdzXVrevlf9IG5UbPUEcEA96W8tYrh2uYbi0kmaPakhIPzZwGY9mPQAVyr6jfwQvZXJLIo2eVPGCU9hkZWqMj75CwRU9l6UAd5f2E+v2x228lpLEfL8sNlc/wC136jg1f0jWn1EjR762jgvIk+UE/fZf6n/ABrz621W/tiDBdzpgg/fJ6dKiN7cm9N2Z5PtJbd5u75s/WgD26OOKO2N5dPCkaJ+8jkxtkP/ANielS2cNpPZq8zGW3cbV4BJLjB46E/yxXlVl4xv4dq3SpcxBSNrcbs9SfWtW28ZWCtbFrO4hVT86wuABxjK9Mn6+tAjb8T6Hpa6d9p0mB/t1uiJHsHRlOcn1J96vaDcahrsBsdNguY9eTBkgaBsRsOm9iON2OhrLv8Axd4dXT1+yJcyyfLJ5RBQiQMGHzegIrmx8QfECXeqXMF2IJ9R8vznjXDfJ0wfpweuaAPpf9nHRZvtetavqljPbalERYv5n3Sw+Ztnt93869zr57+Efx20CLwxZad4tuprfUocq915DPHLzwxKgkHscjHGa9N/4Wt4JNsZ08QWzxA4JRHb+S0hnnHxH0FrbxJdyS5MDbnUKSfNL5JVuw9c+1eU+LbnUnhNtols91d3EYFxKqYMYOcKvuOea9l+J99pXjDTLe80PU0cxSq2bdgS65Aww9MHqa86vJxpxeRpWiWaVSvlctyCM4A5HHSqEcn4S8Nvp2mvf6hp0f8AaK8wrLNyc8A+nPP4VvXsctxPbQTFJFZ97gk/MP7mOwHrV5riV4o5JVZ/K3EqgGCw9PzrHuLk6dqT394VjKxhIy5wqp2Depzj8KANy8jSzgjJjklVBsO9dxHGArDvzgA1ga1plrqeY5y8cdsgaZIsKjZPcjnism88a2MlxE8dz5axZbCRsdxOMj0wOcGsqXxrZxSSLbWTyKWJMkjY3n1YdwfSkBoaNC1rcF4YVOmKxMbhNzL06gdR3zTtUjuNklx5SLJcAq68IoQ/8tGB6/T61iXPjSdSDZmOBtuD5UPG7PJG4+nbFc3capc3uBevJc7eIw7nC854AoGd9Jq2m6PblRfidx96KID8Rj8euelefajctczFUmuJYFJ8vzjlgDTyLqJlYWQTdnbmHOfXGeuKS002+vQxghYr94kkIv64FADUt4IMNePu4P7qJgW/E9B+tVp3WSZnSNY1PRF6CtL+zLWAE32pQKduQluDM2fQkYA/OkW80+2JNrYGZscPdPuwe/yjA/PNAEum6ettbjU9TRBbLzDBJkG5b0A/ujgk9O1Z+oX1xf3DTXUhZieB0VR6AdhRf31zqFwZryVpZMYGeAo9AOgHsKrUAFFFFABRRRQAUUUUAFFFFABX6bV+ZNfptQwPzv8Aij/yUzxd/wBhe7/9HPXM103xR/5KZ4u/7C93/wCjnrmaACiiigAooooAKKKKACiiigAooooAtjUbny/Lkk82PduKygNk/jzTxc2UgInsipOPmglK/oc1RooA0jDpUgzHd3MJ9JYQR+an+lSjSLeVh9n1iwKnvKXjP5FayKKANqLw/JMB5Wo6WzkgBPtQBOfrQnhnVHK7YoDuGQftMeP/AEKsWigDdj8K6m/X7IvOPmuo/wD4qph4TnVgJ9U0aDK7v3l4v9M81zlFAHQNaaHptxH9o1CXUiPvpZoY1B9N7dfwFdXpnj7QLWMwnw1OiZIEq3u9yPfK15pRQB63Kng/xCsc2gau+h6mQFZZiYtzHpkj5Tz/AErmvEF54p0IiC91GO5t1JVJEkSVTn0PJriaKAOgm8Ya3J5R+2lGjBAZEVSc9c8c1jXl5c3sm+7nlmbJOXYnH09KgooAtWVjPeCRoQmyMZdndUCj6k1Y+x2MUTm41APKrYEdvEWyPXccCs2igCzmzUHCTucnBLBQR2yMH+dRRTSRNmJyh9V4P51HRQA6SR5WLSuzsepY5NNoooAKKKKACiiigAooooAKKKKACiiigAooooAK/TavzJr9NqGBzt14G8J3d1Nc3fhfQp7iZzJJLLp8LO7E5LMSuSSTkk1H/wAK+8Gf9Cj4e/8ABbD/APE0UUgD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDiaP8AhX3gz/oUfD3/AILYf/iaKKAD/hX3gz/oUfD3/gth/wDia6aiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan through the upper abdomen shows high attenuation throughout the liver (L), which normally has a similar attenuation to the spleen (white arrow). Other deposition diseases producing this appearance include amiodarone toxicity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36337=[""].join("\n");
var outline_f35_31_36337=null;
var title_f35_31_36338="Patient information: When to worry about a fever (The Basics)";
var content_f35_31_36338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/18/36129\">",
"         Patient information: Appendicitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/35/16946\">",
"         Patient information: Aseptic meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/1/31762\">",
"         Patient information: Bacterial meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/33/41489\">",
"         Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/59/25521\">",
"         Patient information: Neutropenia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/2/22562\">",
"         Patient information: Rocky Mountain spotted fever (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/11/176\">",
"         Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When to worry about a fever (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H580209379\">",
"      <span class=\"h1\">",
"       What is a fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A fever is a rise in body temperature that goes above a certain level. The level that is considered a fever depends on how you take the temperature. Here are the values that are considered a fever:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Oral (mouth) temperature above 100&ordm;F (37.8&ordm;C)",
"       </li>",
"       <li>",
"        Armpit temperature above 99&ordm;F (37.2&ordm;C)",
"       </li>",
"       <li>",
"        Ear temperature above 100.4&ordm;F (38&ordm;C) in rectal mode or 99.5&ordm;F (37.5&ordm;C) in oral mode",
"       </li>",
"       <li>",
"        Forehead temperature above 100.4&ordm;F (38&ordm;C)",
"       </li>",
"       <li>",
"        Rectal temperature above 100.4&ordm;F (38&ordm;C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209394\">",
"      <span class=\"h1\">",
"       What is the best way to take my temperature?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Armpit, ear, and forehead temperatures are easier to measure than rectal or oral temperatures, but they are not as accurate.",
"     </p>",
"     <p>",
"      Here is the right way to take an oral temperature:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wait at least 30 minutes after you eat or drink anything hot or cold.",
"       </li>",
"       <li>",
"        Wash the thermometer with cool water and soap. Then rinse it.",
"       </li>",
"       <li>",
"        Place the tip of the thermometer under your tongue toward the back. Hold the thermometer with your lips, not your teeth.",
"       </li>",
"       <li>",
"        Keep your lips closed around the thermometer. A glass thermometer takes about 3 minutes to work. Most digital thermometers take less than 1 minute.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The height of the temperature is less important than how sick you feel. If you think you have a fever and you feel sick, your doctor or nurse might want you to double-check by getting an oral or rectal temperature.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209411\">",
"      <span class=\"h1\">",
"       What causes fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of fever in adults is infection. Common infections that can cause fever include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A cold or the flu",
"       </li>",
"       <li>",
"        An airway infection, such as bronchitis",
"       </li>",
"       <li>",
"        A stomach bug",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of these infections are not serious and get better on their own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209426\">",
"      <span class=\"h1\">",
"       When should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you get a fever and you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are pregnant",
"       </li>",
"       <li>",
"        Recently got back from a trip to Africa, Asia, or Latin America",
"       </li>",
"       <li>",
"        Just got out of the hospital, or had surgery or another medical procedure",
"       </li>",
"       <li>",
"        Get infections often",
"       </li>",
"       <li>",
"        Are on chemotherapy &ndash; Call your doctor or nurse if your oral temperature goes above 100&ordm;F (37.8&ordm;C) for more than 1 hour. Also call if it goes above 101&ordm;F (38.3&ordm;C) even just 1 time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also call if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever that lasts several days or keeps coming back",
"       </li>",
"       <li>",
"        A recent bite from an insect called a tick &ndash; Infections you can catch from tick bites can cause fever and other symptoms.",
"       </li>",
"       <li>",
"        A serious health condition, such as diabetes, heart disease, cancer, lupus, or sickle cell anemia",
"       </li>",
"       <li>",
"        Fever plus 1 or more of these symptoms:",
"       </li>",
"       <li>",
"        Rash",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Severe headache or neck pain",
"       </li>",
"       <li>",
"        Seizure or confusion",
"       </li>",
"       <li>",
"        Severe vomiting or diarrhea",
"       </li>",
"       <li>",
"        Severe pain in the belly, back, or sides",
"       </li>",
"       <li>",
"        Any other symptom that is unusual or worries you",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209441\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse will do an exam and talk with you about your symptoms. You might also have the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Chest X-ray or CT scan &ndash; These imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will talk to you about any other tests you might need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209456\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can stay home, rest, and drink plenty of fluids. You can also take",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      &nbsp;(sample brand name: Tylenol) to relieve fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209471\">",
"      <span class=\"h1\">",
"       How are fevers treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on the cause. Many people do not need treatment. If you do, treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics to fight the infection. But antibiotics only work on infections caused by bacteria, not infections caused by viruses. For example, antibiotics will NOT work on a cold.",
"       </li>",
"       <li>",
"        Medicines, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        &nbsp;(sample brand name: Tylenol) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil, Motrin). These medicines can help bring down a fever. But they are not always necessary.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H580209153\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/18/36129?source=see_link\">",
"       Patient information: Appendicitis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/35/16946?source=see_link\">",
"       Patient information: Aseptic meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/33/41489?source=see_link\">",
"       Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/59/25521?source=see_link\">",
"       Patient information: Neutropenia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/2/22562?source=see_link\">",
"       Patient information: Rocky Mountain spotted fever (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=see_link\">",
"       Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/31/36338?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87294 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36338=[""].join("\n");
var outline_f35_31_36338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209379\">",
"      What is a fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209394\">",
"      What is the best way to take my temperature?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209411\">",
"      What causes fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209426\">",
"      When should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209441\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209456\">",
"      Can I do anything on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209471\">",
"      How are fevers treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H580209153\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/18/36129?source=related_link\">",
"      Patient information: Appendicitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/35/16946?source=related_link\">",
"      Patient information: Aseptic meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/11/176?source=related_link\">",
"      Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/33/41489?source=related_link\">",
"      Patient information: Mono, the &ldquo;kissing disease&rdquo; (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/59/25521?source=related_link\">",
"      Patient information: Neutropenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/2/22562?source=related_link\">",
"      Patient information: Rocky Mountain spotted fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36339="Celiac disease in adults";
var content_f35_31_36339=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Celiac disease in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/31/36339/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36339/contributors\" id=\"au6610\">",
"       Ciar&aacute;n P Kelly, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36339/contributors\" id=\"au3114\">",
"       Melinda Dennis, MS, RD, LDN",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/31/36339/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36339/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?35/31/36339/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36339/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/31/36339?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Celiac disease is a condition in which the immune system responds abnormally to a protein called gluten, which can cause damage to the lining of the small intestine. Gluten is found in wheat, rye, barley, and a multitude of prepared foods. Celiac disease is also known as gluten sensitive enteropathy (enter-OH-pathy), celiac sprue, and nontropical sprue.",
"    </p>",
"    <p>",
"     The small intestine is responsible for absorbing food and nutrients. Thus, damage to the lining of the small intestines can lead to difficulty absorbing important nutrients; this problem is referred to as malabsorption. Although celiac disease cannot be cured, avoiding gluten usually stops the damage to the intestinal lining and the malabsorption that results. Celiac disease can occur in people of any age and it affects both genders.",
"    </p>",
"    <p>",
"     This topic discusses celiac disease in adults. Celiac disease in children is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/14/11492?source=see_link\">",
"      \"Patient information: Celiac disease in children (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about celiac disease is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"      \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"      \"Diagnosis of celiac disease\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"      \"Management of celiac disease in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of celiac disease vary from one person to another. In its mildest form, there may be no symptoms whatsoever. However, even if you have no symptoms, you may not be absorbing nutrients adequately, which can be detected with blood tests. As an example, you can develop a low blood count as a result of decreased iron absorption.",
"    </p>",
"    <p>",
"     Some people have bothersome symptoms of celiac disease, including diarrhea, weight loss, abdominal discomfort, excessive gas, and other signs and symptoms caused by vitamin and nutrient deficiencies.",
"    </p>",
"    <p>",
"     Some conditions are more common in people with celiac disease, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Osteopenia or osteoporosis (weakening of the bones)",
"      </li>",
"      <li>",
"       Iron deficiency anemia (low blood count due to lack of iron)",
"      </li>",
"      <li>",
"       Diabetes mellitus (type I or so-called juvenile onset diabetes mellitus)",
"      </li>",
"      <li>",
"       Thyroid problems (usually hypothyroidism, an underactive thyroid) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=see_link\">",
"        \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       A skin disease called dermatitis herpetiformis (see",
"       <a class=\"local\" href=\"#H15\">",
"        'Skin conditions'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       Nervous system disorders",
"      </li>",
"      <li>",
"       Liver disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     It is not clear what causes celiac disease. A combination of environmental and genetic factors is important. Celiac disease occurs widely in Europe, North and South Americas, Australia, North Africa, the Middle East and in South Asia. Celiac disease occurs rarely in people from other parts of Asia or sub-Saharan Africa.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Celiac disease can be difficult to diagnose because the signs and symptoms are similar to other conditions. Fortunately, testing is available that can distinguish celiac disease from other disorders. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"      \"Diagnosis of celiac disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;A blood test can determine the blood level of antibodies (proteins) that become elevated in people with celiac disease. Over 90 percent of people with untreated celiac disease have elevated antibody levels, while these levels are rarely elevated in those without celiac disease.",
"    </p>",
"    <p>",
"     Before having these tests, it is important to continue eating a normal diet, including foods that contain gluten. Avoiding or eliminating gluten could cause the antibody levels to be normal, delaying the diagnosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Small intestine biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your blood test is positive, the diagnosis must be confirmed by examining a small sample of the intestinal lining with a microscope. The sample (called a biopsy) is usually collected during an upper endoscopy, a test that involves swallowing a small flexible instrument with a camera. The camera allows a physician to examine the upper part of the gastrointestinal system and remove a small piece (biopsy) of the small intestine. The biopsy is not painful. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In people with celiac disease, the lining of the small intestine has a characteristic appearance when viewed with a microscope. Normally, the lining has distinct finger-like structures, which are called villi. Villi allow the small intestine to absorb nutrients. The villi become flattened in people with celiac disease. Once you stop eating gluten, the villi can resume a normal growth pattern. Approximately 70 percent of people begin to feel better within two weeks after stopping gluten.",
"    </p>",
"    <p>",
"     One way to determine if the gluten free diet is working is to monitor the levels of antibodies in your blood. If your levels decline on a gluten free diet, this indicates that the diet has been effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      \"Potential\" celiac disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with a positive IgA endomysial antibody test",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a positive IgA-tTG test and a normal small bowel biopsy are considered to have potential celiac disease. People with potential celiac disease are NOT usually advised to eat a gluten free diet. However, ongoing monitoring (with a blood test) is recommended and a repeat biopsy may be needed if you develop symptoms. Biopsies should be taken from several areas in the bowel since the abnormality can be patchy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      \"Silent\" celiac disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have a positive blood test for celiac disease and an abnormal small bowel biopsy, but you have no other symptoms of celiac disease, you are said to have \"silent\" celiac disease. It is not clear if people with silent celiac disease should eat a gluten free diet. Blood tests for malabsorption are recommended, and a gluten free diet may be needed if you have evidence of malabsorption.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Testing for malabsorption",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should be tested for nutritional deficiencies if your blood test and bowel biopsy indicates celiac disease. Common tests include measurement of iron, folic acid, or vitamin B12, and vitamin D. You may have other tests if you have signs of mineral or fat deficiency, such as changes in taste or smell, poor appetite, changes in your nails, hair, or skin, or diarrhea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Other tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other standard tests include a CBC (complete blood count), lipid levels (total cholesterol, HDL, LDL, and triglycerides), and thyroid levels. Once your celiac antibody levels return to normal, you should have a repeat test once per year.",
"    </p>",
"    <p>",
"     Many clinicians recommend a test for bone loss 12 months after beginning a gluten free diet. One method involves using a bone density (DEXA) scan to measures your bone density. The test is not painful and is similar to having an x-ray. If you have significant bone loss, you may need calcium and vitamin D supplements, an exercise program, and possibly a medicine to stop bone loss and encourage new bone growth. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE COMPLICATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24125447\">",
"     <span class=\"h2\">",
"      Nonresponsive celiac disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 10 percent of people with celiac disease experience ongoing symptoms despite adhering to a gluten free diet. There are many causes including other food intolerances or food allergies, bacterial overgrowth in the small intestine or conditions such as microscopic colitis, irritable bowel syndrome, or refractory celiac disease. However, the most common cause is ongoing, often inadvertent, gluten ingestion. Thus, an essential first step in evaluating nonresponsive celiac disease is consultation with an experienced celiac dietician.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Refractory celiac disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;A small percentage of people develop intestinal symptoms that do not improve despite use of a strict gluten free diet. In other cases, intestinal symptoms initially improve with dietary changes but then return.",
"    </p>",
"    <p>",
"     People who have these problems may have refractory celiac disease. The cause of this problem is not known. Treatment involves medications that suppress the immune system's abnormal response (eg, steroids). Treatment is important because people with untreated celiac disease can develop anemia, bone loss, and other consequences of malabsorption.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Ulcerative jejunitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with refractory celiac disease who do not improve with steroids (glucocorticoids) may have a condition known as ulcerative jejunitis. This condition causes the small intestine to develop multiple ulcers that do not heal; other symptoms may include a lack of appetite, weight loss, abdominal pain, diarrhea, and fever. This condition can be difficult to treat. Treatment may require surgery to remove the ulcerated area.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Lymphoma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cancer of the intestinal lymph system (lymphoma) is an uncommon complication of celiac disease. Avoiding gluten can usually prevent this complication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Skin conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Celiac disease is associated with a number of skin disorders, of which dermatitis herpetiformis is the most common. Dermatitis herpetiformis is characterized by intensely itchy, raised, fluid filled areas on the skin, usually located on the elbows, knees, buttocks, lower back, face, neck, trunk, and occasionally within the mouth.",
"    </p>",
"    <p>",
"     The most bothersome symptoms are itching and burning. This feeling is quickly relieved when the blister ruptures. Scratching causes the area to rupture, dry up, and leave an area of darkened skin and scarring. The condition will improve after eliminating gluten from the diet, although it may take several weeks to see significant improvement. In the meantime, an oral medication called dapsone may be recommended. Dapsone relieves the itching but does not heal the lining of the small intestine; thus, the gluten free diet is the most effective therapy for those with dermatitis herpetiformis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      CELIAC DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Gluten free diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cornerstone of treatment for celiac disease is complete elimination of gluten from the diet for life. Gluten is the group of proteins found in wheat, rye and barley that are toxic to those with celiac disease. Gluten is not only contained in these most commonly consumed grains in the Western world; it is also hidden as an ingredient in a large number of prepared foods, as well as medications and supplements.",
"    </p>",
"    <p>",
"     Maintaining a gluten free diet is a challenging task that may require major lifestyle adjustments. Strict gluten avoidance is recommended since even small amounts can aggravate the disease. It is important to avoid both eating gluten and being exposed to it in the air. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"      \"Management of celiac disease in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Get help from a dietitian",
"     </span>",
"     &nbsp;&mdash;&nbsp;Working with an experienced celiac dietitian can help you to learn how to eat a gluten free diet, what foods to avoid, and what foods to add for a nutritionally balanced diet.",
"    </p>",
"    <p>",
"     Your celiac dietitian can also educate you on shopping, food preparation and lifestyle resources. Excellent resources are also available from celiac medical centers, organizations, and support groups. (See",
"     <a class=\"local\" href=\"#H22\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Fortunately, life on a gluten free diet becomes increasingly easier each year due to the rising popularity of gluten free foods among those with celiac disease, non-celiac gluten sensitivity, and wheat allergies. Excellent gluten free substitute foods are now widely available in supermarkets, health food stores, and on-line.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      General tips",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid foods containing wheat, rye, barley, malt, brewer's yeast, and oats (unless pure, uncontaminated, labeled gluten free oats).",
"      </li>",
"      <li>",
"       Naturally gluten free foods include rice, wild rice, corn, potato, and other foods listed in the table (",
"       <a class=\"graphic graphic_table graphicRef54353 \" href=\"mobipreview.htm?26/14/26859\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Read labels on prepared foods and condiments carefully, paying particular attention to the \"Contains\" statement and the ingredient list. The word \"wheat\" will be included if the product is FDA regulated and it contains wheat. The following table has a list of prepared foods that sometimes contain gluten (",
"       <a class=\"graphic graphic_table graphicRef56053 \" href=\"mobipreview.htm?7/4/7245\">",
"        table 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Distilled alcoholic beverages and vinegars, as well as wine, are gluten free unless gluten-containing flavorings are added after production. However, beers, ales, lagers, and malt vinegars should be avoided because they are often made from gluten-containing grains and are not distilled.",
"      </li>",
"      <li>",
"       You may not tolerate dairy products initially while your intestines are healing. If you tolerated lactose before your diagnosis, you may be able to tolerate it again after the intestine heals. In the mean time, choose lactose-reduced or lactose-free products if your symptoms are worsened by dairy products. Choose labeled gluten free, dairy-free alternatives, such as rice, soy, hemp, or nut (almond, hazelnut) beverages that are enriched with calcium and vitamin D. Keep in mind that gluten free rice, hemp, and nut milks have minimal protein per serving compared with cow&rsquo;s or soy milk. Gluten free lactase enzyme supplements are also available, which may help you to tolerate foods that contain lactose.",
"      </li>",
"      <li>",
"       Discuss your need for calcium and vitamin D supplements with your healthcare provider or dietitian.",
"      </li>",
"      <li>",
"       A small percentage of people with celiac disease cannot tolerate oats. If you choose to eat oats, consult with a healthcare provider or dietitian, who can help to monitor your symptoms. In addition, you should avoid oats unless the package specifically indicates that the product is gluten free and was processed in a gluten free facility. Do not eat more than 50 grams (about",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       cup dry rolled oats,",
"       <span class=\"nowrap\">",
"        1/4",
"       </span>",
"       cup dry steel cut oats) of oats per day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Is gluten avoidance really necessary?",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have no symptoms of celiac disease often find it difficult to follow a strict gluten free diet. Indeed, some healthcare providers have questioned the need for a gluten free diet in this group. However, certain factors support a gluten free diet, even in those without symptoms:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Strictly following a gluten free diet sometimes helps you to feel more energetic and have an improved sense of health and well being.",
"      </li>",
"      <li>",
"       Some people with celiac disease have vitamin or nutrient deficiencies that do not cause them to feel ill, such as anemia due to iron deficiency or bone loss due to vitamin D deficiency. However, these deficiencies can cause problems over the long term.",
"      </li>",
"      <li>",
"       Untreated celiac disease can increase the risk of developing certain types of gastrointestinal cancer. This risk can be reduced by eating a gluten free diet.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      IMPLICATIONS FOR THE FAMILY",
"     </span>",
"    </p>",
"    <p>",
"     Eliminating gluten requires a major lifestyle change you as well as you family. However, with time and practice, it will be easier to know which foods, medications, supplements, and body care products contain gluten and what alternatives are available. Although eating out can be challenging initially, restaurants have become increasingly interested in serving people with celiac disease by offering a gluten free menu or ingredient substitutions.",
"    </p>",
"    <p>",
"     Families also need to be aware of their increased risk of celiac disease. Thus, your first-degree relatives (parents, brothers, sisters, children) should consider being tested, especially if anyone has signs or symptoms of the condition. Testing is typically done with a blood antibody test, as described above (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Blood tests'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804596630\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142982\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/6/13410?source=see_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/36/25154?source=see_link\">",
"      Patient information: Microscopic colitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/9/25746?source=see_link\">",
"      Patient information: Gluten-free diet (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9142999\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/14/11492?source=see_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=see_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"      Management of celiac disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable information for people living with celiac disease or nonceliac gluten sensitivity.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Academy of Nutrition and Dietetics (formerly American Dietetic Association)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.eatright.org/search.aspx?search=celiac+disease\">",
"      www.eatright.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Celiac Disease Alliance",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.americanceliac.org/\">",
"      www.americanceliac.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/celiac-disease\">",
"      file://www.gastro.org/patient-center/digestive-conditions/celiac-disease",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Celiac Disease Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.celiac.org/\">",
"      www.celiac.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gluten Intolerance Group of North America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.gluten.net/\">",
"      www.gluten.net",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Foundation for Celiac Awareness (NFCA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.celiaccentral.org/\">",
"      www.celiaccentral.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/celiacdisease.html\">",
"      www.nlm.nih.gov/medlineplus/celiacdisease.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       North American Society for the Study of Celiac Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.nasscd.org\">",
"      www.nasscd.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Celiac Disease Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://celiacdisease.about.com/forum\">",
"      file://celiacdisease.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Celiac.com",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.celiac.com/\">",
"      www.celiac.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Celiac List-serv",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Send email message to: celiac@listserv.icors.org",
"      </li>",
"      <li>",
"       Leave the subject line blank",
"      </li>",
"      <li>",
"       Text: type SUB celiac your first name your last name (eg, &ldquo;SUB celiac Joan Smith&rdquo;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?35/31/36339/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/31/36339?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36339/abstract/1\">",
"      Ciclitira PJ, King AL, Fraser JS. AGA technical review on Celiac Sprue. American Gastroenterological Association. Gastroenterology 2001; 120:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36339/abstract/2\">",
"      Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol 2001; 96:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36339/abstract/3\">",
"      Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163:286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f35_31_36339=[""].join("\n");
var outline_f35_31_36339=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CELIAC DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CELIAC DISEASE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CELIAC DISEASE CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CELIAC DISEASE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           CELIAC DISEASE COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           CELIAC DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           IMPLICATIONS FOR THE FAMILY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/14/26859\" title=\"table 1\">",
"           Gluten free foods PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/4/7245\" title=\"table 2\">",
"           Overlooked sources of gluten or potential gluten",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36340="Wound eversion B";
var content_f35_31_36340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Proper technique for wound edge eversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The proper technique for everting the edges of a wound is illustrated in the panels on the left. A) The needle has been inserted at a 90 degree angle. B) The suture loop is as wide at the base as it is at the skin surface. The width and depth of the suture loop are the same on both sides of the wound. In the panels on the right, improper technique has resulted in inversion of the wound edges, which will interfere with wound healing. C) The needle has entered the skin at an angle. D) The base of the wound is narrower than the skin surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36340=[""].join("\n");
var outline_f35_31_36340=null;
var title_f35_31_36341="Azelastine and fluticasone: Drug information";
var content_f35_31_36341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelastine and fluticasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/1/38932?source=see_link\">",
"    see \"Azelastine and fluticasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14970004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dymista&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14264744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Nasal;",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14965008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Intranasal: 1 spray (137 mcg azelastine/50 mcg fluticasone) per nostril twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14965007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14965009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14965024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dymista&trade;: Azelastine hydrochloride 0.1% [137 mcg/spray] and fluticasone propionate 0.037% [50 mcg /spray] (23 g) [contains benzalkonium chloride; 120 metered sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14964798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14965014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intranasal administration only. Prime pump (press 6 times until fine spray appears) prior to first use. If 14 or more days have elapsed since last use, then reprime pump with 1 spray or until a fine mist appears. Shake bottle gently before using. Blow nose to clear nostrils. Keep head tilted downward when spraying. Insert applicator tip",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Alternate sprays between nostrils. After each use, wipe the spray tip with a clean tissue or cloth and replace cap. Avoid spraying directly into nasal septum, eyes or mouth. Discard after 120 medicated sprays have been used, even if bottle is not completely empty.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14264746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of seasonal allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14964860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (&ge;2%), headache (&ge;2%), pain (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abnormal taste (&ge;2% to 4%), diarrhea (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (&ge;2%), epistaxis (&ge;2%), nasal congestion (&ge;2%), pharyngitis (&ge;2%), rhinitis (&ge;2%), upper respiratory tract infection (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Viral infection (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Somnolence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14964820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturers&rsquo; product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14964838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Effects may be additive with CNS depressants and/or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should be used with caution, if at all, in patients with ocular herpes simplex, latent tuberculosis, and/or TB reactivity, or in patients with untreated fungal, viral, or bacterial infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized",
"     <i>",
"      Candida albicans",
"     </i>",
"     infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular disease: Increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts, and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14471002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14471000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Nasal). Management: Consider using an alternative nasal corticosteroid when possible, partiularly for longer-term concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Fluticasone (Nasal). Management: Concurrent use of telaprevir with inhaled fluticasone is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14964898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort: In theory, St John's wort may decrease serum levels of fluticasone by inducing CYP3A3/4 isoenzymes",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14964799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14964800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14964818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14964819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Dymista Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     137-50 mcg/ACT (23 g): $173.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14965016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including Churg-Strauss syndrome)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azeflo (IN);",
"     </li>",
"     <li>",
"      Duonase (IN);",
"     </li>",
"     <li>",
"      Nezalast (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14964901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Azelastine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     receptor sites on effector cells and inhibits the release of histamine and other mediators involved in the allergic response; when used intranasally, reduces hyper-reactivity of the airways; increases the motility of bronchial epithelial cilia, improving mucociliary transport.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14964903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, \"IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-e112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36341/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al, \"Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology,\"",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 1998, 81(5 Pt 2):478-518.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36341/abstract-text/9860027/pubmed\" id=\"9860027\" target=\"_blank\">",
"        9860027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al, \"The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2008, 122(2 Suppl):1-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36341/abstract-text/18662584/pubmed\" id=\"18662584\" target=\"_blank\">",
"        18662584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83881 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36341=[""].join("\n");
var outline_f35_31_36341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14970004\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264744\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965008\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965007\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965009\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673240\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673241\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965024\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964798\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965014\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264746\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964860\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964820\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964838\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471002\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471000\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964898\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964799\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964800\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964818\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964819\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570438\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965016\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721651\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964901\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14964903\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/1/38932?source=related_link\">",
"      Azelastine and fluticasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36342="Baclofen: Drug information";
var content_f35_31_36342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Baclofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/48/41732?source=see_link\">",
"    see \"Baclofen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7878?source=see_link\">",
"    see \"Baclofen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gablofen&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Baclofen&reg;;",
"     </li>",
"     <li>",
"      Ava-Baclofen;",
"     </li>",
"     <li>",
"      Dom-Baclofen;",
"     </li>",
"     <li>",
"      Lioresal&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg; D.S.;",
"     </li>",
"     <li>",
"      Lioresal&reg; Intrathecal;",
"     </li>",
"     <li>",
"      Med-Baclofen;",
"     </li>",
"     <li>",
"      Mylan-Baclofen;",
"     </li>",
"     <li>",
"      Novo-Baclofen;",
"     </li>",
"     <li>",
"      Nu-Baclo;",
"     </li>",
"     <li>",
"      PHL-Baclofen;",
"     </li>",
"     <li>",
"      PMS-Baclofen;",
"     </li>",
"     <li>",
"      ratio-Baclofen;",
"     </li>",
"     <li>",
"      Riva-Baclofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     5 mg 3 times/day, may increase 5 mg/dose every 3 days to a maximum of 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrathecal:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Test dose: 50-100 mcg, doses &gt;50 mcg should be given in 25 mcg increments, separated by 24 hours. A screening dose of 25 mcg may be considered in very small patients. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion/implanted pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: After positive response to test dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump. Initial dose via pump: Infusion at a 24-hourly rate dosed at twice the test dose. Avoid abrupt discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hiccups (unlabeled use):",
"     </b>",
"     Oral: 10-20 mg 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7878?source=see_link\">",
"      see \"Baclofen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (avoid abrupt withdrawal of drug) (unlabeled use):",
"     </i>",
"     Caution: Pediatric dosing expressed as a daily amount, and NOT in mg/kg. Limited published data in children; the following is a compilation of small prospective studies (Albright, 1996; Milla, 1977; Scheinberg, 2006) and one large retrospective study (Lubsch, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 10-20 mg daily divided every 8 hours; titrate dose every 3 days in increments of 5-15 mg/day to a maximum of 40 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-7 years: Initial: 20-30 mg daily divided every 8 hours; titrate dose every 3 days in increments of 5-15 mg/day to a maximum of 60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;8 years: 30-40 mg daily divided every 8 hours; titrate dose every 3 days in increments of 5-15 mg/day to a maximum of 120 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Baclofen dose may need to be increased over time. One retrospective analysis (Lubsch, 2006) suggested that increased doses were needed as the time increased from spasticity onset, as age increased, and as the number of concomitant antispasticity medications increased.  A small number of patients required daily doses exceeding 200 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intrathecal:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity in cerebral palsy (unlabeled use):",
"     </b>",
"     Oral: Initial: 5-10 mg/day in 3 divided doses (Delgado, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (the lowest effective dose is recommended): Initial: 5 mg 2-3 times/day, increasing gradually as needed; if benefits are not seen withdraw the drug slowly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F138903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: No dosage adjustment provided in the manufacturer&rsquo;s labeling. However, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intrathecal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gablofen&reg;: 500 mcg/mL (20 mL); 1000 mcg/mL (20 mL); 2000 mcg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lioresal&reg;: 500 mcg/mL (20 mL); 2000 mcg/mL (5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intrathecal [for screening, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gablofen&reg;: 50 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lioresal&reg;: 50 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablets",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F138878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intrathecal: For screening dosages, administer as a bolus injection (50 mcg/mL concentration) into the subarachnoid space,  followed by maintenance infusion (500-2000 mcg/mL concentration).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F138949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in sterile, preservative-free NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of reversible spasticity associated with multiple sclerosis or spinal cord lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orphan drug:",
"     </b>",
"     Intrathecal: Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal disease (spinal ischemia or tumor, transverse myelitis, cervical spondylosis, degenerative myelopathy)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F138938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intractable hiccups, intractable pain relief, bladder spasticity, trigeminal neuralgia, cerebral palsy, short-term treatment of spasticity in children with cerebral palsy, Huntington's chorea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Baclofen may be confused with Bactroban&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lioresal&reg; may be confused with lisinopril, Lotensin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, vertigo, dizziness, psychiatric disturbances, insomnia, slurred speech, ataxia, hypotonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, confusion, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Chest pain, dyspnea, dysuria, enuresis, hematuria, impotence, inability to ejaculate, nocturia, palpitation, syncope, urinary retention; withdrawal reactions have occurred with abrupt discontinuation (particularly severe with intrathecal use).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to baclofen or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder. Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse CNS effects, especially at higher doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid abrupt withdrawal of the drug; abrupt withdrawal of intrathecal baclofen has resulted in severe sequelae (hyperpyrexia, obtundation, rebound/exaggerated spasticity, muscle rigidity, and rhabdomyolysis), leading to organ failure and some fatalities.",
"     </b>",
"     Risk may be higher in patients with injuries at T-6 or above, history of baclofen withdrawal, or limited ability to communicate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal use: Cases (most from pharmacy compounded preparations) of intrathecal mass formation at the implanted catheter tip have been reported; may lead to loss of clinical response, pain or new/worsening neurological effects. Neurosurgical evaluation and/or an appropriate imaging study should be considered if a mass is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F138894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Withdrawal symptoms in the neonate were noted in a case report following the maternal use of oral baclofen 20 mg 4 times/day throughout pregnancy (Ratnayaka, 2001). Plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited (Morton, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13273273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of baclofen were found in the breast milk of a woman 14 days postpartum after oral use. Following a single oral dose of baclofen 20 mg, the total amount of baclofen excreted in breast milk within 26 hours was 22 mcg (Eriksson, 1981). Adverse events were not observed in a nursing infant following maternal use of intrathecal baclofen 200 mcg/day throughout pregnancy and while nursing (Morton, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F138884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gablofen Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/mL (1 mL): $96.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 mcg/20 mL (20 mL): $258.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 mcg/20 mL (20 mL): $516.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40000 mcg/20 mL (20 mL): $1032.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lioresal Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (1 mL): $84.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/20 mL (20 mL): $258.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (5 mL): $258.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/20 mL (20 mL): $1032.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Baclofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $59.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $108.52",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Baclofen (NZ);",
"     </li>",
"     <li>",
"      Baclan (KP);",
"     </li>",
"     <li>",
"      Baclofen-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Baclofene (FR);",
"     </li>",
"     <li>",
"      Baclon (FI, TW);",
"     </li>",
"     <li>",
"      Baclopar (IE);",
"     </li>",
"     <li>",
"      Baclosal (IL);",
"     </li>",
"     <li>",
"      Baclosan (RU);",
"     </li>",
"     <li>",
"      Bacofen (KP);",
"     </li>",
"     <li>",
"      Bacron (KP);",
"     </li>",
"     <li>",
"      Barapa (KP);",
"     </li>",
"     <li>",
"      Clofen (AU);",
"     </li>",
"     <li>",
"      Colmifen (SG);",
"     </li>",
"     <li>",
"      Curofen (KP);",
"     </li>",
"     <li>",
"      Diafen (UY);",
"     </li>",
"     <li>",
"      Espast (PE);",
"     </li>",
"     <li>",
"      Liobac (TH);",
"     </li>",
"     <li>",
"      Lioresal (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lioresyl (CN);",
"     </li>",
"     <li>",
"      Lyflex (GB, IE);",
"     </li>",
"     <li>",
"      Onelaxant-R (PH);",
"     </li>",
"     <li>",
"      Pacifen (NZ, TW);",
"     </li>",
"     <li>",
"      Prex (KP);",
"     </li>",
"     <li>",
"      Solofen (TW);",
"     </li>",
"     <li>",
"      Spinax (TW);",
"     </li>",
"     <li>",
"      Stelax (AU, HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals, with resultant relief of muscle spasticity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption (dose dependent): Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (15% of dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Within 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (85% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abarbanel J, Herishanu Y, Frisher S, &ldquo;Encephalopathy Associated With Baclofen,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 1985, 17(6):617-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/4026235/pubmed\" id=\"4026235\" target=\"_blank\">",
"        4026235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Albright AL, &ldquo;Baclofen in Treatment of Cerebral Palsy,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 1996, 11(2):77-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/8881981/pubmed\" id=\"8881981\" target=\"_blank\">",
"        8881981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooke DE and Glasstone MA, &ldquo;Baclofen Poisoning in Children,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36(5):448-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/7839572/pubmed\" id=\"7839572\" target=\"_blank\">",
"        7839572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delgado MR, Hirtz D, Aisen M, et al, &ldquo;Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 74(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/20101040/pubmed\" id=\"20101040\" target=\"_blank\">",
"        20101040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson G and Swahn CG, \"Concentrations of Baclofen in Serum and Breast Milk From a Lactating Woman,\"",
"      <i>",
"       Scand J Clin Lab Invest",
"      </i>",
"      , 1981, 41(2):185-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/7313501/pubmed\" id=\"7313501\" target=\"_blank\">",
"        7313501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khorasani A and Peruzzi WT, &ldquo;Dantrolene Treatment for Abrupt Intrathecal Baclofen Withdrawal,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1995, 80(5):1054-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/7726408/pubmed\" id=\"7726408\" target=\"_blank\">",
"        7726408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lubsch L, Habersang R, Haase M, et al, &ldquo;Oral Baclofen and Clonidine for Treatment of Spasticity in Children,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2006, 21(12):1090-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/17156708/pubmed\" id=\"17156708\" target=\"_blank\">",
"        17156708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      May CR, &ldquo;Baclofen Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1983, 12:171-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/6829997/pubmed\" id=\"6829997\" target=\"_blank\">",
"        6829997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milla PJ and Jackson AD, &ldquo;A Controlled Trial of Baclofen in Children With Cerebral Palsy,&rdquo;",
"      <i>",
"       J Int Med Res",
"      </i>",
"      , 1977, 5(6):398-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/338390/pubmed\" id=\"338390\" target=\"_blank\">",
"        338390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morton CM, Rosenow J, Wong C, et al, \"Intrathecal Baclofen Administration During Pregnancy: A Case Series and Focused Clinical Review,\"",
"      <i>",
"       PM R",
"      </i>",
"      , 2009, 1(11):1025-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/19942189/pubmed\" id=\"19942189\" target=\"_blank\">",
"        19942189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ratnayaka BD, Dhaliwal H, and Watkin S, \"Drug Points: Neonatal Convulsions After Withdrawal of Baclofen,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2001, 323(7304):85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/11451783/pubmed\" id=\"11451783\" target=\"_blank\">",
"        11451783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberge RJ, Martin TG, Hodgman M, et al, &ldquo;Supraventricular Tachyarrhythmia Associated With Baclofen Overdose,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1994, 32(3):291-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/8007036/pubmed\" id=\"8007036\" target=\"_blank\">",
"        8007036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheinberg A, Hall K, Lam LT, et al, &ldquo;Ora Baclofen in Children With Cerebral Palsy: A Double-Blind Cross-Over Pilot Study,&rdquo;",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2006, 42(11):715-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/17044900/pubmed\" id=\"17044900\" target=\"_blank\">",
"        17044900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan AK and Tan CB, &ldquo;The Syndrome of Painful Legs and Moving Toes - A Case Report,&rdquo;",
"      <i>",
"       Singapore Med J",
"      </i>",
"      , 1996, 37(4):446-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/31/36342/abstract-text/8993154/pubmed\" id=\"8993154\" target=\"_blank\">",
"        8993154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9062 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36342=[""].join("\n");
var outline_f35_31_36342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708644\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138942\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138901\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138920\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138902\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138903\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682666\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138878\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138949\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138877\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138938\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138951\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138940\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138882\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138865\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138870\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138894\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138905\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273273\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138884\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038536\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138864\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138881\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/48/41732?source=related_link\">",
"      Baclofen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7878?source=related_link\">",
"      Baclofen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36343="Pseudofolliculitis barbae";
var content_f35_31_36343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pseudofolliculitis barbae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36343/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/31/36343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudofolliculitis barbae (pseudofolliculitis of the beard), often colloquially referred to as \"razor bumps,\" \"shave bumps,\" or &ldquo;ingrown hairs,&rdquo; is a common cutaneous condition that develops as a result of the removal of facial hair. Pseudofolliculitis barbae most frequently occurs in association with shaving and results from an inflammatory response to the cutaneous entrapment of recently cut, short hairs.",
"   </p>",
"   <p>",
"    Pseudofolliculitis barbae typically presents with firm papules and pustules in the beard area. The appearance of the disorder can be cosmetically distressing for affected patients. Postinflammatory hyperpigmentation, secondary bacterial infection, scarring, and keloid formation are potential complications.",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, and management of pseudofolliculitis barbae will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015817\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudofolliculitis barbae is most prevalent in black men. Between 45 and 83 percent of black men and 3 percent of white men who shave facial hair develop pseudofolliculitis barbae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Women who remove facial hair also may develop the condition.",
"   </p>",
"   <p>",
"    While the cheeks and neck are the most common sites of pseudofolliculitis, the condition can occur in any hairy area. Individuals who remove hair from sites such as the axilla, pubic area, and legs may develop pseudofolliculitis in these areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings of pseudofolliculitis result from a cutaneous inflammatory reaction against hair that has penetrated the interfollicular skin. This may occur through two mechanisms: extrafollicular and transfollicular penetration of the skin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Extrafollicular penetration",
"      </strong>",
"      &ndash; Extrafollicular penetration describes entry of the distal end of a hair into the interfollicular skin after it has already exited the follicular orifice (",
"      <a class=\"graphic graphic_figure graphicRef87582 \" href=\"mobipreview.htm?29/49/30480\">",
"       figure 1A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"       2",
"      </a>",
"      ]. This occurs when the distal end of a hair comes in contact with the surface of the skin. Shaving contributes to extrafollicular penetration by creating short, sharp-ended hairs that are capable of penetrating the skin.",
"     </li>",
"     <li>",
"      <strong>",
"       Transfollicular penetration",
"      </strong>",
"      &ndash; Transfollicular penetration occurs when the distal end of a hair penetrates the dermis prior to exiting the follicular orifice (",
"      <a class=\"graphic graphic_figure graphicRef87583 \" href=\"mobipreview.htm?12/28/12736\">",
"       figure 1B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"       2",
"      </a>",
"      ]. This event can result from shaving techniques that result in retraction of the cut edge of the hair into the follicle, such as can occur when the skin is stretched during shaving. The use of double-edged or multiple-edged razors also may contribute to transfollicular penetration; the first razor edge pulls the hair upward and the subsequent razor edge cuts the hair, resulting in retraction of the cut hair into the skin after shaving [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After entry into the interfollicular skin, the distal end of the hair may penetrate 2 to 3 mm into the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"     3",
"    </a>",
"    ]. Eventually, continued hair growth leads to the spontaneous release of the embedded distal tip of the hair; this usually occurs within three to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although shaving is commonly associated with pseudofolliculitis barbae, other hair removal techniques (eg, plucking, waxing) may result in the development of this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominance of pseudofolliculitis barbae in black individuals is considered attributable to the prevalence of tightly curled hair in this population. The ends of tightly curled hair have a greater tendency to curve back towards the surface of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, in individuals with tightly curled hair, the hair follicle sits at an oblique angle to the skin, which may contribute to the formation of sharp-tipped hairs during shaving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ]. One study identified a defect in a hair follicle keratin gene (",
"    <em>",
"     K6hf",
"    </em>",
"    ) as a potential additional risk factor for this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory response that develops against hair in the interfollicular epidermis and dermis leads to the formation of firm papules at the site of embedded hairs. The papules may be skin-colored, erythematous, or hyperpigmented (",
"    <a class=\"graphic graphic_picture graphicRef51138 graphicRef63934 \" href=\"mobipreview.htm?19/52/20297\">",
"     picture 1A-B",
"    </a>",
"    ). Loops of hair emerging from the follicular orifice and reentering the skin may be visible on the skin surface (",
"    <a class=\"graphic graphic_picture graphicRef76686 \" href=\"mobipreview.htm?40/57/41874\">",
"     picture 2",
"    </a>",
"    ). Pustules may develop as a result of a sterile, acute inflammatory response to embedded hair or as a manifestation of secondary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of involvement varies widely, from patients with fewer than a dozen papules and pustules to those with more than 100 lesions. The anterior neck, mandible, cheeks, and chin are the most common sites for involvement. The lesions often itch, and scratching can lead to bacterial superinfection. Keloidal scarring may develop at sites of involvement in susceptible patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87492034\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pseudofolliculitis barbae is made based upon the clinical appearance. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical features and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87492248\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsies typically are not necessary for the diagnosis of pseudofolliculitis barbae. If a biopsy is performed, intraepidermal neutrophils, foci of abscess formation in the dermis, and granulomatous inflammation with foreign-body giant cells surrounding the tip of the penetrating hair may be detected on histological examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87492276\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pseudofolliculitis barbae includes other conditions that may result in papules or pustules in areas of terminal hair growth. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bacterial folliculitis",
"      </strong>",
"      &ndash; Bacterial folliculitis usually presents as an acute condition with pustules and erythematous papules as the primary features (",
"      <a class=\"graphic graphic_picture graphicRef62916 \" href=\"mobipreview.htm?11/25/11667\">",
"       picture 3",
"      </a>",
"      ). This contrasts with the chronic course and firm papules characteristic of pseudofolliculitis barbae. Cultures are useful for diagnosing bacterial folliculitis. In pseudofolliculitis barbae, cultures are usually negative or demonstrate normal skin flora in the absence of secondary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2,4,6\">",
"       2,4,6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=see_link\">",
"       \"Folliculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Traumatic folliculitis",
"      </strong>",
"      &ndash; Traumatic folliculitis describes transient inflammation of the hair follicle due to irritation from shaving too closely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients present with perifollicular erythematous papules and excoriations. Unlike pseudofolliculitis barbae, the condition usually subsides rapidly (within a few days) if shaving is discontinued.",
"     </li>",
"     <li>",
"      <strong>",
"       Tinea barbae",
"      </strong>",
"      &ndash; Dermatophyte infections involving the beard area are referred to as tinea barbae. Patients may present with pustules, inflammatory papules and nodules, or scaly erythematous plaques (",
"      <a class=\"graphic graphic_picture graphicRef86999 graphicRef87000 \" href=\"mobipreview.htm?0/12/202\">",
"       picture 4A-B",
"      </a>",
"      ). The detection of fungal forms on a potassium hydroxide preparation confirms the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to the patient with pustular skin lesions\", section on 'Tinea barbae'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acne keloidalis nuchae",
"      </strong>",
"      &ndash; Acne keloidalis nuchae is a hair and scalp disorder that may present with dome-shaped papules, pustules, and keloidal plaques on the occipital scalp (",
"      <a class=\"graphic graphic_picture graphicRef87490 \" href=\"mobipreview.htm?32/9/32921\">",
"       picture 5",
"      </a>",
"      ). The disorder most commonly occurs in young black men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"       3",
"      </a>",
"      ]. The location of acne keloidalis on the scalp distinguishes this condition from pseudofolliculitis barbae.",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous sarcoidosis",
"      </strong>",
"      &ndash; Cutaneous sarcoidosis may present with a variety of manifestations, including firm papules or plaques that may be skin-colored, yellow-brown, red-brown, violaceous, or hypopigmented (",
"      <a class=\"graphic graphic_picture graphicRef73271 graphicRef69405 \" href=\"mobipreview.htm?27/28/28104\">",
"       picture 6A-B",
"      </a>",
"      ). Like pseudofolliculitis, sarcoidosis occurs at increased frequency in black patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/7\">",
"       7",
"      </a>",
"      ]. Unlike pseudofolliculitis barbae, embedded hairs are not a feature of cutaneous sarcoidosis, and lesions may be seen outside of the beard area. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=see_link&amp;anchor=H18191778#H18191778\">",
"       \"Cutaneous manifestations of sarcoidosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015801\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the clinical manifestations of pseudofolliculitis are a consequence of the entry of hair into the interfollicular skin, the primary approach to therapy consists of measures to prevent this occurrence. Few randomized trials have evaluated interventions for pseudofolliculitis barbae, and the approach to patient management primarily is guided by clinical experience.",
"   </p>",
"   <p>",
"    The most effective and safe intervention for the treatment of pseudofolliculitis barbae is the permanent discontinuation of shaving or other hair removal practices that have induced the condition. Patients who are able to do this usually notice significant clinical improvement within a few months. (See",
"    <a class=\"local\" href=\"#H1015941\">",
"     'Cessation of shaving'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, occupational requirements, cultural values, and individual preferences prevent many patients from discontinuing hair removal indefinitely. When feasible, we encourage these patients to discontinue shaving until the condition improves (usually one to six months). Following this, changes in hair removal practices to methods that may reduce the risk for recurrent pseudofolliculitis can be implemented. Patients who are unable to discontinue hair removal for this transient period can implement such measures immediately. (See",
"    <a class=\"local\" href=\"#H89240656\">",
"     'Alternative hair removal techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laser hair removal is an effective treatment option for pseudofolliculitis barbae that works by reducing the density and thickness of hair in treated areas. Patients who are willing to have long-term reduction in the density of hair can attain improvement with this intervention. (See",
"    <a class=\"local\" href=\"#H1015976\">",
"     'Laser hair removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Topical treatments, such as topical retinoids, low potency topical corticosteroids, topical antimicrobials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    , and alpha-hydroxy acids, are often used as adjunctive therapy in an attempt to accelerate improvement and reduce the signs and symptoms of pseudofolliculitis barbae. However, data on the efficacy of these therapies are limited. (See",
"    <a class=\"local\" href=\"#H87492315\">",
"     'Adjunctive medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176530633\">",
"    <span class=\"h2\">",
"     Preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major methods for inhibiting the development of pseudofolliculitis barbae are the cessation of shaving, the altering of hair removal practices, and long-term hair reduction with laser therapy. Although the cessation of shaving and long-term hair reduction can lead to the resolution of pseudofolliculitis barbae, the benefit attained from altered hair removal practices is usually limited to improved control of the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015941\">",
"    <span class=\"h3\">",
"     Cessation of shaving",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuing shaving, hair waxing, and hair plucking, and allowing the hair to remain at a length that makes penetration of the skin unlikely is the treatment of choice for pseudofolliculitis barbae. Patients may continue to groom the beard with scissors or an electric clipper. We suggest initially trimming the hair to a length of no less than 0.5 cm. If the patient desires, trials of shorter trim lengths can be performed after the patient attains lesion clearance.",
"   </p>",
"   <p>",
"    Patients should be cautioned that pseudofolliculitis may continue to progress during the first few weeks after the discontinuation of shaving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This occurs due to the continued embedding of previously shaved hairs in the skin. In the interim, the distal tips of visible embedded hairs may be carefully dislodged by the patient with a toothpick, though hair should not be plucked from the follicle because doing so may cause additional irritation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"     3",
"    </a>",
"    ]. A low potency topical corticosteroid, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    2.5% cream, can be applied twice daily to inflamed lesions for up to three to four weeks. If secondary infection is present, the patient should be given appropriate antibiotic therapy.",
"   </p>",
"   <p>",
"    Depending on the severity of the condition, marked improvement in papules and pustules is usually noted within one to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ]. Associated hyperpigmentation may take several months or longer to resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89240656\">",
"    <span class=\"h3\">",
"     Alternative hair removal techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not want to maintain a beard should attempt to incorporate hair removal methods that may reduce penetration of the interfollicular skin by the hair shaft. As noted above, we prefer to do this after improvement has been attained during an initial period of beard growth (see",
"    <a class=\"local\" href=\"#H1015801\">",
"     'Approach to therapy'",
"    </a>",
"    above). Patients who decline to discontinue hair removal for several weeks to a few months may try these methods as initial treatment.",
"   </p>",
"   <p>",
"    Adjustments to the patient&rsquo;s shaving routine or the use of electric clippers or chemical depilatories instead of razors may be attempted. The choice of intervention is influenced by patient preference. If a particular intervention does not yield favorable results, one of the other approaches may be implemented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1016168\">",
"    <span class=\"h4\">",
"     Adjustments to shaving routine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustments to the shaving routine that may be useful for patients with pseudofolliculitis barbae who desire to continue shaving include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"       application",
"      </strong>",
"      <strong>",
"       of generous amounts of a highly lubricating shaving cream or gel for 5 to 10 minutes",
"      </strong>",
"      prior to shaving softens the hair and may help to reduce the formation of sharp hair tips during shaving. The application of",
"      <strong>",
"       warm compresses",
"      </strong>",
"      prior to shaving may also be used to achieve this goal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of a",
"      <strong>",
"       single blade razor",
"      </strong>",
"      rather than a double-bladed or multiple-bladed razor may help to reduce the production of very short cut hairs that subsequently become embedded in the interfollicular skin. In addition,",
"      <strong>",
"       shaving should be performed only in the direction of hair growth",
"      </strong>",
"      . Specialized razors that use a guard system to prevent a very close shave (eg, Bump Fighter razor) may also be helpful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/8\">",
"       8",
"      </a>",
"      ].",
"      <strong>",
"       Stretching of the skin during shaving should be avoided.",
"      </strong>",
"     </li>",
"     <li>",
"      Gentle",
"      <strong>",
"       washing of the beard area in a circular motion with a mildly abrasive cloth or sponge for a few minutes daily",
"      </strong>",
"      may help to free embedded hairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"       2",
"      </a>",
"      ]. Some authors have advocated using a magnifying mirror to identify embedded hairs, after which the embedded distal tips can be dislodged with a toothpick or sterile needle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2,9\">",
"       2,9",
"      </a>",
"      ].",
"      <strong>",
"       Plucking of hairs from the follicle should be avoided",
"      </strong>",
"      , since this may lead to follicular inflammation and the subsequent growth of hair that penetrates the follicular wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015962\">",
"    <span class=\"h4\">",
"     Electric clippers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electric clippers can be used to shave hair in a manner that leaves the remaining hair at a greater length than razor shaves. Patients should be encouraged to leave the remaining hair at a length of at least 1 mm to reduce the risk of lesion recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015969\">",
"    <span class=\"h4\">",
"     Depilatories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with pseudofolliculitis barbae improve with the replacement of shaving by the use of depilatories, which contain substances such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfide or calcium thioglycolate and remove hair by inducing the lysis of disulfide bonds in hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/4\">",
"     4",
"    </a>",
"    ]. Hair removal with depilatories tends to leave the distal ends of hairs with soft, brush-like tips rather than the sharp tips produced by shaving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Chemical depilatories are usually applied to the skin for several minutes. Long hair in the treatment area should be clipped prior to use.",
"   </p>",
"   <p>",
"    Irritation is a potential side effect of depilatories, and some patients are unable to tolerate these products on facial skin. Patients should test the product on a nonfacial area and follow the site for irritation for 48 hours prior to facial use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"     3",
"    </a>",
"    ]. If significant irritation occurs, the product should not be used. For patients who use depilatories, limiting the frequency of use to every other day or less may help to minimize irritation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1016209\">",
"    <span class=\"h3\">",
"     Long-term hair reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because pseudofolliculitis barbae occurs only in areas of hair regrowth, the destruction of hair follicles can lead to improvement in the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Laser hair removal is the preferred method for hair reduction in patients with pseudofolliculitis barbae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015976\">",
"    <span class=\"h4\">",
"     Laser hair removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser hair removal works through selective destruction of hair follicles, and results in a reduction in the density and thickness of hair. Multiple treatment sessions are usually required to achieve a major reduction in hair growth because only a minority of hair follicles are destroyed during each treatment. Since melanin is the follicular component targeted by hair removal lasers, patients with darkly pigmented hairs are the best candidates for this procedure. The treatment is poorly effective for white or gray hairs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=see_link&amp;anchor=H2286670#H2286670\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Large versus small structures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=see_link&amp;anchor=H11#H11\">",
"     \"Removal of unwanted hair\", section on 'Laser and intense pulsed light'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple lasers have demonstrated benefit for the treatment of pseudofolliculitis barbae, including long-pulsed neodymium:yttrium-aluminum-garnet (Nd:YAG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/10-14\">",
"     10-14",
"    </a>",
"    ], diode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], alexandrite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/18\">",
"     18",
"    </a>",
"    ], and ruby [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/19\">",
"     19",
"    </a>",
"    ] lasers. As an example, in an open study in which 37 men with primarily mild pseudofolliculitis barbae had a 15 x 15 mm area in the submental region treated with one session with a long-pulsed Nd:YAG laser, examination 90 days after treatment revealed that mean papule counts were significantly lower in the treated sites than in adjacent control sites (1.0 &plusmn; 1.36 versus 6.9 &plusmn; 5.25, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    (an inhibitor of hair growth) as an adjunct to laser therapy was investigated in a split-face randomized trial of 27 men with pseudofolliculitis barbae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/11\">",
"     11",
"    </a>",
"    ]. In the trial, men were treated with a long-pulsed Nd:YAG laser every 4 weeks for 16 weeks. In addition, the patients applied eflornithine 13.9% cream to one side of the face and a placebo cream to the other side of the face twice daily. Throughout the study, the median percentage reduction in hair was significantly greater on the side of the face treated with eflornithine than on the side of the face treated with the placebo cream (99.5 versus 85.0 percent at 16 weeks). Although significantly greater improvement in papular lesions was also noted on the side of the face treated with eflornithine at every study time point, excellent results were attained in both groups and the clinical difference in improvement in papular lesions was negligible after 16 weeks. Studies with longer follow-up are necessary to determine the role of eflornithine in the management of pseudofolliculitis barbae. (See",
"    <a class=\"local\" href=\"#H87492315\">",
"     'Adjunctive medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential risks of laser hair removal include transient or permanent pigmentary changes, blistering, and scarring. The risk for pigmentary abnormalities is greatest in individuals with dark skin. Performing a test spot in an inconspicuous area may reduce the risk for side effects by allowing the clinician to adjust laser settings appropriately prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1015984\">",
"    <span class=\"h4\">",
"     Electrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrolysis of beard hairs is generally not recommended for pseudofolliculitis barbae since it is painful, tedious, and often unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ]. Exacerbation of pseudofolliculitis barbae is also a concern because failure of the electrolysis needle to reach the hair bulb of a curved hair follicle theoretically could result in an increased risk for subsequent transfollicular penetration during regrowth (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"     2",
"    </a>",
"    ]. Hyperpigmentation at sites of needle insertion and scarring are additional potential adverse effects of electrolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=see_link&amp;anchor=H12#H12\">",
"     \"Removal of unwanted hair\", section on 'Electrolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87492315\">",
"    <span class=\"h2\">",
"     Adjunctive medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the efficacy of medical therapies for pseudofolliculitis barbae. The most common medical therapies utilized for pseudofolliculitis barbae are topical retinoids, low potency topical corticosteroids, and topical antimicrobials (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    ). Further studies are necessary to clarify the efficacy of these and other agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical retinoids",
"      </strong>",
"      &ndash; The rationale for the use of topical retinoids in pseudofolliculitis is uncertain; some authors have postulated that retinoids may improve follicular hyperkeratosis that might contribute to the development of the condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/6\">",
"       6",
"      </a>",
"      ]. Two small uncontrolled studies have documented clinical improvement in patients treated with daily application of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      for several weeks, one of which involved the use of tretinoin in combination with a low potency topical corticosteroid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/6,20\">",
"       6,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Topical corticosteroids",
"      </strong>",
"      &ndash; In addition to use in combination with topical retinoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], low potency topical corticosteroids have been used to treat inflamed lesions (see",
"      <a class=\"local\" href=\"#H1015941\">",
"       'Cessation of shaving'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"       3",
"      </a>",
"      ]. Due to the potential for adverse effects on the skin, the treatment course is usually limited to less than three to four weeks on a particular area. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"       \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Topical antimicrobials",
"      </strong>",
"      &ndash; Since pseudofolliculitis barbae is not an infectious condition, authors have disagreed on the indications for antimicrobial therapy. While some authors have primarily limited use to the setting of secondary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3,9\">",
"       3,9",
"      </a>",
"      ], others have used these agents more routinely based upon the idea that antibiotics may reduce skin flora that may aggravate inflammation or lead to secondary infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2,9,22\">",
"       2,9,22",
"      </a>",
"      ]. One 10-week, randomized trial comparing the efficacy of a gel containing 5%",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      and 1%",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      to a vehicle gel in men using a specialized razor (Bump Fighter razor) for pseudofolliculitis barbae found that the reduction in lesion counts was significantly greater in the active treatment group than in the placebo group at two, four, or six weeks after treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/23\">",
"       23",
"      </a>",
"      ]. However, the difference between the groups was no longer statistically significant at week 10.",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"       eflornithine",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Eflornithine is a topical agent used most commonly for the treatment of unwanted facial hair. The drug slows hair growth by inhibiting ornithine decarboxylase. Although the use of this agent has been advocated by some authors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3,21,24\">",
"       3,21,24",
"      </a>",
"      ], study data on the efficacy of eflornithine specifically for pseudofolliculitis barbae are limited to a randomized trial in which eflornithine was administered in combination with laser therapy. (See",
"      <a class=\"local\" href=\"#H1015976\">",
"       'Laser hair removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha hydroxy acids",
"      </strong>",
"      &ndash; Topical glycolic acid therapy was associated with significantly greater reduction in papules and pustules associated with pseudofolliculitis barbae in two small split-face placebo-controlled randomized trials published by the same investigator [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/25\">",
"       25",
"      </a>",
"      ]. In the first trial (n = 20), the average number of lesions on the side of the face treated with a topical 8% glycolic acid lotion decreased from 27 to 4 after eight weeks, compared with a reduction from 29 to 22 lesions on the placebo-treated side. In the other trial (n = 15), the average number of lesions on the side of the face treated with 8% glycolic acid in a nonlipid soap fell from 32 to 7, compared with a fall from 35 to 21 papules on the placebo-treated side of the face.",
"      <br/>",
"      <br/>",
"      The rationale for a beneficial response to glycolic acid is uncertain. The author postulated that an effect of glycolic acid on sulfhydryl bonds in the hair shaft could contribute to the growth of straighter hair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/25\">",
"       25",
"      </a>",
"      ]. Additional studies would be useful for confirming the efficacy of glycolic acid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our opinion, the approach to the treatment of pseudofolliculitis barbae should focus heavily on preventive measures (see",
"    <a class=\"local\" href=\"#H176530633\">",
"     'Preventive measures'",
"    </a>",
"    above). The medical therapies reviewed here represent generally well-tolerated options for adjunctive treatment that can be tried to achieve additional benefit.",
"   </p>",
"   <p>",
"    Hyperpigmentation commonly occurs in sites of pseudofolliculitis barbae. Topical treatments such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , kojic acid, and chemical peels can be helpful for accelerating improvement in the hyperpigmentation associated with this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36343/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865943\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudofolliculitis barbae is a common disorder that occurs as a result of hair removal in the beard area. The distal ends of regrowing hairs penetrate the interfollicular skin and elicit an inflammatory reaction (",
"      <a class=\"graphic graphic_figure graphicRef87582 graphicRef87583 \" href=\"mobipreview.htm?19/10/19621\">",
"       figure 1A-B",
"      </a>",
"      ). Shaving is a common cause of pseudofolliculitis barbae. Waxing or plucking hairs also may lead to this condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with tightly curled hair, such as is prevalent in the black population, are most susceptible to pseudofolliculitis barbae. (See",
"      <a class=\"local\" href=\"#H1015817\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with pseudofolliculitis barbae typically present with multiple inflammatory papules and pustules in areas of hair removal (",
"      <a class=\"graphic graphic_picture graphicRef51138 graphicRef63934 \" href=\"mobipreview.htm?19/52/20297\">",
"       picture 1A-B",
"      </a>",
"      ). Close examination of the affected areas may reveal loops of hair exiting and reentering the skin (",
"      <a class=\"graphic graphic_picture graphicRef76686 \" href=\"mobipreview.htm?40/57/41874\">",
"       picture 2",
"      </a>",
"      ). Postinflammatory hyperpigmentation may be prominent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pseudofolliculitis barbae, we suggest discontinuation of shaving or other causative methods of hair removal as first-line treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Discontinuation of shaving often leads to improvement in pseudofolliculitis barbae within a few months. Some degree of improvement in pseudofolliculitis may also be obtained by changing shaving techniques and engaging in alternative hair removal methods. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are willing to undergo laser hair removal can achieve improvement in pseudofolliculitis barbae with this therapy. Electrolysis is not recommended for the treatment of pseudofolliculitis barbae. (See",
"      <a class=\"local\" href=\"#H1016209\">",
"       'Long-term hair reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive medical therapies, such as topical retinoids, low potency topical corticosteroids, topical antimicrobials,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"       eflornithine",
"      </a>",
"      hydrochloride, and alpha-hydroxy acids (eg, glycolic acid) have been used for patients with pseudofolliculitis barbae. Although evidence for the efficacy of these agents is limited, they may be useful as adjunctive therapy. (See",
"      <a class=\"local\" href=\"#H87492315\">",
"       'Adjunctive medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/1\">",
"      Coquilla BH, Lewis CW. Management of pseudofolliculitis barbae. Mil Med 1995; 160:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/2\">",
"      Perry PK, Cook-Bolden FE, Rahman Z, et al. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol 2002; 46:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/3\">",
"      Kelly AP. Pseudofolliculitis barbae and acne keloidalis nuchae. Dermatol Clin 2003; 21:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/4\">",
"      KLIGMAN AM, STRAUSS JS. Pseudofolliculitis of the beard. AMA Arch Derm 1956; 74:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/5\">",
"      Winter H, Schissel D, Parry DA, et al. An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J Invest Dermatol 2004; 122:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/6\">",
"      Kligman AM, Mills OH Jr. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Dermatol 1973; 107:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/7\">",
"      Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/8\">",
"      Alexander AM. Evaluation of a foil-guarded shaver in the management of pseudofolliculitis barbae. Cutis 1981; 27:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/9\">",
"      Quarles FN, Brody H, Johnson BA, et al. Pseudofolliculitis barbae. Dermatol Ther 2007; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/10\">",
"      Ross EV, Cooke LM, Timko AL, et al. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol 2002; 47:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/11\">",
"      Xia Y, Cho S, Howard RS, Maggio KL. Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. J Am Acad Dermatol 2012; 67:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/12\">",
"      Schulze R, Meehan KJ, Lopez A, et al. Low-fluence 1,064-nm laser hair reduction for pseudofolliculitis barbae in skin types IV, V, and VI. Dermatol Surg 2009; 35:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/13\">",
"      Weaver SM 3rd, Sagaral EC. Treatment of pseudofolliculitis barbae using the long-pulse Nd:YAG laser on skin types V and VI. Dermatol Surg 2003; 29:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/14\">",
"      Ross EV, Cooke LM, Overstreet KA, et al. Treatment of pseudofolliculitis barbae in very dark skin with a long pulse Nd:YAG laser. J Natl Med Assoc 2002; 94:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/15\">",
"      Smith EP, Winstanley D, Ross EV. Modified superlong pulse 810 nm diode laser in the treatment of pseudofolliculitis barbae in skin types V and VI. Dermatol Surg 2005; 31:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/16\">",
"      Yamauchi PS, Kelly AP, Lask GP. Treatment of pseudofolliculitis barbae with the diode laser. J Cutan Laser Ther 1999; 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/17\">",
"      Kauvar AN. Treatment of pseudofolliculitis with a pulsed infrared laser. Arch Dermatol 2000; 136:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/18\">",
"      Leheta TM. Comparative evaluation of long pulse Alexandrite laser and intense pulsed light systems for pseudofolliculitis barbae treatment with one year of follow up. Indian J Dermatol 2009; 54:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/19\">",
"      Chui CT, Berger TG, Price VH, Zachary CB. Recalcitrant scarring follicular disorders treated by laser-assisted hair removal: a preliminary report. Dermatol Surg 1999; 25:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/20\">",
"      Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol 1998; 39:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/21\">",
"      Bridgeman-Shah S. The medical and surgical therapy of pseudofolliculitis barbae. Dermatol Ther 2004; 17:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/22\">",
"      Chu T. Pseudofolliculitis barbae. Practitioner 1989; 233:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/23\">",
"      Cook-Bolden FE, Barba A, Halder R, Taylor S. Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae. Cutis 2004; 73:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/24\">",
"      Garcia-Zuazaga J. Pseudofolliculitis barbae: review and update on new treatment modalities. Mil Med 2003; 168:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36343/abstract/25\">",
"      Perricone NV. Treatment of pseudofolliculitis barbae with topical glycolic acid: a report of two studies. Cutis 1993; 52:232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3323 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36343=[""].join("\n");
var outline_f35_31_36343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H865943\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1015817\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87492034\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87492248\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87492276\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1015801\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176530633\">",
"      Preventive measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1015941\">",
"      - Cessation of shaving",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89240656\">",
"      - Alternative hair removal techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1016168\">",
"      Adjustments to shaving routine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1015962\">",
"      Electric clippers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1015969\">",
"      Depilatories",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1016209\">",
"      - Long-term hair reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1015976\">",
"      Laser hair removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1015984\">",
"      Electrolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87492315\">",
"      Adjunctive medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865943\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/3323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3323|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/49/30480\" title=\"figure 1A\">",
"      Extrafollicular penetration in pseudofolliculitis barbae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/28/12736\" title=\"figure 1B\">",
"      Transfollicular penetration in pseudofolliculitis barbae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3323|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/62/21475\" title=\"picture 1A\">",
"      Pseudofolliculitis barbae - chin and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/58/2982\" title=\"picture 1B\">",
"      Pseudofolliculitis barbae - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/57/41874\" title=\"picture 2\">",
"      Pseudofolliculitis barbae - hair loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/25/11667\" title=\"picture 3\">",
"      Scalp folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/62/23526\" title=\"picture 4A\">",
"      Tinea barbae 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/16/3333\" title=\"picture 4B\">",
"      Tinea barbae 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/9/32921\" title=\"picture 5\">",
"      Acne keloidalis nuchae on posterior scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/62/19426\" title=\"picture 6A\">",
"      Sarcoidosis resembling lichen nitidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/31/32244\" title=\"picture 6B\">",
"      Sarcoidosis - facial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/20/19786?source=related_link\">",
"      Cutaneous manifestations of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37014?source=related_link\">",
"      Removal of unwanted hair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36344="Treatment of respiratory infections in pregnant women";
var content_f35_31_36344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of respiratory infections in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Lucia Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Raymond Powrie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36344/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/31/36344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features, diagnosis, and management of respiratory infection are generally similar in pregnant and nonpregnant patients. However, some additional factors need to be considered in pregnancy, including changes in susceptibility to infection, changes in maternal physiology, and the effect of the infection and its treatment on the fetus.",
"   </p>",
"   <p>",
"    This topic review will discuss issues specific to respiratory infections in the setting of pregnancy. Clinical manifestations, diagnosis, and management of respiratory infections in the general population are reviewed separately. (See individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awareness of pregnancy-associated changes in respiratory physiology is important to the management of respiratory disease in pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef59101 \" href=\"mobipreview.htm?36/24/37261\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80850 \" href=\"mobipreview.htm?17/37/18015\">",
"     figure 2",
"    </a>",
"    ). Such changes allow the pregnant woman to meet the metabolic needs of her fetus and are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important points to consider when evaluating pregnant women with respiratory illness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although pregnant women often experience dyspnea, tachypnea is not normal. The respiratory system adapts to increased needs largely by an increase in tidal volume without an increase in respiratory rate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link\">",
"       \"Respiratory tract changes during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy is a state of mild respiratory alkalosis related to alveolar hyperventilation. Normal third trimester arterial blood gas levels are approximately pH 7.39 to 7.45, PC0",
"      <sub>",
"       2",
"      </sub>",
"      25 to 33 mmHg, PO",
"      <sub>",
"       2",
"      </sub>",
"      92 to 107 mmHg, and bicarbonate 16 to 22",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14454?source=see_link\">",
"       \"Normal reference ranges for laboratory values in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women have less buffering capacity to an acidotic insult, a 10 to 25 percent decrease in functional residual capacity (FRC), and increased oxygen consumption. As a result, an apneic pregnant woman will develop hypoxia and acidosis more quickly than a nonpregnant woman. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link\">",
"       \"Respiratory tract changes during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women are prone to acute pulmonary edema related to pre-existing conditions (eg, cardiovascular disease), pregnancy complications (eg,",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia,",
"      </span>",
"      peripartum cardiomyopathy, multiple gestation, amniotic fluid embolism, pyelonephritis), drugs for treatment of preterm labor (eg, beta-adrenergic tocolytic agents,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      , corticosteroids), and iatrogenic intravenous volume overload [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnant women are prone to aspiration pneumonia because of decreased lower esophageal sphincter tone and increased intraabdominal pressure associated with the gravid state. The risk is highest during labor and delivery due to the effects of sedation,",
"      <span class=\"nowrap\">",
"       analgesia/anesthesia,",
"      </span>",
"      and recumbency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37032?source=see_link\">",
"       \"Acute respiratory failure during pregnancy and the peripartum period\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Theoretically, pregnancy-related alterations in cell mediated immunity may increase the risk of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11616732\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to caring for pregnant women with respiratory illness is to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the appropriate clinical evaluation and treatment. The initial approach to evaluating a pregnant woman with respiratory illness is similar to that of a nonpregnant patient and includes a complete history, physical examination, and differential diagnosis. Tachycardia, tachypnea, and decreased oxygen saturation are not normal physiologic changes in pregnancy, thus the presence of these, or other abnormal lung findings such as rales or other signs of consolidation, are indicative of an underlying disease process that requires further investigation.",
"     </li>",
"     <li>",
"      Determine whether implementing this diagnostic and therapeutic plan carries any additional risks for the pregnant patient or fetus. These additional risks may be related to increased maternal susceptibility to severe disease or complications in pregnancy (eg, influenza)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to potential fetal risks related to the disease, its evaluation, or its treatment (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      may stain developing teeth). If so, are there alternative investigations or treatments that reduce or eliminate these risks? What are the risks in not implementing this plan in the pregnant patient?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SELECTED DISORDERS AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The common cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in nonpregnant patients, symptoms related to the common cold are usually mild and self-limited, and generally do not require or respond well to intervention. However, many pregnant women with the common cold will seek advice and symptomatic therapy from their clinician. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/55/24440?source=see_link\">",
"     \"The common cold in adults: Diagnosis and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link\">",
"     \"The common cold in adults: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with the common cold can be reassured that their symptoms will generally resolve within 10 days, although the cough may linger longer. Drug therapy may relieve some symptoms; however, treatment does not shorten the duration of symptoms and the risks of drug therapy for the common cold in pregnancy have not been studied in randomized trials. If the patient still seeks symptomatic relief after being informed of the self-limited nature of the illness, the limited efficacy of all available treatments, and the absence of strong evidence of safety, she should be steered towards those agents with the best evidence of no harm to the fetus. Data about the safety and efficacy of several drugs used to treat the common cold are provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef62846 graphicRef75622 graphicRef51533 graphicRef77865 \" href=\"mobipreview.htm?15/54/16239\">",
"     table 1A-D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, use of heated humidified air for congestion and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for sore throat and headache offer the best balance of safety and efficacy. If fever is present, it is reasonable to suggest use of acetaminophen as an antipyretic. A case control study reported an association between use of acetaminophen and decreased risk of some congenital abnormalities related to maternal hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/3\">",
"     3",
"    </a>",
"    ]. Limited data from a study in rats and two epidemiologic studies in humans did not show an increased risk of teratogenesis from maternal use of throat lozenges made from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26802?source=see_link\">",
"     cetylpyridinium",
"    </a>",
"    chloride (eg, Cepacol); no data are available on the teratogenic risk of most other over-the-counter agents for relief of cold symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/4\">",
"     4",
"    </a>",
"    ]. For anesthetic sprays, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is US FDA pregnancy category B and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    is US FDA pregnancy category C.",
"   </p>",
"   <p>",
"    For patients with severe rhinorrhea,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide nasal spray (US FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    )) is an option; animal studies have not observed teratogenic effects, but there are no human data. The 0.06 percent ipratropium bromide nasal spray is typically administered as two 42 mcg sprays to each nostril three to four times a day. Other options for patients with severe cold symptoms include intranasal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    (US FDA pregnancy category B) or cough suppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    (US FDA pregnancy category C for both). Inhaled cromolyn preparations may cause transient bronchospasm, throat irritation, and cough; caution is warranted in asthmatics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H3#H3\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Ipratropium bromide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H4#H4\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Cromolyn sodium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H6#H6\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Antitussives'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H7#H7\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Expectorants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotics are not indicated for treatment of the common cold, except in the small subset of patients (less than 2 percent) with evidence of secondary bacterial sinus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Sinusitis'",
"    </a>",
"    below.) The pregnant state does not change the usual standards for administering or withholding antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link&amp;anchor=H17#H17\">",
"     \"The common cold in adults: Treatment and prevention\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11799327\">",
"    <span class=\"h2\">",
"     Bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bronchitis is characterized by self-limited inflammation of the bronchi, which is clinically expressed as cough, usually with sputum production. Acute bronchitis cannot be distinguished from the common cold in the first few days of illness, but acute bronchitis should be considered when cough persists for more than five days. The absence of abnormalities on chest radiography distinguishes acute bronchitis from pneumonitis. Febrile patients are more likely to have influenza or pneumonia than bronchitis or the common cold. A chest x-ray should generally be performed when there are findings suggestive of pneumonia, such as tachypnea, tachycardia, hypoxia, fever, rales, or evidence of consolidation on exam. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchitis is caused by a virus in approximately 90 percent of cases. Etiologic agents include influenza A and B, parainfluenza virus 3, coronavirus, adenovirus, metapneumovirus, rhinovirus, and respiratory syncytial virus. Purulent sputum is reported in 50 percent of patients with acute bronchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/6\">",
"     6",
"    </a>",
"    ]. This usually represents sloughing of cells from the tracheobronchial epithelium, along with inflammatory cells. Purulence and sputum discoloration do",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;signify bacterial infection. Occasional patients have acute bronchitis caused by M. pneumoniae, C. pneumoniae or, increasingly, Bordetella pertussis. These etiologies should be suspected in patients with prolonged cough, even in the absence of the classic posttussive emesis, cough paroxysms, or inspiratory whoop seen in children with pertussis. In general, testing or empiric treatment for these pathogens is not recommended unless there is evidence of a local outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic treatment is the same as for the common cold (see",
"    <a class=\"local\" href=\"#H6\">",
"     'The common cold'",
"    </a>",
"    above). Antibiotic therapy of viral bronchitis is not beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/8\">",
"     8",
"    </a>",
"    ]. Some patients experience symptomatic relief from cough with use of a steam humidifier. Since cough suppressants are not generally useful for treatment of the cough associated with bronchitis, pregnant women should be discouraged from using such agents. Supportive care and reassurance are the preferred treatment measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with the common cold are at increased risk of developing sinusitis and Eustachian tube dysfunction, which has been attributed to congestion from hormonal effects on the nasal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/9\">",
"     9",
"    </a>",
"    ]. However, many gravidas with documented sinusitis do not have classic historical and physical findings, which include nasal congestion, purulent nasal discharge, maxillary tooth discomfort, hyposmia, and facial pain or pressure that is worse when bending forward [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/10\">",
"     10",
"    </a>",
"    ]. Despite the increased risk and the increased likelihood of atypical presentations, there are no distinct recommendations for distinguishing the common cold from bacterial rhinosinusitis in pregnant women. Therefore, we recommend following the Infectious Disease Society of America (IDSA) recommendations for the adult nonpregnant population when deciding whether a pregnant patient has bacterial sinusitis. Patients with rhinosinusitis with any of the following characteristics should generally be given antibiotics: (1) persistent symptoms for 10 days without improvement; (2) severe symptoms or temperature &gt;39 degrees Celsius for at least three to four days; or (3) worsening symptoms after five to six days of improving symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When indicated for the evaluation of refractory sinusitis symptoms, sinus imaging (with appropriate pelvic shielding) should be performed during pregnancy. As an example, imaging studies are indicated in patients with clinical signs or symptoms of complicated acute bacterial rhinosinusitis, including diminished visual acuity, diplopia, periorbital edema, severe headache, or altered mental status. If imaging is necessary, sinus radiographs are usually obtained initially in order to avoid the higher doses of radiation associated with computed tomography (CT). CT and magnetic resonance imaging (MRI) are usually reserved for complicated cases. Ultrasonography is not a good substitute because of variable performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in nonpregnant individuals, antibiotics for acute bacterial sinusitis are directed against the most likely pathogens, including H. influenzae, M. catarrhalis, and S. pneumoniae.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    clavulanate (either 500",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg orally three times per day or 875",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg orally twice a day) is the preferred agent for treatment of acute bacterial sinusitis in patients who are not allergic to penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/13\">",
"     13",
"    </a>",
"    ]. While increasing rates of macrolide resistant S. pneumoniae are reported,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    remains the preferred agent for pregnant women with bacterial sinusitis who are penicillin allergic since fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    are generally",
"    <strong>",
"     avoided in pregnancy",
"    </strong>",
"    because of potential effects on fetal cartilage, bones, and teeth.",
"   </p>",
"   <p>",
"    Acceptable adjunct treatments in pregnancy include saline nasal spray or buffered saline nasal irrigation, and steroid nasal sprays (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) for patients who cannot tolerate ongoing nasal congestion and pain while awaiting resolution of the infection with antibiotic therapy. Oral and topical nasal decongestants, antihistamines, and mucolytics do not appear to have a role in the symptomatic relief of acute bacterial sinusitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=see_link&amp;anchor=H12#H12\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Glucocorticoid nasal sprays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influenza pandemics of 1918, 1957, and 2009 were associated with increased morbidity and mortality in pregnant women. Because of the potential seriousness of influenza infection in pregnancy, and the safety of immunization, universal vaccination of pregnant women across gestation is recommended by the American College of Obstetricians and Gynecologists (ACOG) and the United States Centers for Disease Control and Prevention (CDC). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunizations during pregnancy\", section on 'Influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course of influenza in pregnancy, as well as various approaches to its prevention and treatment, is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=see_link\">",
"     \"Influenza and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pneumonia in pregnancy appears to be similar to that in nonpregnant patients, with reported incidences varying from 0.2 to 8.5 per 1000 deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/8\">",
"     8",
"    </a>",
"    ]. This range is likely related to differences in the patient populations studied, as well as the availability and state of medical care at the time of the study. Pneumonia is associated with significant maternal and fetal morbidities, but death of pregnant women is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/2,15-18\">",
"     2,15-18",
"    </a>",
"    ]. Risk factors for pneumonia in pregnancy include anemia, asthma, smoking, illicit drug use, and immunosuppressive illness (eg,",
"    <span class=\"nowrap\">",
"     HIV/AIDS)",
"    </span>",
"    or immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic symptoms of pneumonia are sudden onset of rigors followed by fever, pleuritic chest pain, shortness of breath, and cough productive of purulent sputum; however, most patients do not present with classic symptoms. The clinical manifestations and diagnosis of pneumonia are similar to that in nonpregnant individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A chest x-ray is required to diagnose pneumonia and should never be withheld from a pregnant woman in whom this diagnosis is suspected. The indications for obtaining a chest x-ray (posteroanterior and lateral views) in pregnancy are the same as in nonpregnant patients and include shortness of breath",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough in association with fever, tachycardia, tachypnea, decreased oxygen saturation, or rales or signs of consolidation on lung exam. The estimated fetal absorption for the chest X-rays is &lt;0.01 mGy (&lt;0.001 rad); this dose is well below doses that have been associated with any short- or long-term adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/20\">",
"     20",
"    </a>",
"    ]. The abdomen should be shielded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung ultrasound is emerging as a valuable diagnostic tool, particularly in the emergency room and intensive care unit (ICU). Currently, there are no recommendations for use of ultrasound instead of diagnostic chest x-ray in nonpregnant patients; therefore, while it may be an additional tool to consider in specific circumstances where there is local expertise, more research is needed about its diagnostic use in pregnancy. The chest x-ray currently remains the gold standard for diagnosis of pneumonia in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant women with pneumonia are prone to preterm labor and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/25\">",
"     25",
"    </a>",
"    ], as well as pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/26\">",
"     26",
"    </a>",
"    ]. While there does not appear to be an increase in perinatal mortality, the frequency of low birth weight infants born to mothers with pneumonia is higher than among controls without pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/27\">",
"     27",
"    </a>",
"    ]. Pregnant women may be predisposed to a severe pneumonia course because of physiologic changes of pregnancy, including elevation of the diaphragm by up to 4 cm, decrease in functional residual capacity, increase in oxygen consumption, and increase in lung water. These changes make the pregnant woman less able to tolerate even brief periods of hypoxia. In addition, tachypnea can cause respiratory alkalosis, which reduces uterine blood flow. Given these factors, these authors admit pregnant women with pneumonia to the hospital, where they can receive intravenous hydration, supplemental oxygen, and close maternal-fetal monitoring until there is clinical improvement.",
"    <br/>",
"    <br/>",
"    While most pregnant women with pneumonia can be managed on the general ward, ICU admission is clearly needed for pregnant women requiring mechanical ventilation or with septic shock needing vasopressors. In the United States, the Infectious Diseases Society of",
"    <span class=\"nowrap\">",
"     America/American",
"    </span>",
"    Thoracic Society",
"    <span class=\"nowrap\">",
"     (IDSA/ITS)",
"    </span>",
"    consensus guidelines recommend ICU admission for nonpregnant patients with severe community acquired pneumonia with three of the following minor criteria: respiratory rate &gt;30",
"    <span class=\"nowrap\">",
"     breaths/minute,",
"    </span>",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    &lt;250, multilobar infiltrates,",
"    <span class=\"nowrap\">",
"     confusion/disorientation,",
"    </span>",
"    uremia (blood urea nitrogen [BUN] &gt;20), leukopenia (white blood cell [WBC] count &lt;4000",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    hypothermia (core temperature &lt;36 degrees Celsius), or hypotension requiring aggressive fluid resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/28\">",
"     28",
"    </a>",
"    ]. Given the physiologic changes, decreased pulmonary reserve, and potential fetal complications associated with pregnancy, these authors feel it is prudent to consider ICU admission for some pregnant women with pneumonia who have two, or even one, minor criteria. However, there are no data to support this recommendation and the decision to admit a pregnant woman to the ICU is complex, as most hospitals do not have an obstetric ICU. Discussions regarding the best place in the hospital to manage the sick pregnant women with pneumonia need to include the input of the obstetrician and intensivist.",
"   </p>",
"   <p>",
"    Blood cultures and sputum gram stain and cultures are appropriate in selected patients, as indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef77432 \" href=\"mobipreview.htm?4/63/5117\">",
"     table 3",
"    </a>",
"    ). Fever should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and fluid status should be monitored closely since pregnant women are prone to pulmonary edema. Maternal oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) should be maintained at &ge;95 percent during pregnancy, which is necessary to maintain adequate fetal oxygenation. If SaO",
"    <sub>",
"     2",
"    </sub>",
"    falls below 95 percent, an arterial blood gas is obtained to measure PaO2. Maternal PaO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 mmHg is desirable to maintain a favorable oxygen diffusion gradient from the maternal to the fetal side of the placenta.",
"   </p>",
"   <p>",
"    The table summarizes major points in treatment (",
"    <a class=\"graphic graphic_table graphicRef53414 \" href=\"mobipreview.htm?17/54/18284\">",
"     table 4",
"    </a>",
"    ). Antibiotics therapy is targeted to cover the infecting organisms typically associated with community acquired pneumonia in nonpregnant patients. Streptococcus pneumonia is the most common pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/29\">",
"     29",
"    </a>",
"    ]; others include Haemophilus influenzae, mycoplasma, chlamydia, viruses, legionella, Staphylococcus aureus, and gram negative bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/29\">",
"     29",
"    </a>",
"    ]. Since gram negative bacilli tend to cause pneumonia in patients with underlying morbidities, it is not as likely to be seen in young, otherwise healthy, pregnant women. &nbsp;",
"   </p>",
"   <p>",
"    Gravidas with community acquired pneumonia may be treated safely with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or azithromycin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    in severe cases. Other antibiotics with a good safety profile in pregnancy include the penicillins, beta-lactams,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and aminoglycosides. Antibiotics to be avoided in pregnancy include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and the fluoroquinolones (",
"    <a class=\"graphic graphic_table graphicRef55702 \" href=\"mobipreview.htm?3/3/3131\">",
"     table 5",
"    </a>",
"    ). Although azithromycin has a good safety profile, clarithromycin has produced adverse pregnancy outcome in animal studies at low-order multiples of human doses; human experience is very limited but has not suggested an increase in congenital anomalies in exposed pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], but an increased risk of miscarriage has been reported, possibly related to the underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The fluoroquinolones are avoided during pregnancy because of concerns about fetal arthropathy and malformations based on animal studies. However, safe use in pregnancy has been reported, suggesting that they may be used if alternatives are less safe or effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of hospital acquired pneumonia in pregnancy include the same causes as in the nonpregnant patient, but certain caveats exist. Pregnant women are prone to aspiration during labor and delivery and this must always be a major consideration. Gram negative rods including Pseudomonas also become more likely in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Varicella-zoster pneumonia is especially severe in pregnant women; fulminate pneumonia develops in approximately 10 to 20 percent of gravidas infected with chickenpox. Maternal mortality is as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/34\">",
"     34",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is warranted in pregnant patients to reduce the risk of respiratory failure and maternal death. The maternal complications along with the potentially serious",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    consequences of varicella underline the importance of establishing the immune status of women with respect to varicella and vaccinating those who are not immune prior to a planned pregnancy. The clinical features and treatment of varicella pneumonia in pregnancy are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumonia may result in respiratory failure. Early anticipation of possible intubation allows for better preparation and execution, should it be needed. Management of respiratory failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34248?source=see_link\">",
"     \"Airway management of pregnant women at delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37032?source=see_link\">",
"     \"Acute respiratory failure during pregnancy and the peripartum period\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSTPARTUM ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who deliver while being treated for a respiratory infection rarely need to be separated from their newborns, but should use liberal hand washing and wear a mask to minimize transmission of the illness. Active tuberculosis is an exception and requires at least temporary separation between mother and newborn. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29096?source=see_link&amp;anchor=H17#H17\">",
"     \"Tuberculosis in pregnancy\", section on 'Controlling transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, breastfeeding should",
"    <strong>",
"     not",
"    </strong>",
"    be discouraged because of maternal respiratory infection. Breastfeeding is the preferred method of feeding and will likely confer some passive immunity to the newborn. The medications (antibiotics) used to treat respiratory illness in pregnancy are also acceptable for use in breastfeeding mothers. Medications that should be avoided in breastfeeding include the quinolones and tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36344/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations about infection control of influenza-infected women in the peripartum and postpartum settings can be found on the United States Centers for Disease Control and Prevention&rsquo;s (CDC) website:",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/infectioncontrol/peri-post-settings.htm\">",
"     file://www.cdc.gov/flu/professionals/infectioncontrol/peri-post-settings.htm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Awareness of pregnancy-associated changes in respiratory physiology is important to the management of respiratory disease in pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major considerations when medically treating pregnant women for respiratory infection are to first determine the appropriate clinical evaluation and treatment of a nonpregnant patient with the same presentation and then to determine whether implementing this diagnostic and therapeutic plan carries any additional risks for the pregnant patient or fetus. These additional risks may be related to increased maternal susceptibility to severe disease or complications in pregnancy (eg, influenza)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to potential fetal risks related to the disease (eg, congenital infection), its evaluation (eg, radiation from diagnostic imaging), or its treatment (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      may stain developing teeth). (See",
"      <a class=\"local\" href=\"#H11616732\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     The common cold",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest heated humidified air for congestion and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      for sore",
"      <span class=\"nowrap\">",
"       throat/headache/fever",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If drug therapy is elected for symptomatic relief of rhinorrhea, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide and cromolyn nasal spray (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The common cold'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sinusitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      for most patients and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      in patients with penicillin allergies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The fluoroquinolones,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      should be",
"      <strong>",
"       avoided",
"      </strong>",
"      . Acceptable adjunct treatment includes saline nasal spray, buffered saline nasal irrigation, or steroid nasal sprays (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bronchitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest use of a steam humidifier (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11799327\">",
"       'Bronchitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest pregnant women with community acquired pneumonia be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      depending on the level of illness&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives include the penicillins, beta-lactams,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and aminoglycosides. Antibiotics that are generally avoided in pregnancy include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , and the fluoroquinolones. Gravid women with pneumonia are prone to develop preterm labor and delivery, as well as pulmonary edema. They are best treated as inpatients until there is clinical improvement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoxia and acidosis are poorly tolerated by the fetus and should be aggressively avoided. Maternal PO",
"      <sub>",
"       2",
"      </sub>",
"      should be kept at &ge;70 mmHg (or at an oxygen saturation of at least 95 percent) to maintain adequate fetal oxygenation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/1\">",
"      Dennis AT, Solnordal CB. Acute pulmonary oedema in pregnant women. Anaesthesia 2012; 67:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/2\">",
"      Lim WS, Macfarlane JT, Colthorpe CL. Pneumonia and pregnancy. Thorax 2001; 56:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/3\">",
"      Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.com (Accessed on January 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/5\">",
"      Fokkens W, Lund V, Mullol J, European Position Paper on Rhinosinusitis and Nasal Polyps Group. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 2007; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/6\">",
"      Wenzel RP, Fowler AA 3rd. Clinical practice. Acute bronchitis. N Engl J Med 2006; 355:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/7\">",
"      Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med 2001; 134:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/8\">",
"      Lim WS, Macfarlane JT, Colthorpe CL. Treatment of community-acquired lower respiratory tract infections during pregnancy. Am J Respir Med 2003; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/9\">",
"      Incaudo GA. Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation. Clin Rev Allergy Immunol 2004; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/10\">",
"      Sorri M, Hartikainen-Sorri AL, K&auml;rj&auml; J. Rhinitis during pregnancy. Rhinology 1980; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/11\">",
"      Hadley JA, M&ouml;sges R, Desrosiers M, et al. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. Laryngoscope 2010; 120:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/12\">",
"      Engels EA, Terrin N, Barza M, Lau J. Meta-analysis of diagnostic tests for acute sinusitis. J Clin Epidemiol 2000; 53:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/13\">",
"      Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/14\">",
"      Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007; 137:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/15\">",
"      Kaunitz AM, Hughes JM, Grimes DA, et al. Causes of maternal mortality in the United States. Obstet Gynecol 1985; 65:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/16\">",
"      Visscher HC, Visscher RD. Indirect obstetric deaths in the state of Michigan 1960-1968. Am J Obstet Gynecol 1971; 109:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/17\">",
"      Men&eacute;ndez C, Romagosa C, Ismail MR, et al. An autopsy study of maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med 2008; 5:e44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/18\">",
"      Chen YH, Keller J, Lin CC, et al. Pneumonia and pregnancy outcomes: a nationwide population-based study. Am J Obstet Gynecol 2012; 207:288.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Khan S, Niederman MS. Pneumonia in the",
"pregnant patient. In: Rosene-Montela K, Bourjeily G,",
"editors. Pulmonary problems in pregnancy. New York",
"(NY): Humana Press; 2009. p. 177e96.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/20\">",
"      Groen RS, Bae JY, Lim KJ. Fear of the unknown: ionizing radiation exposure during pregnancy. Am J Obstet Gynecol 2012; 206:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/21\">",
"      Gillman LM, Kirkpatrick AW. Portable bedside ultrasound: the visual stethoscope of the 21st century. Scand J Trauma Resusc Emerg Med 2012; 20:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/22\">",
"      Testa A, Soldati G, Copetti R, et al. Early recognition of the 2009 pandemic influenza A (H1N1) pneumonia by chest ultrasound. Crit Care 2012; 16:R30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/23\">",
"      Tsung JW, Kessler DO, Shah VP. Prospective application of clinician-performed lung ultrasonography during the 2009 H1N1 influenza A pandemic: distinguishing viral from bacterial pneumonia. Crit Ultrasound J 2012; 4:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/24\">",
"      Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 2012; 38:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/25\">",
"      B&aacute;nhidy F, Acs N, Puh&oacute; EH, Czeizel AE. Maternal acute respiratory infectious diseases during pregnancy and birth outcomes. Eur J Epidemiol 2008; 23:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/26\">",
"      Munn MB, Groome LJ, Atterbury JL, et al. Pneumonia as a complication of pregnancy. J Matern Fetal Med 1999; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/27\">",
"      Yost NP, Bloom SL, Richey SD, et al. An appraisal of treatment guidelines for antepartum community-acquired pneumonia. Am J Obstet Gynecol 2000; 183:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/28\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/29\">",
"      Sheffield JS, Cunningham FG. Community-acquired pneumonia in pregnancy. Obstet Gynecol 2009; 114:915.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed on September 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/31\">",
"      Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998; 15:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/32\">",
"      Andersen JT, Petersen M, Jimenez-Solem E, et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One 2013; 8:e53327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/33\">",
"      Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36344/abstract/34\">",
"      Duong CM, Munns RE. Varicella pneumonia during pregnancy. J Fam Pract 1979; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactaton. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2011",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4793 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36344=[""].join("\n");
var outline_f35_31_36344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11616732\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SELECTED DISORDERS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The common cold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11799327\">",
"      Bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSTPARTUM ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      The common cold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4793\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4793|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/24/37261\" title=\"figure 1\">",
"      Ventilation in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/37/18015\" title=\"figure 2\">",
"      Pulmonary function in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4793|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/43/18109\" title=\"table 1A\">",
"      Common cold treatments in pregnancy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/33/24092\" title=\"table 1B\">",
"      Common cold treatments in pregnancy 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/33/37404\" title=\"table 1C\">",
"      Common cold treatments in pregnancy 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/8/20620\" title=\"table 1D\">",
"      Common cold treatments in pregnancy 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/63/5117\" title=\"table 3\">",
"      CAP diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/54/18284\" title=\"table 4\">",
"      Rx pneumonia pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/3/3131\" title=\"table 5\">",
"      Antibx not used in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37032?source=related_link\">",
"      Acute respiratory failure during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34248?source=related_link\">",
"      Airway management of pregnant women at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14454?source=related_link\">",
"      Normal reference ranges for laboratory values in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/55/24440?source=related_link\">",
"      The common cold in adults: Diagnosis and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36345="Monitoring the HIV-infected patient taking hepatitis C therapy";
var content_f35_31_36345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring the HIV-infected patient taking hepatitis C therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36345/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/31/36345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20762130\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of hepatitis C virus (HCV) infection in HIV-infected patients are significant and include accelerated liver disease progression, high rates of end-stage liver disease, and shortened lifespan after hepatic decompensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/1\">",
"     1",
"    </a>",
"    ]. These observations provide the rationale for treatment consideration in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients. However, the treatment of HCV infection is associated with significant adverse events, such as bone marrow suppression; thus, close patient monitoring is required. Furthermore, measurement of hepatitis C RNA levels at prespecified time points is critical, since this key parameter predicts therapeutic outcomes and determines whether treatment should be continued or halted for futility.",
"   </p>",
"   <p>",
"    This topic will address treatment monitoring of the HIV-infected patient who is undergoing HCV therapy. Pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    is given as dual therapy to all HCV-infected patients with significant liver disease, except those with HCV genotype 1 infection; those patients are also given an HCV protease inhibitor.",
"   </p>",
"   <p>",
"    The epidemiology, natural history, diagnosis, and treatment approach of this patient population are discussed elsewhere. Detailed clinical data from pivotal randomized controlled trials are also available for review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38536?source=see_link\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1659759\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820787\">",
"    <span class=\"h2\">",
"     Pegylated interferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of patients for symptoms and laboratory evidence of serious side effects requires a thorough knowledge of the generally expected adverse effects of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     ,",
"    </span>",
"    such as fatigue, flu-like symptoms, anemia, and loss of appetite.",
"   </p>",
"   <p>",
"    Additional issues of concern related specifically to the HIV-infected patient who is coinfected with hepatitis C virus (HCV) are discussed below and elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38536?source=see_link&amp;anchor=H16230082#H16230082\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\", section on 'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1659766\">",
"    <span class=\"h3\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    combination therapy has been associated with significant weight loss, sometimes leading to treatment discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/2\">",
"     2",
"    </a>",
"    ]. One study that included 63 patients with",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection and 64 with HCV alone demonstrated a higher incidence of clinically significant weight loss among patients with concomitant HIV infection (76 versus 39 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We have found that nutritional supplements along with eating smaller, more frequent meals are somewhat helpful in staving off further weight declines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1659787\">",
"    <span class=\"h3\">",
"     Neuropsychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many premature discontinuations in the clinical trials of",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection were related to neuropsychiatric side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Neuropsychiatric disorders are common in HIV-infected patients and interferon can exacerbate depression, insomnia, mood swings, and generalized irritability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Early initiation of antidepressants or mood stabilizers can stabilize these symptoms without cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/8\">",
"     8",
"    </a>",
"    ]. In our clinic, psychiatric consultation is routinely utilized for all patients prior to treatment to assess for any history of mood disorder. If treatment with a mood stabilizer or antidepressant is recommended, we delay HCV therapy for approximately one month.",
"   </p>",
"   <p>",
"    One study examined whether the antiretroviral medication,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , which frequently produces neuropsychiatric side effects, increased the risk of these adverse events in patients taking interferon therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/9\">",
"     9",
"    </a>",
"    ]. Although mood disorders were reported more frequently, the use of antidepressant therapy was similar in patients with or without efavirenz exposure and overall treatment discontinuation was low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820597\">",
"    <span class=\"h3\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also a myriad of other potential side effects associated with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , including thyroid abnormalities and teratogenicity, which are discussed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820860\">",
"    <span class=\"h2\">",
"     HCV protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV protease inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , in combination with pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , increase the sustained virologic response (SVR) rates among HIV-infected patients with HCV genotype 1 infection compared with dual therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link&amp;anchor=H1659199#H1659199\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'HCV-specific protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common side effects associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      are rash, pruritus, anemia, nausea, hemorrhoids, diarrhea, dysgeusia, fatigue, vomiting, and anal",
"      <span class=\"nowrap\">",
"       discomfort/pruritus",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/12\">",
"       12",
"      </a>",
"      ]. Serious skin reactions, including drug rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been rarely reported in patients using telaprevir in combination with pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and warrant immediate discontinuation of all three agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/13\">",
"       13",
"      </a>",
"      ]. Different approaches to patients with less severe skin reactions during use of a telaprevir-containing regimen are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148836537#H148836537\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Telaprevir'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      include fatigue, anemia, nausea, headache, and dysgeusia. Other less common side effects include dry mouth, vomiting, and diarrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of adverse events secondary to the HCV protease inhibitors is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148836436#H148836436\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Side effects of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660409\">",
"    <span class=\"h1\">",
"     LABORATORY MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764660\">",
"    <span class=\"h2\">",
"     Hematologic laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the well-known hematologic dyscrasias associated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , it is important to monitor the platelet count, hemoglobin, and white blood cell with differential during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/14\">",
"     14",
"    </a>",
"    ]. We suggest a complete blood count at baseline and every two weeks for the first two months in the HIV-infected patient coinfected with hepatitis C virus (HCV) taking dual therapy, and monthly thereafter. If laboratories are stable, less frequent monitoring may be considered thereafter. (See",
"    <a class=\"local\" href=\"#H6130516\">",
"     'Management of anemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    to regimens using peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has been associated with decreases in hemoglobin concentration beyond those with peginterferon and ribavirin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In patients taking triple therapy, we continue to monitor for anemia every two weeks for the first 12 weeks of treatment. If laboratories are stable, less frequent monitoring (eg, once monthly) may be considered.",
"   </p>",
"   <p>",
"    Strategies for the management of anemia are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660417\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of serum creatinine is important at baseline and at a minimum of every three months since both interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are renally cleared. We also assess a urinalysis prior to treatment to determine if the patient has proteinuria, which can be a sign of underlying renal disease in an HIV-infected patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660455\">",
"    <span class=\"h2\">",
"     HIV parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV RNA and CD4 cell counts should be obtained quarterly during HCV therapy.",
"   </p>",
"   <p>",
"    Treatment with interferon has been associated with a decline in CD4+ T-cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/17\">",
"     17",
"    </a>",
"    ], although CD4 percentages are not affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/4\">",
"     4",
"    </a>",
"    ]. The patient should be counseled prior to therapy that the emphasis on future CD4 monitoring will be on the stability of the CD4 percentage.",
"   </p>",
"   <p>",
"    Although CD4 cell counts do decline, few opportunistic infections have occurred on therapy; in the APRICOT trial, only 10 opportunistic infections were reported in a study population of more than 860 patients, although most of the patients had relatively preserved CD4 cell counts at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The APRICOT trial also demonstrated that HIV RNA levels actually declined during the treatment phase of the study in those patients who had detectable levels of viremia at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Mathematical modeling suggests that this observed effect is related to blocking of de novo cellular infection of HIV by interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764667\">",
"    <span class=\"h2\">",
"     Other routine laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminotransferases and thyroid function tests should be monitored quarterly. In addition, we obtain a lipid profile at six months since interferon can occasionally lead to hypertriglyceridemia; patients with HIV may also be at risk for hypertriglyceridemia due to certain antiretroviral medications (eg, lopinavir). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764674\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of child-bearing age should also undergo baseline pregnancy testing and monthly thereafter. Prior to therapy, women must be advised about the importance of using two forms of contraception due to the teratogenicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Men who are undergoing HCV therapy should also be counseled to use two forms of contraception since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    can cause sperm abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764681\">",
"    <span class=\"h1\">",
"     HEPATITIS C VIRUS VIRAL LOAD MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of monitoring hepatitis C virus (HCV) RNA levels during treatment is similar in the",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patient as in the patient with HCV infection alone.",
"   </p>",
"   <p>",
"    HCV RNA monitoring is required before, during, and after cessation of treatment to assess response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is an inadequate response at prespecified time points, treatment is discontinued.",
"     </li>",
"     <li>",
"      &ldquo;Response-guided therapy\" refers to shortening the treatment duration based on the rapidity of HCV suppression. However, in",
"      <span class=\"nowrap\">",
"       HIV/HCV",
"      </span>",
"      coinfection, we generally treat all patients for 48 weeks, with some notable exceptions. (See",
"      <a class=\"local\" href=\"#H822052\">",
"       'Duration of therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise frequency and interpretation of test results depends on whether the patient is taking dual therapy alone (eg, peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) for non-1 genotype infection or triple therapy (with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ) for HCV genotype 1 infection. Triple therapy is reserved for patients with HCV genotype 1 infection while dual therapy is generally used for all other HCV genotypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link&amp;anchor=H820402#H820402\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'Treatment of HCV genotype 1 infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332669\">",
"    <span class=\"h2\">",
"     Pegylated interferon plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The schedule of HCV RNA monitoring for patients taking dual therapy is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3690756\">",
"    <span class=\"h3\">",
"     Week 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general,",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients who achieve a rapid virologic response (RVR) at week four (ie, complete viral suppression) have a much higher chance of a sustained virologic response (eg, viral eradication) than those who don&rsquo;t achieve this benchmark [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/20\">",
"     20",
"    </a>",
"    ]. Such information can be used to encourage patients to continue high rates of medication adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3690790\">",
"    <span class=\"h3\">",
"     Week 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;At week 12, patients taking pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    are classified by the log decline in HCV RNA, which has prognostic significance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with &lt;2 log decline are &ldquo;null responders&rdquo;",
"     </li>",
"     <li>",
"      Those with &gt;2 log decline, but still have detectable HCV RNA, are &ldquo;partial responders&rdquo;",
"     </li>",
"     <li>",
"      Those with full viral suppression by 12 weeks are &ldquo;complete responders&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally discontinue dual therapy in null responders and partial responders due to the low chance of sustained virologic response (SVR) (less than 5 percent and 20 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, patients with a complete response have a high probability of sustained clearance (eg, greater than 60 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332733\">",
"    <span class=\"h3\">",
"     Week 24",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with any detectable HCV RNA at this time point should be discontinued from therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332741\">",
"    <span class=\"h2\">",
"     HCV protease inhibitors, pegylated interferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of viral load monitoring and treatment discontinuation varies somewhat depending on whether the patient is taking pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    . For example, the first viral load testing in patients taking telaprevir is week four while among patients taking boceprevir it is week eight. This variance in scheduling is partly related to differences in drug administration; boceprevir is added after a four-week &ldquo;lead-in&rdquo; phase of pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    while telaprevir is initiated together with pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    from the onset of",
"    <span class=\"nowrap\">",
"     therapy.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332749\">",
"    <span class=\"h3\">",
"     Week 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HCV-coinfected",
"    patients who have more than 1000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of HCV RNA on",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"      telaprevir",
"     </a>",
"     /pegylated",
"    </span>",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    should be discontinued from therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332726\">",
"    <span class=\"h3\">",
"     Week 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;Week 8 is an important time point for viral load monitoring among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing triple therapy since HCV RNA measures the efficacy of the addition of boceprevir after the four-week lead-in phase of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"    However, no decisions about treatment discontinuation are made based on HCV RNA changes at this time point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332757\">",
"    <span class=\"h3\">",
"     Week 12",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -containing triple therapy, treatment should be discontinued if the HCV RNA is &gt;1000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    at week 12. In patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing triple therapy, treatment should be discontinued if the HCV RNA is &gt;100",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    at week 12 (ie, week 8 of boceprevir).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332764\">",
"    <span class=\"h3\">",
"     Week 24",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of which HCV protease inhibitor regimen is administered, patients with any detectable viremia at week 24 should have therapy discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3690798\">",
"    <span class=\"h2\">",
"     Monitoring HCV RNA after treatment discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treatment is complete, all patients, regardless of regimen, should have viral load monitoring at three (SVR-12) and six months (SVR-24) after stopping treatment to determine if viral suppression has been maintained. Most episodes of virologic relapse occur within 12 weeks of treatment discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1291569\">",
"    <span class=\"h1\">",
"     ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of adherence in optimizing treatment response needs to be stressed at each patient encounter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/22\">",
"     22",
"    </a>",
"    ]. One retrospective study of hepatitis C virus (HCV) genotype 1-infected patients found that those who took 80 percent of their medications for 80 percent of the duration had better overall treatment responses than those who were less adherent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/22\">",
"     22",
"    </a>",
"    ]. This kind of information is usually familiar to HIV-infected patients who know that adherence is critically important for optimal HIV viral suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6130516\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ANEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6130554\">",
"    <span class=\"h2\">",
"     Ribavirin and anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    plays an important role in preventing relapse after discontinuation of pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Pharmacodynamic data among patients taking dual therapy suggest that the optimum dose of ribavirin ranges from 11 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    continues to be important in preliminary data emerging from trials of directly-acting antiviral (DAA) agents for hepatitis C virus (HCV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/24\">",
"     24",
"    </a>",
"    ]. However, ribavirin is also associated with a dose-dependent hemolytic anemia, which can lead to symptoms of shortness of breath and severe fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/10,23\">",
"     10,23",
"    </a>",
"    ]. Hemoglobin declines may necessitate dose reduction or early treatment discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. In",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients, it is important to avoid co-administration of ribavirin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , which increases the risk of anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of anemia in major clinical trials using dual therapy is approximately 30 percent, although the proportion of patients who drop below a hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is much lower at about 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/27\">",
"     27",
"    </a>",
"    ]. Among genotype 2 or 3 infected patients, the incidence of anemia is lower because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dosing is fixed at 400 mg twice daily compared with higher, weight-based ribavirin dosing used for genotype 1 (eg, 13",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or up to 1200 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As seen in patients with HCV alone, the incidence of anemia is higher among",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection who are taking triple therapy including a protease inhibitor, compared with patients taking dual therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. For example, in the",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    treatment trial, anemia occurred in 41 percent of patients assigned to the boceprevir arm compared with 26 percent in the placebo arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin declines may be a pharmacokinetic marker of serum drug concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , which has marked interpatient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. In trials of dual or triple therapy in patients with HCV alone, anemia has been identified as a positive predictor of virologic clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/25,33\">",
"     25,33",
"    </a>",
"    ]. These observations are also supported by pharmacokinetic data in patients with and without HIV coinfection, which show a direct association between ribavirin drug serum concentrations and the degree of anemia and improved virologic responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1291839\">",
"    <span class=\"h2\">",
"     Potential therapeutic strategies for the management of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia can be managed by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      dose reduction",
"     </li>",
"     <li>",
"      Use of epoetin",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose reduction and epoetin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dose modification of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the primary strategy used by most clinicians. Ribavirin should be dose-reduced (eg, to 600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    when hemoglobin concentrations drop below 10",
"    <span class=\"nowrap\">",
"     g/dL;",
"    </span>",
"    treatment discontinuation may be necessary when the hemoglobin concentration is less than 8.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Patients who remain severely anemic despite ribavirin discontinuation may require a blood transfusion, particularly if symptomatic.",
"   </p>",
"   <p>",
"    There has been ongoing interest as to whether epoetin can help to modulate the severity of anemia during HCV treatment. Clinical trials in patients taking pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    have demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with HCV alone, epoetin sustains",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dosing and improves quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of four trials in patients with HCV suggests that epoetin positively impacts outcome among patients taking dual therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/38\">",
"       38",
"      </a>",
"      ], yet some of these studies used epoetin in all study participants regardless of whether they developed anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/39\">",
"       39",
"      </a>",
"      ]. Such an approach is more costly and increases the risk of adverse events in patients who may not need an erythrocyte stimulating growth factor.",
"     </li>",
"     <li>",
"      There are few data on the use of epoetin in",
"      <span class=\"nowrap\">",
"       HIV/HCV",
"      </span>",
"      coinfection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]; one small clinical trial suggested that the level of anemia improved on erythropoietin compared with placebo; however, since there were a large number of drop-outs in the trial, the researchers were unable to demonstrate that growth factor ameliorated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose reductions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical trials among HCV-infected patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing triple therapy, sustained virologic response (SVR) rates appear similar regardless of whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose reduction, growth factors, or a combination of both approaches were used; in the registration trials of boceprevir, most of these decisions were made at the discretion of the investigator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. A subsequent controlled trial randomly assigned HIV-seronegative patients with a hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    during HCV therapy to a ribavirin dose reduction arm or to the addition of erythropoietin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/43\">",
"     43",
"    </a>",
"    ]. SVR rates were equivalent, regardless of treatment strategy.",
"   </p>",
"   <p>",
"    The timing of these interventions may also be important. In a retrospective analysis of one treatment trial where clinicians were allowed to prescribe growth factors at their discretion, SVR rates were higher among HCV-infected patients who received epoetin during the first eight weeks of treatment, whereas later administration was not associated with any improvement in treatment outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These favorable outcomes may be related to the relatively high proportion of patients who achieve rapid viral suppression with triple therapy compared with dual therapy.",
"   </p>",
"   <p>",
"    The optimal strategy of anemia management has not been studied formally in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients. In a small study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    in 98",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients, erythropoietin was used at the discretion of the investigator in 38 percent of those taking boceprevir compared with 21 percent in the placebo arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epoetin is costly and has been associated with cardiovascular morbidity and thromboembolic events among patients with cancer and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/44\">",
"     44",
"    </a>",
"    ]. However, similar risks among HCV-infected patients or",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients have not been demonstrated to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2628327\">",
"    <span class=\"h2\">",
"     Management of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of anemia in the coinfected patient is similar to that in the patient with HCV infection alone. Dose reduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the preferred first step in management when the patient&rsquo;s hemoglobin drops below 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    We prefer to reduce the daily dose of ribavirin by 200 mg with weekly reassessment of possible further dose reductions, in order to keep the hemoglobin level &gt;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Greater dosage reductions may be required in patients with precipitous drops in hemoglobin (&gt;3 g), especially among those taking HCV protease inhibitors, which can potentiate anemia.",
"   </p>",
"   <p>",
"    If a patient has continued hemoglobin declines to &lt;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    despite",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose reductions, we suggest the addition of epoetin (ie, 40,000 IU subcutaneously weekly). If the hemoglobin is &lt;8.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    ribavirin should be discontinued.",
"   </p>",
"   <p>",
"    Detailed information on these therapeutic strategies is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, HCV protease inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , should never be dose-reduced for any reason since this would increase the risk of HCV drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1292143\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NEUTROPENIA AND THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated interferon is a bone marrow suppressant and frequently causes neutropenia and thrombocytopenia, although severe laboratory abnormalities leading to drug discontinuation are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/18,23\">",
"     18,23",
"    </a>",
"    ]. In addition, HIV patients coinfected with hepatitis C virus (HCV) with cirrhosis often have baseline leukopenia and thrombocytopenia due to portal hypertension and splenic sequestration.",
"   </p>",
"   <p>",
"    In general, we favor dose reduction of pegylated interferon as the first response in the management of thrombocytopenia or neutropenia, except in the patient with cirrhosis, where we prefer the use of growth factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929443\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who develop thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    on HCV therapy, interferon dose reduction is the primary strategy for patient management. Guidance on dose reductions and indications for treatment discontinuation is found in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef53213 graphicRef75290 \" href=\"mobipreview.htm?23/60/24525\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pretreatment thrombocytopenia is common among patients with cirrhosis. Although HCV combination therapy can lead to a sustained virologic response with regression of liver disease, thrombocytopenia may limit, or entirely prevent, the initiation or continuation of antiviral therapy among those who need it most. Although there are no studies of platelet growth factors in coinfected patients, trials in patients with HCV alone with baseline thrombocytopenia demonstrate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases platelet counts during HCV therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreases the need for pegylated interferon dose reduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Is associated with improved sustained virologic response rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11543?source=see_link\">",
"     eltrombopag",
"    </a>",
"    to avoid dose",
"    <span class=\"nowrap\">",
"     reduction/treatment",
"    </span>",
"    interruption of pegylated interferon in coinfected patients with cirrhosis. Among patients with thrombocytopenia, we start with a low dose of 25 mg daily and titrate up as necessary on a weekly basis during the course of therapy. Our therapeutic goal is",
"    <span class=\"nowrap\">",
"     &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H929450\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose reductions of pegylated interferon are used as the initial strategy for patients who develop an absolute neutrophil count (ANC) &lt;750",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    due to the pharmacologic effects of interferon (",
"    <a class=\"graphic graphic_table graphicRef53213 graphicRef75290 \" href=\"mobipreview.htm?23/60/24525\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are few clinical data assessing the use of colony stimulating growth factors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    , for treatment of neutropenia in HCV patients with or without HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/41\">",
"     41",
"    </a>",
"    ]. In our practice, we use granulocyte stimulating growth factors (eg, filgrastim 5",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    subcutaneously) which are well tolerated and effective; however, growth factors are not commonly needed unless the ANC decline is severe (ie, &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    which is associated with an increased risk for bacterial infections. &nbsp;",
"   </p>",
"   <p>",
"    Among patients with baseline leukopenia secondary to cirrhosis, we favor use of granulocyte stimulating factors, prior to interferon dose reduction, in patients with an ANC &lt;750",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    in order to optimize the chance of virologic suppression. Our therapeutic target is 750",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H822052\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the larger clinical trials of hepatitis C virus (HCV) therapy in HIV-infected patients have used 48 weeks of treatment, regardless of genotype. In contrast, in HIV-uninfected patients with HCV genotype 2 or 3 infection, six months of therapy is considered standard; shorter courses have also been used among those with rapid viral clearance. In addition, the duration of treatment among those with genotype 1 infection who receive triple therapy (including an HCV protease inhibitor), is determined according to a &ldquo;response-guided therapy&rdquo; paradigm. Those with a rapid viral response receive a shorter course of therapy than those with slower rates of suppression.",
"   </p>",
"   <p>",
"    As noted above, viral load monitoring time points in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients are mainly used for decisions regarding discontinuation of therapy among those with an insufficient response. Response-guided therapy has not yet been applied in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection. Instead, all HIV-infected patients who are taking triple therapy for HCV genotype 1 infection are treated for 48 weeks, even if they have a favorable virologic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764695\">",
"    <span class=\"h2\">",
"     Genotype 1 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until more data are available,",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection with an appropriate viral load treatment response should be treated for 48 weeks of antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link&amp;anchor=H1659199#H1659199\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'HCV-specific protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20764702\">",
"    <span class=\"h2\">",
"     Genotype 2 or 3 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;One small study suggested that high sustained virologic response (SVR) rates could be achieved with six months of pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy in coinfected patients with rapid virologic clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/48\">",
"     48",
"    </a>",
"    ]. However, we suggest 48 weeks of treatment in patients with genotype 2 or 3 infection with baseline HCV RNA levels &gt;400,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    who are tolerating therapy well, pending more data. If side effects are significant, a shorter course of therapy should be considered in the patients who attained rapid virologic suppression at week four.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3690705\">",
"    <span class=\"h1\">",
"     SUPPORTIVE MEASURES DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV patients coinfected with hepatitis C virus (HCV) often have complex psychosocial issues and need additional support throughout therapy. For example, baseline and ongoing psychiatric evaluations are critical for continuance of therapy, due to the known association of interferon with worsening of depression and irritability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1674?source=see_link\">",
"     \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At each clinic visit, clinicians should inquire about substance abuse issues.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    maintenance programs play an important role in supporting some patients through therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Patients should be strongly advised to avoid heavy alcohol use, which has direct liver toxicity. In addition, alcohol has been shown in vitro to increase the replication of HCV and to attenuate the antiviral activity of interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36345/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31575517\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The consequences of hepatitis C virus (HCV) infection in HIV-infected patients are significant and include accelerated liver disease progression, high rates of end-stage liver disease, and shortened lifespan after hepatic decompensation. These observations provide the rationale for treatment consideration in",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients. However, the treatment of HCV infection is associated with significant adverse events. (See",
"      <a class=\"local\" href=\"#H20762130\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pegylated interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      combination therapy has been associated with significant weight loss, sometimes leading to treatment discontinuation. We have found that nutritional supplements along with eating smaller, more frequent meals are somewhat helpful in staving off further weight declines. (See",
"      <a class=\"local\" href=\"#H1659759\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropsychiatric disorders are common in HIV-infected patients and interferon can exacerbate depression, insomnia, mood swings, and generalized irritability. Early initiation of antidepressants or mood stabilizers can stabilize these symptoms without cessation of therapy. (See",
"      <a class=\"local\" href=\"#H1659787\">",
"       'Neuropsychiatric effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HCV protease inhibitors are used in combination with pegylated",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      therapy for genotype 1 infection.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       Boceprevir",
"      </a>",
"      is associated with dysgeusia and headaches;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      is associated with rash and anal pruritis. Both can cause fatigue, gastrointestinal symptoms and anemia. Triple therapy is associated with more severe anemia than dual therapy with pegylated",
"      <span class=\"nowrap\">",
"       interferon/ribavirin",
"      </span>",
"      alone. (See",
"      <a class=\"local\" href=\"#H820860\">",
"       'HCV protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete blood count should be monitored every two weeks for the first eight weeks during dual therapy and for the first 12 weeks during triple therapy; if the complete blood count is stable, then less frequent monitoring is reasonable. Quarterly thyroid function tests and monthly aminotransferases are also advised. All patients must be counseled regarding the teratogenicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and female patients should have pregnancy testing at baseline and during the course of treatment. (See",
"      <a class=\"local\" href=\"#H1659759\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with interferon alfa has been associated with a decline in CD4+ T-cell counts, although CD4 percentages are not affected. The patient should be counseled prior to therapy that the emphasis on future CD4 monitoring will be on the stability of the CD4 percentage. (See",
"      <a class=\"local\" href=\"#H1660455\">",
"       'HIV parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV RNA monitoring is required before, during and after cessation of treatment to assess response. The precise frequency and interpretation of test results depends to some extent on whether the patient is taking dual therapy alone (eg, peginterferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      ) or triple therapy (with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20764681\">",
"       'Hepatitis C virus viral load monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who respond to therapy (ie, undetectable HCV RNA) as quickly as four weeks (rapid virologic responders) have the best chance of achieving a sustained virologic response. In contrast, those who do not achieve more than 2 log",
"      <sub>",
"       10",
"      </sub>",
"      viral suppression by 12 weeks should be counseled that achievement of a sustained virologic response is unlikely. For patients on HCV protease inhibitors, additional stopping rules apply. (See",
"      <a class=\"local\" href=\"#H20764681\">",
"       'Hepatitis C virus viral load monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose reduction as the primary therapeutic strategy among HIV-infected patients who develop anemia on HCV therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those who continue to have a hemoglobin less than 10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      despite ribavirin dose reductions (ie, down to 600 mg daily), we suggest the addition of epoetin (40,000 IU weekly subcutaneously) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest pegylated interferon dose reduction for most patients who develop neutropenia (eg, &lt;750",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      or thrombocytopenia (eg,",
"      <span class=\"nowrap\">",
"       &lt;50,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      during HCV therapy rather than use of growth factors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The schedules for dose reduction will depend on the formulation of drug that they are taking. In patients who develop an absolute neutrophil count &lt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      we use colony stimulating growth factors, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      subcutaneously). (See",
"      <a class=\"local\" href=\"#H1292143\">",
"       'Management of neutropenia and thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without cirrhosis who develop thrombocytopenia can usually be managed with pegylated interferon dose reduction. (See",
"      <a class=\"local\" href=\"#H1292143\">",
"       'Management of neutropenia and thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cirrhosis often have baseline thrombocytopenia or neutropenia related to portal sequestration. We suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      (25 mg daily orally), rather than pegylated interferon dose reduction, for severe thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;50,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      in cirrhotic patients who have not yet achieved viral suppression on antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our therapeutic target is a platelet count of approximately",
"      <span class=\"nowrap\">",
"       50,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1292143\">",
"       'Management of neutropenia and thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similarly, we suggest the use of granulocyte stimulating factors for cirrhotic patients with an absolute neutrophil count &lt;750",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      rather than interferon dose reduction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We aim to titrate the use of granulocyte growth factors to maintain an absolute neutrophil count within the 500 to 750 cell range. (See",
"      <a class=\"local\" href=\"#H1292143\">",
"       'Management of neutropenia and thrombocytopenia'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      HCV protease inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      , should never be dose reduced. (See",
"      <a class=\"local\" href=\"#H6130554\">",
"       'Ribavirin and anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until more data are available, the duration of therapy for HCV infection in the HIV-infected host is generally 48 weeks, regardless of genotype. (See",
"      <a class=\"local\" href=\"#H822052\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/1\">",
"      McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007; 45 Suppl 2:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/2\">",
"      P&eacute;rez-Olmeda M, N&uacute;&ntilde;ez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/3\">",
"      Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007; 21:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/4\">",
"      Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/5\">",
"      Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/6\">",
"      Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/7\">",
"      Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/8\">",
"      Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther 2004; 9:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/9\">",
"      Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2008; 49:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/10\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     Fried M, et al. Peginterferon alpha 2a in combination therapy. In: Digestive Diseases Week, Dallas, Texas 2001.",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. www.fda.gov/Drugs/DrugSafety/ucm332731.htm (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/14\">",
"      Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/15\">",
"      Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/16\">",
"      Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/17\">",
"      Soriano V, Bravo R, Samaniego JG, et al. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group. AIDS 1994; 8:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/18\">",
"      Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/19\">",
"      Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007; 21:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/20\">",
"      Martin-Carbonero L, Nu&ntilde;ez M, Mari&ntilde;o A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/21\">",
"      Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis 2009; 49:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/22\">",
"      McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/23\">",
"      Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/24\">",
"      McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/25\">",
"      Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/26\">",
"      Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/27\">",
"      Morello J, Rodr&iacute;guez-Novoa S, Jim&eacute;nez-N&aacute;cher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/28\">",
"      Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346.",
"     </a>",
"    </li>",
"    <li>",
"     Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV coinfected pateints: interim on-treatment results [Abstract LB-37]. In: Programs and abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA. (Accessed on (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     D Dieterich, V Soriano, K Sherman, et al. Telaprevir in Combination with Pegylated Interferon-alfa-2a + Ribavirin in HCV/HIV-coinfected Patients: A 24-Week Treatment Interim Analysis. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, WA. March 5-8, 2012. Abstract 46. (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2011/Abstracts/42467.htm (Accessed on June 13, 2011). (Accessed on June 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/32\">",
"      Hung CH, Lee CM, Lu SN, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006; 26:1079.",
"     </a>",
"    </li>",
"    <li>",
"     Sulkowski M, Poordad F, Manns MP, et al. Anemia During Treatment With Peginterferon Alfa-2b/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous Treatment-Failure Patients. EASL 46th Annual Meeting, March 30th - April 3rd 2011, Berlin, Germany. file://www.natap.org/2011/EASL/EASL_93.htm (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/34\">",
"      Rend&oacute;n AL, N&uacute;&ntilde;ez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/35\">",
"      Morello J, Rodr&iacute;guez-N&oacute;voa S, Cantillano AL, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/36\">",
"      Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/37\">",
"      Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/38\">",
"      Alavian SM, Tabatabaei SV, Behnava B. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. J Viral Hepat 2012; 19:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/39\">",
"      Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/40\">",
"      Sulkowski MS, Dieterich DT, Bini EJ, et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005; 39:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/41\">",
"      Talal AH, Liu RC, Zeremski M, et al. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr 2011; 58:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/42\">",
"      Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195.",
"     </a>",
"    </li>",
"    <li>",
"     Poordad F, Lawitz E, Reddy R, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus pegylated interferon/ribavirin. European Association for the Study of Liver Disea (Accessed on May 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/44\">",
"      Dr&uuml;eke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/45\">",
"      Gallegos-Orozco JF, Werner KT, Rosati M, et al. Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy. Am J Gastroenterol 2008; 103:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/46\">",
"      McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227.",
"     </a>",
"    </li>",
"    <li>",
"     Afdhal NH, et al \"Final results of ENABLE 1, a phase III, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia\" AASLD 2011; Abstract LB-3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/48\">",
"      Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/49\">",
"      Kresina TF, Eldred L, Bruce RD, Francis H. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. AIDS 2005; 19 Suppl 3:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/50\">",
"      Sylvestre DL. Approaching treatment for hepatitis C virus infection in substance users. Clin Infect Dis 2005; 41 Suppl 1:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36345/abstract/51\">",
"      McCartney EM, Semendric L, Helbig KJ, et al. Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon. J Infect Dis 2008; 198:1766.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16501 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36345=[""].join("\n");
var outline_f35_31_36345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31575517\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20762130\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1659759\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820787\">",
"      Pegylated interferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1659766\">",
"      - Weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1659787\">",
"      - Neuropsychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H820597\">",
"      - Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820860\">",
"      HCV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1660409\">",
"      LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20764660\">",
"      Hematologic laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1660417\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1660455\">",
"      HIV parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20764667\">",
"      Other routine laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20764674\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20764681\">",
"      HEPATITIS C VIRUS VIRAL LOAD MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332669\">",
"      Pegylated interferon plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3690756\">",
"      - Week 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3690790\">",
"      - Week 12",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332733\">",
"      - Week 24",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332741\">",
"      HCV protease inhibitors, pegylated interferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332749\">",
"      - Week 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332726\">",
"      - Week 8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332757\">",
"      - Week 12",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H332764\">",
"      - Week 24",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3690798\">",
"      Monitoring HCV RNA after treatment discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1291569\">",
"      ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6130516\">",
"      MANAGEMENT OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6130554\">",
"      Ribavirin and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1291839\">",
"      Potential therapeutic strategies for the management of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2628327\">",
"      Management of anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1292143\">",
"      MANAGEMENT OF NEUTROPENIA AND THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929443\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H929450\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H822052\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20764695\">",
"      Genotype 1 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20764702\">",
"      Genotype 2 or 3 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3690705\">",
"      SUPPORTIVE MEASURES DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31575517\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/25/21916\" title=\"table 1A\">",
"      Pegintron Rebetol dose mod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/43/6844\" title=\"table 1B\">",
"      Pegasys Copegus dose mod",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38536?source=related_link\">",
"      Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1674?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36346="Pathogenesis of type 2 diabetes mellitus";
var content_f35_31_36346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     R Paul Robertson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/31/36346/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/31/36346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes mellitus is characterized by hyperglycemia, insulin resistance, and relative impairment in insulin secretion. It is a common disorder with a prevalence that rises markedly with increasing degrees of obesity (",
"    <a class=\"graphic graphic_figure graphicRef51105 \" href=\"mobipreview.htm?12/44/13006\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of type 2 diabetes has risen alarmingly in the past decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/2\">",
"     2",
"    </a>",
"    ], in large part linked to the trends in obesity and sedentary lifestyle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the pathogenesis of type 2 diabetes is complicated by several factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients present with a combination of varying degrees of insulin resistance and relative insulin deficiency, and it is likely that both contribute to type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Furthermore, each of the clinical features can arise through genetic or environmental influences, making it difficult to determine the exact cause in an individual patient. Moreover, hyperglycemia itself can impair pancreatic beta cell function and exacerbate insulin resistance, leading to a vicious cycle of hyperglycemia causing a worsening metabolic state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 2 diabetes is often accompanied by other conditions, including hypertension, high serum low-density-lipoprotein (LDL) cholesterol concentrations, and low serum high-density-lipoprotein (HDL) cholesterol concentrations that, like type 2 diabetes, increase cardiovascular risk. This constellation of clinical conditions is referred to as the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/9\">",
"     9",
"    </a>",
"    ]. Hyperinsulinemia occurring in response to insulin resistance may play an important role in the genesis of these abnormalities. Increased free fatty acid levels, inflammatory cytokines from fat, and oxidative factors, have all been implicated in the pathogenesis of metabolic syndrome, type 2 diabetes, and their cardiovascular complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impaired insulin secretion and insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative importance of impaired insulin release and insulin resistance in the pathogenesis of type 2 diabetes has been evaluated in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. As an example, in a prospective study of over 6500 British civil servants without diabetes at baseline, 505 subjects were diagnosed with diabetes during 9.7 years (median) of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/13\">",
"     13",
"    </a>",
"    ]. In those who developed diabetes compared with those who did not, there was a marked decrease in insulin sensitivity during the five years prior to diagnosis. Beta cell function (insulin secretion) increased three to four years prior to diagnosis and then decreased until diagnosis. In addition, a seven-year prospective study of 714 non-diabetic Mexican-Americans suggested that decreased insulin secretion and insulin resistance were independent risk factors for type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/11\">",
"     11",
"    </a>",
"    ]. Among Pima Indians, in whom the frequency of diabetes is very high, the transition from normal glucose tolerance to impaired glucose tolerance to diabetes is characterized by concomitant decreases in insulin-stimulated glucose disposal and glucose-stimulated insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Insulin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin secretion by beta cells requires glucose transport into the cell, which is at least in part mediated by the glucose transporter 2 (GLUT-2). A mouse model with a genetic alteration affecting GLUT-2 expression produced mice with glucose intolerance; similar changes in GLUT-2 could be induced in normal mice fed a high-fat diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/14\">",
"     14",
"    </a>",
"    ] and suggests a possible mechanism for the link between high-fat diet and the development of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired insulin secretion has also been demonstrated to occur in mice lacking Abca1, a cellular cholesterol transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/16\">",
"     16",
"    </a>",
"    ]. Mice with inactivation of Abca1 in beta cells have defective insulin secretion, impaired glucose tolerance, but normal insulin sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance may be the best predictor of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The vast majority of patients appear to have a genetic risk for type 2 diabetes. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Genetic susceptibility'",
"    </a>",
"    below.) It is possible, for example, that insulin resistance becomes more severe with increasing age and weight, thereby unmasking a concurrent defect in insulin secretion in susceptible subjects to cause impaired glucose tolerance and eventually overt hyperglycemia. In normal-weight nondiabetic subjects at high risk for type 2 diabetes, both fasting and post-glucose hyperinsulinemia predict future weight gain, which in turn predisposes to hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Hyperglycemia itself may contribute to further progression by a toxic effect on beta cells, possibly by decreasing insulin gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin resistance may, at least in part, be related to substances secreted by adipocytes (\"adipokines\" including leptin adiponectin, tumor necrosis factor alpha, and resistin) (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Factors released from adipose tissue'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The importance of genetic factors in the pathogenesis of type 2 diabetes is suggested by the observation that lean, normoglycemic offspring of parents with type 2 diabetes have reduced nonoxidative glucose metabolism associated with reduced muscle glycogen synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, insulin resistance is present years before the onset of hyperglycemia. An increase in intracellular lipid content in muscle has been identified in these insulin-resistant offspring, suggesting that dysregulation of fatty acid metabolism may mediate the insulin resistance in these individuals. In one study, this dysregulation appeared to be due to an inherited defect in mitochondrial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the combination of genetic and environmental factors is suggested by another study of nondiabetic offspring of two parents with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6\">",
"     6",
"    </a>",
"    ]. Their insulin sensitivity was similar to that of normal subjects with no first-degree relatives with type 2 diabetes at near ideal body weight; with increasing degrees of obesity, however, the progressive decrease in insulin sensitivity was much more pronounced in those with a family history of type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70645 \" href=\"mobipreview.htm?32/37/33373\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Impaired insulin processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin production in normal subjects involves cleavage of insulin from proinsulin; 10 to 15 percent of secreted insulin is proinsulin and its conversion intermediates. In contrast, the proportion of immunoreactive insulin that is proinsulin in type 2 diabetes is increased considerably in the basal state (&gt;40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/22\">",
"     22",
"    </a>",
"    ]. The difference between normal and diabetic subjects becomes even more pronounced after stimulation with arginine or glucagon&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/23\">",
"     23",
"    </a>",
"    ]. The increase in proinsulin secretion persists after matching for degree of obesity, suggesting that it represents beta cell dysfunction, and not merely the response to the increased secretory demand imposed by the insulin resistance of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/23\">",
"     23",
"    </a>",
"    ]. These findings suggest that the processing of proinsulin to insulin in the beta cells is impaired in type 2 diabetes, or that there is insufficient time for granules to mature properly so that they release more proinsulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of islet amyloid polypeptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Islet amyloid polypeptide (amylin) is stored in insulin secretory granules in the pancreatic beta cells. It is cosecreted with insulin, resulting in serum concentrations about one-tenth those of insulin, and is present in increased amounts in the pancreas of many patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/24\">",
"     24",
"    </a>",
"    ]. First-phase serum insulin and amylin concentrations are lower in patients with impaired glucose tolerance compared with patients with normal glucose tolerance, and the concentrations are very low in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High concentrations of amylin decrease glucose uptake and inhibit endogenous insulin secretion, suggesting that amylin may be directly involved in the pathogenesis of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/26\">",
"     26",
"    </a>",
"    ]. However, administration of physiologic amounts of amylin has no acute effect on insulin secretion or insulin action in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/27\">",
"     27",
"    </a>",
"    ]. On the other hand, the administration of an amylin antagonist to rats results in a fall in blood glucose and an increase in insulin secretion, suggesting that amylin may tonically inhibit insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, it remains unclear whether amylin has a causative role in type 2 diabetes or is merely present in increased amounts as a consequence of the defect in insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/29\">",
"     29",
"    </a>",
"    ]. There is no apparent association between the amylin gene and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/22/13669?source=see_link\">",
"     Pramlintide",
"    </a>",
"    is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and improves A1C concentrations in patients with type 1 and type 2 diabetes when given subcutaneously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=see_link\">",
"     \"Amylin analogs for the treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENETIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes most likely represents a complex interaction among many genes and environmental factors. Monogenic causes of type 2 diabetes represent only a small fraction of cases and commonly inherited polymorphisms individually contribute only small degrees of risk for, or protection from, diabetes (",
"    <a class=\"graphic graphic_figure graphicRef61582 \" href=\"mobipreview.htm?4/0/4111\">",
"     figure 3",
"    </a>",
"    ). Most of the genetic risk for type 2 diabetes results from complex polygenic risk factors.",
"   </p>",
"   <p>",
"    Observations which demonstrate a genetic influence on the development of type 2 diabetes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of type 2 diabetes varies remarkably between ethnic groups living in the same environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/31\">",
"       31",
"      </a>",
"      ]. Type 2 diabetes is two to six times more prevalent in African Americans, Native Americans, Pima Indians, and Hispanic Americans in the United States than in whites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thirty-nine percent of patients with type 2 diabetes have at least one parent with the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among monozygotic twin pairs with one affected twin, approximately 90 percent of unaffected twins eventually develop the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      First-degree relatives of patients with type 2 diabetes frequently have impaired nonoxidative glucose metabolism (indicative of insulin resistance) long before they develop type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/36\">",
"       36",
"      </a>",
"      ]. In addition, they may have beta cell dysfunction, as evidenced by decreases in insulin and amylin release in response to glucose stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lifetime risk for a first-degree relative of a patient with type 2 diabetes is 5 to 10 times higher than that of age- and weight-matched subjects without a family history of diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even among groups with increased genetic risk for diabetes, however, environmental factors play a major role in the development of diabetes. As an example, the prevalence of diabetes among Pima Indians in Mexico is less than one-fifth that in US Pima Indians (6.9 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The search for plausible candidate genes has focused upon genes coding for proteins that might be involved in pancreatic development, insulin synthesis, secretion, or action (",
"    <a class=\"graphic graphic_table graphicRef64684 \" href=\"mobipreview.htm?28/3/28733\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pancreatic development and beta cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome wide association analysis has played an important role in identifying several new diabetes susceptibility loci. Some of these loci are in genes involved in pancreatic development and insulin synthesis. As an example, a genome wide association study to find genetic loci associated with type 2 diabetes in a French population confirmed the known association with the transcription factor 7-like 2 gene (TCF7L2) (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Transcription factor genes'",
"    </a>",
"    below) and identified four new loci associated with an increased risk of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/39\">",
"     39",
"    </a>",
"    ]. These loci (SLC30A8,",
"    <span class=\"nowrap\">",
"     HHEX/IDE,",
"    </span>",
"    and KCNJ11) are involved in beta cell development and insulin synthesis and appear to contribute substantially to type 2 diabetes risk. The population attributable risk for the four new loci plus TCF7L2 was 70 percent. The results of the original genome wide association study were quickly confirmed by four independent studies in diverse populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of three genome wide association studies found six new loci associated with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/44\">",
"     44",
"    </a>",
"    ]. Some of the loci (NOTCH 2, JAZF1) may be involved in pancreatic beta cell growth and development.",
"   </p>",
"   <p>",
"    In subsequent genome wide association studies, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A new susceptibility locus in the KCNQ1 gene was noted in Japanese individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/45\">",
"       45",
"      </a>",
"      ]. The association was subsequently confirmed in samples from Singaporean and Danish populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/46\">",
"       46",
"      </a>",
"      ]. The KCNQ1 gene encodes the alpha subunit of the slowly acting component of the outward-rectifying potassium channel (KvLQT1). Mutations in KCNQ1 are responsible for a subset of long-QT interval syndromes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=see_link&amp;anchor=H4#H4\">",
"       \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 1'",
"      </a>",
"      .) KCNQ1 is also expressed in pancreatic islet cells and KCNQ1 risk alleles disrupt beta cell function. Twelve new loci were noted in individuals of European descent, including a second independent signal at the KCNQ1 locus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/47\">",
"       47",
"      </a>",
"      ]. The identified loci affected both beta cell function and insulin action.",
"     </li>",
"     <li>",
"      Common variants in WFS1, a gene involved in beta cell survival, were associated with susceptibility to type 2 diabetes. Mutations in this gene also cause a rare syndrome, called Wolfram syndrome, characterized by diabetes insipidus, non-autoimmune diabetes mellitus, optic atrophy, and deafness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H19#H19\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Wolfram syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin release",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Transcription factor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;One gene variant, representing single nucleotide polymorphisms at one of two loci (rs7903146 and rs12255372) in the transcription factor 7-like 2 gene (TCF7L2), was found to significantly increase risk for type 2 diabetes in a case control study of a population in Iceland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/48\">",
"     48",
"    </a>",
"    ]. It was also shown to increase diabetic risk in two other populations, including in the United States (US) where the gene variant is widely prevalent: 38 percent of the US cohort studied were heterozygous and 7 percent homozygous for the variant allele. Compared with non-carriers, the relative risk for type 2 diabetes was 1.45 for heterozygotes and 2.41 for homozygotes. The population attributable risk for diabetes for this gene is estimated at 21 percent.",
"   </p>",
"   <p>",
"    Subsequent analysis for this variant gene in samples from participants (n = 3548) in the Diabetes Prevention Program (DPP trial) found that homozygotes for the variant TCF7L2 gene were more likely to progress from impaired glucose tolerance to diabetes over three years than those without the variant gene (HR 1.55; CI 1.2 to 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/49\">",
"     49",
"    </a>",
"    ]. The impact was strongest in the placebo DPP group where the incidence of diabetes per 100 person-years for the homozygous variant genotype at rs7903146, compared with heterozygous and nonvariant genotypes, was 18.5, 10.7, and 10.8, respectively. This variant genotype predisposing to type 2 diabetes is associated with decreased insulin secretion from the beta cell in response to oral and intravenous glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MODY2 and MODY4",
"    </span>",
"    &nbsp;&mdash;&nbsp;MODY is a rare cause of type 2 diabetes which has autosomal dominant transmission and features of both impaired insulin secretion and insulin resistance. One form, MODY2, appears to be due to mutations in the glucokinase gene on chromosome 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/51\">",
"     51",
"    </a>",
"    ]. Markers in this region have been linked to type 2 diabetes in American blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/52\">",
"     52",
"    </a>",
"    ] and some other ethnic groups, but not in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/53\">",
"     53",
"    </a>",
"    ]. Glucokinase, which phosphorylates glucose to glucose-6-phosphate, probably acts as the glucose sensor within pancreatic beta cells, and therefore, glucokinase defects likely result in decreased insulin secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another form of MODY (MODY4) is associated with mutations in insulin promoter factor-1",
"    <span class=\"nowrap\">",
"     (IPF-1/PDX-1),",
"    </span>",
"    a pancreatic beta cell transcription factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/54\">",
"     54",
"    </a>",
"    ]. These mutations result in decreased insulin secretion in response to glucose due to reduced binding of the protein to the insulin gene promoter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and perhaps by altering fibroblast growth factor signaling in beta cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/56\">",
"     56",
"    </a>",
"    ]. Less severe mutations in",
"    <span class=\"nowrap\">",
"     IPF-1/PDX-1",
"    </span>",
"    may predispose to late onset type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other genes that might affect insulin secretion, including the insulin gene and the genes for amylin and glucose transporters, have not been found to have any relationship to type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. On the other hand, a polymorphism in the human alpha adrenergic receptor gene (ADRA2A) was associated with reduced insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In addition, a mutation in mitochondrial DNA has been associated with a rare subtype of type 2 diabetes that has been called maternally inherited diabetes and deafness; insulin secretion is impaired via an uncertain mechanism in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H18#H18\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Genetic defects in mitochondrial DNA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Insulin action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin exerts its effects by first binding to a specific insulin receptor that is present on many cells throughout the body. The insulin receptor is a large transmembrane protein composed of two extracellular alpha subunits and two transmembrane and intracellular beta subunits that have intrinsic tyrosine kinase activity. When insulin binds to the extracellular portion of the receptor, the tyrosine kinase is activated, initiating a sequence of intracellular responses mediated in part by insulin receptor substrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several genetic syndromes of severe insulin resistance have been identified, many of which are associated with point mutations of the insulin-receptor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/60\">",
"     60",
"    </a>",
"    ]. These patients have marked hyperinsulinemia and sometimes other abnormalities, such as acanthosis nigricans and hyperandrogenism. However, as noted above, impaired glucose tolerance or overt diabetes only occurs in humans or in animals if compensatory increases in insulin secretion are inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/60,62,63\">",
"     60,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of the syndromes associated with an insulin receptor defect plays an important role in the common forms of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the decrease in insulin responsiveness in type 2 diabetes is probably due to a postreceptor defect, presumably affecting one of the intracellular enzymes involved in glucose metabolism. In animals, for example, the gene for glycogen synthase (which promotes the conversion of glucose-6-phosphate to glycogen) (",
"    <a class=\"graphic graphic_figure graphicRef68962 \" href=\"mobipreview.htm?29/3/29757\">",
"     figure 4",
"    </a>",
"    ) is involved in the susceptibility to diet-induced hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation may be relevant to humans, because impaired glycogen synthesis is responsible for the early insulin resistance in nondiabetic first-degree relatives of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/5,36\">",
"     5,36",
"    </a>",
"    ], and an association has been noted between a polymorphism of the glycogen synthase gene and the presence of diabetes in a subgroup of patients with a strong family history of type 2 diabetes, hypertension, and marked insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/65\">",
"     65",
"    </a>",
"    ]. However, a relationship between type 2 diabetes and the promoter or coding regions of the glycogen synthase gene has not been confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6,66\">",
"     6,66",
"    </a>",
"    ]. Furthermore, there is evidence that impaired insulin-stimulated glucose transport is responsible for the reduced muscle glycogen synthesis in patients with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genes that may affect susceptibility to type 2 diabetes are the genes for insulin-receptor substrates, the beta-3-adrenergic receptor, and peroxisome-proliferator-activated receptor gamma-2.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin-receptor substrates are a common substrate for insulin receptor tyrosine kinases. Disruption of the IRS-2 gene in mice results in insulin resistance in the liver and skeletal muscle and hyperglycemia because of an inadequate compensatory increase in insulin secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/68\">",
"       68",
"      </a>",
"      ]. In another mouse study, upregulation of IRS-2 in pancreatic beta cells could prevent the onset of diabetes caused by IRS-2 disruption or diet-induced obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/69\">",
"       69",
"      </a>",
"      ]. Other tissue-specific IRS-2 knockout mouse models suggest that IRS-2 signaling may play an important role in hypothalamic regulation of leptin, peripheral insulin sensitivity, and possibly, regeneration of beta cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"       \"Physiology of leptin\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6522?source=see_link\">",
"       \"Structure and function of the insulin receptor\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, disruption of the IRS-1 gene does not result in diabetes because the insulin resistance is mild, and therefore less of an increase in insulin secretion is needed to overcome it.",
"     </li>",
"     <li>",
"      The beta-3-adrenergic receptor regulates lipolysis in visceral fat (the possible human component of brown fat in animals) and increases thermogenesis in this tissue. Initial observations in humans suggest that a mutation in the gene for the beta-3-adrenergic receptor is associated with a low metabolic rate, high risk of obesity, and the early onset of type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peroxisome-proliferator-activated receptor (PPAR) gamma 2 is a transcription factor that has a key role in adipocyte differentiation. Polymorphisms in this gene may contribute to the variability in body mass index and insulin sensitivity in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/74\">",
"       74",
"      </a>",
"      ]. The common Pro12Ala polymorphism of PPAR gamma has been associated with a modestly decreased risk for type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/75\">",
"       75",
"      </a>",
"      ]. PPAR gamma is also the receptor for the thiazolidinediones, which lower the blood glucose in type 2 diabetes by increasing insulin sensitivity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is possible that impaired action and secretion of insulin in type 2 diabetes share a common pathogenesis. In mice, a gain of function mutation in the Foxo1 gene (which encodes a transcription factor) targeted to the liver and pancreatic beta cells resulted in diabetes (due to an increase in hepatic glucose production and impaired beta cell compensation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calpain-10 locus on chromosome 2A (called NIDDM1) may confer major susceptibility to type 2 diabetes in Mexican-Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/77\">",
"       77",
"      </a>",
"      ]. It may also play a role in other populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/78,79\">",
"       78,79",
"      </a>",
"      ], but its contribution appears less than in Mexican-Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/78,80\">",
"       78,80",
"      </a>",
"      ]. The involved gene encodes calpain-10, a cysteine protease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At least three polymorphisms within this gene can act in concert with a gene on chromosome 15 to increase the predisposition to the development of type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/78\">",
"       78",
"      </a>",
"      ]. How this occurs is not clear, but decreased insulin responsiveness plays at least a contributory role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/80\">",
"       80",
"      </a>",
"      ]. HIV protease inhibitors also are associated with the development of diabetes, suggesting that other proteases may be involved in diabetes susceptibility. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"       \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatocyte nuclear factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three of the recognized forms of what was formerly called maturity onset diabetes of the young (MODY1, MODY3, and MODY5) are due to mutations in the genes for hepatocyte nuclear factors 4-alpha, 1-alpha, and 1-beta, respectively, indicating that genes not directly related to insulin can be responsible for the development of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Genes in the MODY1 region of chromosome 20, and the MODY3 region of chromosome 12 also contribute to the development of type 2 diabetes in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Maturity onset diabetes of the young'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional insights into the genetic influences on the development of type 2 diabetes and on the requirement for both insulin resistance and a relative decrease in insulin secretion are provided by the phenotypes of double transgenic animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double knockout mice homozygous for null alleles of genes for beta-cell glucokinase (which would impair insulin secretion) and IRS-1 (which would impair insulin responsiveness) have overt diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/85\">",
"       85",
"      </a>",
"      ]. By comparison, single knockout mice lacking either one of these genes do not have diabetes.",
"     </li>",
"     <li>",
"      In another model, 40 percent of mice doubly heterozygous for null alleles of the insulin receptor and insulin receptor substrate-1 genes develop diabetes (with marked hyperinsulinemia and beta cell hyperplasia) at the age of four to six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/86\">",
"       86",
"      </a>",
"      ]. In contrast, mice heterozygous for only one of these null alleles do not develop diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings and the animal and human studies cited previously indicate that insulin resistance alone is insufficient to cause diabetes in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/60,62,63\">",
"     60,62,63",
"    </a>",
"    ]. This requirement for multiple abnormalities in the expression and interaction of genes controlling insulin secretion and action may explain the non-Mendelian inheritance and the variable penetrance of type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ROLE OF DIET, OBESITY, AND INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of impaired glucose tolerance and type 2 diabetes has increased dramatically in the US population in the past two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/2\">",
"     2",
"    </a>",
"    ]. The most striking features in these groups and of most patients who develop type 2 diabetes are increased weight gain and decreased physical activity, each of which increases the risk of diabetes (",
"    <a class=\"graphic graphic_figure graphicRef79316 \" href=\"mobipreview.htm?7/3/7230\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H9#H9\">",
"     \"Health hazards associated with obesity in adults\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity, for example, causes peripheral resistance to insulin-mediated glucose uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/9,87,88\">",
"     9,87,88",
"    </a>",
"    ] and may also decrease the sensitivity of the beta-cells to glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/88\">",
"     88",
"    </a>",
"    ]. These defects are largely reversed by weight loss, leading to a fall in blood glucose concentrations toward normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .) Although not as effective as weight loss, an exercise regimen also may improve glucose tolerance and prevent the development of overt diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link&amp;anchor=H11#H11\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which obesity induces insulin resistance is poorly understood. The pattern of fat distribution and perhaps a genetic abnormality in the beta-3-adrenergic receptor, as described above, appear to contribute. The c-Jun amino-terminal kinase (JNK) pathway may be an important mediator of the relationship between obesity and insulin resistance as JNK activity is increased in obesity, an effect that can interfere with insulin action. In animal models of obesity, absence of JNK1 results in decreased adiposity and enhanced insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have focused on the role of inflammation as a common mediator linking obesity to both the pathogenesis of diabetes and atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. The incidence of type 2 diabetes has been correlated with increased levels of markers of inflammation, including C reactive protein, IL-6, plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor (TNF)-alpha, and white cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. Adipokines, factors released from adipose tissue, stimulate inflammatory activity which correlates with insulin resistance as demonstrated in mouse models (see below). Intensive lifestyle interventions have been shown to decrease markers of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/96\">",
"     96",
"    </a>",
"    ]. Anti-inflammatory properties of medications including thiazolidinediones and statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/97\">",
"     97",
"    </a>",
"    ] may contribute therapeutic benefit beyond their activity to lower glucose and cholesterol levels respectively. Among patients with rheumatoid arthritis or psoriasis, use of anti-inflammatory disease-modifying antirheumatic drugs, such as TNF inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , is associated with a lower incidence of diabetes than other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Free fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma FFA concentrations are high in obese patients. A high plasma FFA concentration is a risk factor for type 2 diabetes (relative risk 2.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/99\">",
"     99",
"    </a>",
"    ], may inhibit insulin secretion and can inhibit insulin-stimulated glucose uptake in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pattern of fat distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper body or male-type obesity has a much greater association with insulin resistance and impaired glucose tolerance than lower body or female-type obesity (",
"    <a class=\"graphic graphic_figure graphicRef56394 \" href=\"mobipreview.htm?11/37/11870\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H9#H9\">",
"     \"Health hazards associated with obesity in adults\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Factors released from adipose tissue",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is produced by adipocytes and is secreted in proportion to adipocyte mass. It signals the hypothalamus about the quantity of stored fat. Studies in humans and animals have shown that leptin deficiency and leptin resistance are associated with obesity and insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its hypothalamic actions, leptin also has biologic actions in peripheral tissues, such as the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. In a preliminary study of a pancreas-specific leptin receptor knock out (KO) mouse model, the absence of leptin signaling was associated with improved glucose tolerance in KO mice compared with control mice, when the mice were fed a standard diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/102\">",
"     102",
"    </a>",
"    ]. The administration of a high-fat diet resulted in weight gain and insulin resistance in both KO and control mice. The control mice developed islet cell hyperplasia to compensate for insulin resistance. However, deterioration in the acute insulin response to glucose and poor islet cell growth were seen in the KO mice. These results suggest conflicting roles for leptin, depending upon diet and presence of insulin resistance. Additional studies are required to determine if leptin is important for the regulation of beta cell",
"    <span class=\"nowrap\">",
"     mass/function,",
"    </span>",
"    and whether abnormal leptin receptor signaling in islet cells plays a role in the pathogenesis of obesity-related type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adiponectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adiponectin, an adipocyte-derived cytokine, reduces levels of blood free fatty acids and has been associated with improved lipid profiles, better glycemic control, and reduced inflammation in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/103\">",
"     103",
"    </a>",
"    ]. Adiponectin has also been inversely associated with risk for diabetes in the non-diabetic population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of observations suggest that deficiency of adiponectin, an adipocyte-derived hormone, plays a role in the development of insulin resistance and subsequent type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/105\">",
"     105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower adiponectin levels are more closely related to the degree of insulin resistance and hyperinsulinemia than to the degree of adiposity and glucose intolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of subjects with insulin resistance, administration of thiazolidinediones, which has been shown to decrease the development of diabetes, increased serum adiponectin concentrations without affecting body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adiponectin is down-regulated in obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/108\">",
"       108",
"      </a>",
"      ]. In obese or lipoatrophic mice, adiponectin administration decreases the degree of insulin resistance associated with these conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adiponectin-knockout mice, plasma and adipocyte concentrations of TNFa increased, resulting in severe diet-induced insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two adiponectin receptors have been cloned: AdipoR1 and AdipoR2, which are expressed primarily in skeletal muscle and the liver, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adiponectin, and adiponectin receptors, may become an important target in the management of diabetes. Two studies have suggested that dietary cereal fiber and reduced glycemic load can increase adiponectin in diabetic men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/112\">",
"     112",
"    </a>",
"    ] and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its strong association with type 2 diabetes risk, preliminary data suggest that adiponectin may be moderately associated with cardiovascular morbidity and mortality. High adiponectin concentrations are associated with a favorable cardiovascular risk profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. However, the relationship is more complex. High adiponectin concentrations have also been associated with increased all-cause and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The discrepancy may be related to the patient population studied (men versus women, older versus younger, prevalent cardiovascular disease). In addition, adiponectin may not directly affect cardiovascular risk, but may be a marker of other risks. Additional studies are needed to clarify the relationship between adiponectin and cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in genetically obese animals suggest that increased release of TNF-alpha (TNFa) from adipose tissue may play a major role in the impairment in insulin action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. This suggestion is based on the following observations: administration of anti-TNFa antibody led to marked improvement in glucose utilization in obese rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/119\">",
"     119",
"    </a>",
"    ], and obese mice genetically lacking TNFa have more normal insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/120\">",
"     120",
"    </a>",
"    ]. In another study, weight reduction in obese animals was associated with both improved insulin activity and decreased TNFa gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fatty acid-binding protein in adipocytes, aP2, may provide the link by which FFA in obesity leads to increased expression of TNFa in obesity. Targeted mutations in the gene for this protein are associated with obesity, but not insulin resistance or increased TNFa expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/122\">",
"     122",
"    </a>",
"    ]. In addition, activation of Toll-like receptor 4 (TLR4) by nutritional fatty acids has been reported to increase TNFa and IL-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/123\">",
"     123",
"    </a>",
"    ]. Thus, there may be more than one mechanism by which obesity induces insulin resistance.",
"   </p>",
"   <p>",
"    The applicability of these findings to humans is uncertain. A preliminary study found a strong correlation between the degree of obesity, hyperinsulinemia, and TNFa mRNA in adipose tissue. In addition, in a study of a homogeneous Native Canadian population, plasma TNFa concentrations were positively correlated with insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chemokine molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemokines (chemotactic proinflammatory cytokines) are a family of low molecular weight proteins that are potent chemoattractants of leukocytes and may modulate the formation of reactive oxygen species and cytokines. Chemokines specific for neutrophils, called CXC chemokines, are distinguished from other chemokines by a protein motif in which the first two cysteines are separated by one amino acid. CXC chemokines are produced by many different cell types, including endothelial cells, platelets, neutrophils, T lymphocytes, and monocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17048?source=see_link&amp;anchor=H13#H13\">",
"     \"Determinants of neutrophil movement\", section on 'Chemoattractants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chemokine molecule CXCL5 (CXC ligand 5) is expressed at high levels in the macrophage fraction of white adipose tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/125\">",
"     125",
"    </a>",
"    ]. When it binds to the chemokine receptor CXCR2, it reduces insulin-stimulated glucose uptake in muscle, suggesting a potential role of CXCL5 in mediating insulin resistance. In support of this hypothesis are the observations that serum levels of CXCL5 are higher in obese compared with normal weight individuals and in insulin-resistant obese compared with noninsulin-resistant obese individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/125\">",
"     125",
"    </a>",
"    ]. CXCL5 concentrations decrease with weight loss.",
"   </p>",
"   <p>",
"    In addition, inhibition of CXCL5 via administration of a neutralizing antibody or a selective CXCR2 antagonist in two mice models of insulin resistance resulted in an improvement in insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/125\">",
"     125",
"    </a>",
"    ]. Thus, CXCL5 may be another link between obesity, inflammation, and insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Plasminogen activator inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen activator inhibitor 1, an inhibitor of fibrinolysis, is another protein related to adipocytes. It is also secreted from endothelial cells, mononuclear cells, hepatocytes, and fibroblasts and has been associated with an increased risk for cardiovascular disease. A five-year prospective study of 2356 adults aged 70 to 79 years identified 143 new cases of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/126\">",
"     126",
"    </a>",
"    ]. Elevated levels of plasminogen activator inhibitor 1 were an independent predictor of onset of diabetes (odds ratio [OR] 1.35; 95% CI 1.01-1.81) after controlling for components of the metabolic syndrome (body mass index, visceral fat, lipids, hypertension, and fasting glucose); other adipocytokines, including adiponectin, tumor necrosis factor alpha, and leptin, did not independently predict diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Resistin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diet-induced or genetic obesity in mice, adipocytes secrete a signaling molecule named resistin. Administration of resistin decreases while neutralization of resistin increases insulin-mediated glucose uptake by adipocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/127\">",
"     127",
"    </a>",
"    ]. Hypothalamic administration of resistin also enhances glucose production, independent of changes in glucoregulatory hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/128\">",
"     128",
"    </a>",
"    ]. Thus, resistin may be a hormone that links obesity to diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Retinol-binding protein 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinol-binding protein 4 (RBP4), another protein released from adipocytes, correlates with the degree of insulin resistance in patients with obesity, impaired glucose tolerance, or type 2 diabetes, as well as in non-obese subjects with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/129\">",
"     129",
"    </a>",
"    ] or without [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/130\">",
"     130",
"    </a>",
"    ] a strong family history of type 2 diabetes. Exercise training reduced RBP4 levels in patients whose insulin resistance improved with exercise. In a mouse model, mice lacking adipocyte glucose transporter 4 (GLUT4) had increased levels of RBP4 and RBP4 was shown to cause insulin resistance in mouse muscle and liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/131\">",
"     131",
"    </a>",
"    ]. An inverse relationship between GLUT4 in adipocytes and serum RBP4 was demonstrated in the human study, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/129\">",
"     129",
"    </a>",
"    ]. Whether RBP4 in humans causes, or is correlated with, insulin resistance has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Interleukin-1 beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another cytokine, interleukin-1 beta, a recognized inhibitor of glucose-induced insulin secretion, has been reported to undergo increased synthesis by the islet (presumably the beta cell itself) under conditions of high glucose concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/132\">",
"     132",
"    </a>",
"    ]. This raises the possibility of a negative downward spiral: chronic exposure to hyperglycemia leading to high concentrations of interleukin-1-beta within the islet, which in turn worsens beta cell function. Interleukin -1 receptor antagonists, which decrease the activity of interleukin-1 beta, may therefore improve beta cell function and glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Uncoupling protein 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncoupling protein 2 (UCP2) is an inhibitor of insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/133\">",
"     133",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Ob/ob",
"    </span>",
"    mice are extremely obese, insulin-resistant, and diabetic, with increased levels of UCP2 in pancreatic islet cells. When UCP2 knockout mice were crossed with",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mice to produce",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mice, the obesity and insulin resistance did not change, but the degree of hyperglycemia decreased as a result of increased insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies suggest a possible additional genetic association between obesity and diabetes. Leptin, a hormone released from adipocytes, modulates body weight by regulating food intake and energy expenditure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Obestatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obestatin, a hormone that was isolated from rat stomach, is encoded by the ghrelin gene, and opposes the effects of ghrelin on food intake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .) Treatment of rats with obestatin suppresses food intake, inhibits jejunal contraction, and decreases weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/135\">",
"     135",
"    </a>",
"    ]. Circulating obestatin concentrations are decreased in individuals with diabetes and impaired glucose tolerance compared with normal glucose tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/136\">",
"     136",
"    </a>",
"    ]. In addition, expression of the obestatin receptor in adipose tissue is down-regulated in obesity-associated type 2 diabetes, but not in normoglycemic obese subjects, suggesting that obestatin may play a role in glucose regulation and development of type 2 diabetes, independent of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     ROLE OF INTRAUTERINE DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Low birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of insulin resistance in obesity and type 2 diabetes led to the theory of the \"thrifty\" genotype, in which insulin resistance might improve survival during states of caloric deprivation but would lead to diabetes in states of caloric excess or even adequacy. However, other observations have suggested a different hypothesis: the thrifty genotype might be induced by malnutrition during fetal and early life. In particular, intrauterine growth restriction leading to low birth weight may be associated with an increased risk in adulthood of insulin resistance, glucose intolerance, type 2 diabetes, dyslipidemia, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/138-145\">",
"     138-145",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inverse relationship between birth weight and diabetes mellitus was illustrated in an analysis from the Nurses' Health Study of over 69,000 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/146\">",
"     146",
"    </a>",
"    ]. The relative risk of type 2 diabetes compared with a reference group by ascending birth weight categories decreased progressively from 1.8 for a birth weight less than 2.3 kg to 0.8 for a birth weight greater than 4.5 kg. Adjustment for ethnicity, childhood socioeconomic status, and adult lifestyle factors did not substantially alter this association. A meta-analysis of 30 studies, including the Nurses' Health Study, confirmed the inverse association between birth weight and type 2 diabetes (adjusted odds ratio of diabetes 0.80, 95% CI 0.72-0.89 for each one kg increase in birth weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, thinness at birth and in adult life have opposing effects on insulin resistance, such that subjects who were",
"    <strong>",
"     underweight at birth",
"    </strong>",
"    but who become overweight in middle age have the most severe insulin resistance and the greatest risk for type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef52859 \" href=\"mobipreview.htm?17/56/18318\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/138\">",
"     138",
"    </a>",
"    ]. Even among infants with a normal birth weight (&ge;3.5 kg), those who had slow growth in length in the first three months after birth were more likely to develop diabetes later in life, suggesting that the critical period for pancreatic beta cell development extends beyond the intrauterine period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     High birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher birth weight (&gt;4.0 kg) may also be associated with an increased risk of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/148\">",
"     148",
"    </a>",
"    ]. A meta-analysis of 14 studies (involving 132,180 individuals) of birth weight and subsequent risk of type 2 diabetes demonstrated a U-shaped relationship between birth weight and diabetes risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/149\">",
"     149",
"    </a>",
"    ]. High birth weight was associated with increased risk of diabetes in later life to the same extent as low birth weight (odds ratios 1.36 versus 1.47).",
"   </p>",
"   <p>",
"    The association between high birth weight and risk of type 2 diabetes may be related to maternal hyperglycemia during pregnancy. Prenatal exposure to hyperglycemia may increase the risk of type 2 diabetes, independent of genetic predisposition. This was demonstrated in a study of 31 nondiabetic adults, 15 of whom were exposed to a diabetic environment in utero (mothers with type 1 diabetes) and 15 who had not been exposed, but whose fathers had type 1 diabetes (controls). The exposed subjects had an increased risk of impaired glucose tolerance (5 of 15 versus 0 of 16), and a defective insulin secretory response when compared with control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/150\">",
"     150",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children born prematurely, whether they were appropriate or small for gestational age, may also be at increased risk for type 2 diabetes and other diseases of adulthood associated with insulin resistance. This was illustrated in a study of 50 healthy children ages 4 to 10 years who had been born prematurely (&lt;32 weeks gestation; 38 with a birth weight that was appropriate for gestational age and 12 who were small for gestational age) and 22 control subjects (&ge;37 weeks gestation with a normal birth weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/151\">",
"     151",
"    </a>",
"    ]. A similar reduction in insulin sensitivity (as measured by paired insulin and glucose values on an intravenous glucose tolerance tests) was seen in both groups of children born prematurely (normal or small for gestational age) when compared to the control group. In another study, the reduction in insulin sensitivity associated with preterm birth persisted into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     DRUG-INDUCED HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of drugs can impair glucose tolerance; they act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin (",
"    <a class=\"graphic graphic_table graphicRef67257 \" href=\"mobipreview.htm?10/40/10891\">",
"     table 2",
"    </a>",
"    ). Included in this list are glucocorticoids, oral contraceptives, several classes of antihypertensive drugs such as beta blockers, thiazide diuretics, nicotinic acid, statins, protease inhibitors used for the treatment of HIV infection, gonadotropin releasing hormone agonists used for the treatment of prostate cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    used primarily to prevent transplant rejection, and some of the atypical antipsychotic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/153\">",
"     153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link&amp;anchor=H23#H23\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Effects on glucose and lipid metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H17#H17\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Diabetes mellitus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=see_link&amp;anchor=H25#H25\">",
"     \"Lipodystrophic syndromes\", section on 'Lipodystrophy associated with HIV therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Metabolic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link&amp;anchor=H12#H12\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with thiazide diuretics is associated with an increase in fasting plasma glucose (FPG) and risk of developing type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. However, a substantial increase in FPG is unusual, even in patients with type 2 diabetes, with the currently recommended regimen of low-dose thiazide therapy (eg, 12.5 to a maximum of 25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"mobipreview.htm?37/49/38685\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/156-158\">",
"     156-158",
"    </a>",
"    ]. Concurrent hypokalemia appears to play an important role, as evidenced by a small study showing no change in glucose tolerance if urinary losses are replaced by potassium supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/159\">",
"     159",
"    </a>",
"    ]. Subsequent analyses of larger trials confirmed the association between hypokalemia and a higher probability of developing type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/160,161\">",
"     160,161",
"    </a>",
"    ]. As an example, in the Systolic Hypertension in Elderly Program trial, the risk of diabetes with use of a thiazide (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ) was significantly attenuated when adjusted for changes in serum potassium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/160\">",
"     160",
"    </a>",
"    ]. Each 0.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    decrease in serum potassium was associated with a 45 percent higher risk of new diabetes. The putative mechanism for this association is a failure of potassium channels to close in response to rising plasma glucose concentrations, with a resultant decrease in insulin secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with preexisting diabetes, the initiation of atypical or typical antipsychotic agents has been associated with worsening hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/162\">",
"     162",
"    </a>",
"    ]. In addition, some of the atypical antipsychotic agents, in particular,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , have been associated with weight gain, obesity, hypertriglyceridemia, and development of diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/163-165\">",
"     163-165",
"    </a>",
"    ]. The mechanism(s) by which they cause the metabolic syndrome have not been defined. An American Diabetes Association consensus panel concluded that data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    show an increased risk for weight gain, but conflicting data on diabetes and dyslipidemia risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/31/36346/abstract/166\">",
"     166",
"    </a>",
"    ]. The panel also concluded that patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    are not at increased risk for developing diabetes or dyslipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 2 diabetes mellitus is caused by a combination of varying degrees of insulin resistance and relative insulin deficiency. Its occurrence most likely represents a complex interaction among many genes and environmental factors, which are different among different populations and individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The search for plausible candidate genes has focused upon genes coding for proteins that might be involved in pancreatic development, insulin synthesis, secretion, or action. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most striking environmental risk factors in most patients who develop type 2 diabetes are increased weight gain and decreased physical activity, each of which increases the risk of diabetes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Role of diet, obesity, and inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which obesity induces insulin resistance is poorly understood. Inflammation may be the common mediator linking obesity to the pathogenesis of diabetes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Role of diet, obesity, and inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large number of drugs can impair glucose tolerance. They act by decreasing insulin secretion, increasing hepatic glucose production, or causing resistance to the action of insulin (",
"      <a class=\"graphic graphic_table graphicRef67257 \" href=\"mobipreview.htm?10/40/10891\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Drug-induced hyperglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/1\">",
"      Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/2\">",
"      Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/3\">",
"      Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005; 28:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/4\">",
"      Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/5\">",
"      Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 94:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/6\">",
"      Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/7\">",
"      Robertson RP. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995; 125:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/8\">",
"      Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/9\">",
"      DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/10\">",
"      Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995; 18:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/11\">",
"      Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995; 44:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/12\">",
"      Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/13\">",
"      Tab&aacute;k AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/14\">",
"      Ohtsubo K, Takamatsu S, Minowa MT, et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 2005; 123:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/15\">",
"      Thorens B. A toggle for type 2 diabetes? N Engl J Med 2006; 354:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/16\">",
"      Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/17\">",
"      Sigal RJ, El-Hashimy M, Martin BC, et al. Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes 1997; 46:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/18\">",
"      Odeleye OE, de Courten M, Pettitt DJ, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes 1997; 46:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/19\">",
"      Moran A, Zhang HJ, Olson LK, et al. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J Clin Invest 1997; 99:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/20\">",
"      Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1995; 92:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/21\">",
"      Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/22\">",
"      Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997; 46:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/23\">",
"      R&oslash;der ME, Dinesen B, Hartling SG, et al. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999; 22:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/24\">",
"      Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide--a novel controversy in diabetes research. Diabetologia 1992; 35:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/25\">",
"      M&auml;kimattila S, Fineman MS, Yki-J&auml;rvinen H. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 2000; 85:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/26\">",
"      Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/27\">",
"      Wilding JP, Khandan-Nia N, Bennet WM, et al. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/28\">",
"      Bennet WM, Beis CS, Ghatei MA, et al. Amylin tonally regulates arginine-stimulated insulin secretion in rats. Diabetologia 1994; 37:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/29\">",
"      Gurlo T, Ryazantsev S, Huang CJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 2010; 176:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/30\">",
"      Bell GI, Froguel P, Nishi S, et al. Mutations of the human glucokinase gene and diabetes mellitus. Trends Endocrinol Metab 1993; 4:86.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett, PH. Epidemiology of diabetes mellitus. In: Ellenberg and Rifkin's Diabetes Mellitus, Rifkin, H, Porte, D Jr (Eds), Elsevier, New York 1990. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/32\">",
"      Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996; 125:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/33\">",
"      Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/34\">",
"      Klein BE, Klein R, Moss SE, Cruickshanks KJ. Parental history of diabetes in a population-based study. Diabetes Care 1996; 19:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/35\">",
"      Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981; 20:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/36\">",
"      Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/37\">",
"      Knowles NG, Landchild MA, Fujimoto WY, Kahn SE. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2002; 25:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/38\">",
"      Schulz LO, Bennett PH, Ravussin E, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006; 29:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/39\">",
"      Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/40\">",
"      Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/41\">",
"      Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/42\">",
"      Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/43\">",
"      Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/44\">",
"      Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/45\">",
"      Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/46\">",
"      Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/47\">",
"      Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/48\">",
"      Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/49\">",
"      Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/50\">",
"      Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/51\">",
"      Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/52\">",
"      Chiu KC, Province MA, Permutt MA. Glucokinase gene is genetic marker for NIDDM in American blacks. Diabetes 1992; 41:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/53\">",
"      Cook JT, Hattersley AT, Christopher P, et al. Linkage analysis of glucokinase gene with NIDDM in Caucasian pedigrees. Diabetes 1992; 41:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/54\">",
"      Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/55\">",
"      Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 1999; 104:R33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/56\">",
"      Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000; 408:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/57\">",
"      Hani EH, Stoffers DA, Ch&egrave;vre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104:R41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/58\">",
"      Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes. Science 2010; 327:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/59\">",
"      Gribble FM. Alpha2A-adrenergic receptors and type 2 diabetes. N Engl J Med 2010; 362:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/60\">",
"      Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/61\">",
"      Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/62\">",
"      McCulloch DK, Kahn SE, Schwartz MW, et al. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 1991; 87:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/63\">",
"      Lauro D, Kido Y, Castle AL, et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat Genet 1998; 20:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/64\">",
"      Seldin MF, Mott D, Bhat D, et al. Glycogen synthase: a putative locus for diet-induced hyperglycemia. J Clin Invest 1994; 94:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/65\">",
"      Groop LC, Kankuri M, Schalin-J&auml;ntti C, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 328:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/66\">",
"      Bj&oslash;rbaek C, Echwald SM, Hubricht P, et al. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. Diabetes 1994; 43:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/67\">",
"      Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/68\">",
"      Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/69\">",
"      Hennige AM, Burks DJ, Ozcan U, et al. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 2003; 112:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/70\">",
"      Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/71\">",
"      Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/72\">",
"      Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995; 333:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/73\">",
"      Wid&eacute;n E, Lehto M, Kanninen T, et al. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/74\">",
"      Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/75\">",
"      Gouda HN, Sagoo GS, Harding AH, et al. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010; 171:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/76\">",
"      Nakae J, Biggs WH 3rd, Kitamura T, et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002; 32:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/77\">",
"      Hanis CL, Boerwinkle E, Chakraborty R, et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/78\">",
"      Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/79\">",
"      Hani EH, Hager J, Philippi A, et al. Mapping NIDDM susceptibility loci in French families: studies with markers in the region of NIDDM1 on chromosome 2q. Diabetes 1997; 46:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/80\">",
"      Baier LJ, Permana PA, Yang X, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106:R69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/81\">",
"      Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/82\">",
"      Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/83\">",
"      Ji L, Malecki M, Warram JH, et al. New susceptibility locus for NIDDM is localized to human chromosome 20q. Diabetes 1997; 46:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/84\">",
"      Mahtani MM, Wid&eacute;n E, Lehto M, et al. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 1996; 14:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/85\">",
"      Terauchi Y, Iwamoto K, Tamemoto H, et al. Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. J Clin Invest 1997; 99:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/86\">",
"      Br&uuml;ning JC, Winnay J, Bonner-Weir S, et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997; 88:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/87\">",
"      Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest 1992; 89:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/88\">",
"      Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985; 61:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/89\">",
"      Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/90\">",
"      Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/91\">",
"      Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/92\">",
"      Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/93\">",
"      Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/94\">",
"      Vozarova B, Weyer C, Lindsay RS, et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/95\">",
"      de Rekeneire N, Peila R, Ding J, et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006; 29:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/96\">",
"      Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/97\">",
"      Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/98\">",
"      Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/99\">",
"      Paolisso G, Tataranni PA, Foley JE, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/100\">",
"      Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/101\">",
"      Morioka T, Asilmaz E, Hu J, et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 2007; 117:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/102\">",
"      Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest 2007; 117:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/103\">",
"      Mantzoros CS, Li T, Manson JE, et al. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90:4542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/104\">",
"      Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/105\">",
"      Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/106\">",
"      Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/107\">",
"      Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/108\">",
"      Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/109\">",
"      Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/110\">",
"      Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/111\">",
"      Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/112\">",
"      Qi L, Rimm E, Liu S, et al. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 2005; 28:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/113\">",
"      Qi L, Meigs JB, Liu S, et al. Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes. Diabetes Care 2006; 29:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/114\">",
"      Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/115\">",
"      Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/116\">",
"      Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/117\">",
"      Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/118\">",
"      Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007; 165:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/119\">",
"      Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/120\">",
"      Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/121\">",
"      Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/122\">",
"      Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/123\">",
"      Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/124\">",
"      Zinman B, Hanley AJ, Harris SB, et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/125\">",
"      Chavey C, Lazennec G, Lagarrigue S, et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 2009; 9:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/126\">",
"      Kanaya AM, Wassel Fyr C, Vittinghoff E, et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/127\">",
"      Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/128\">",
"      Muse ED, Lam TK, Scherer PE, Rossetti L. Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest 2007; 117:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/129\">",
"      Graham TE, Yang Q, Bl&uuml;her M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/130\">",
"      Gavi S, Stuart LM, Kelly P, et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007; 92:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/131\">",
"      Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/132\">",
"      Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/133\">",
"      Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001; 345:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/134\">",
"      Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001; 105:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/135\">",
"      Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/136\">",
"      Qi X, Li L, Yang G, et al. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/137\">",
"      Catal&aacute;n V, G&oacute;mez-Ambrosi J, Rotellar F, et al. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/138\">",
"      Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/139\">",
"      Phillips DI, Hirst S, Clark PM, et al. Fetal growth and insulin secretion in adult life. Diabetologia 1994; 37:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/140\">",
"      Valdez R, Athens MA, Thompson GH, et al. Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia 1994; 37:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/141\">",
"      Fors&eacute;n T, Eriksson J, Tuomilehto J, et al. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/142\">",
"      Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004; 350:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/143\">",
"      Eriksson JG, Forsen TJ, Osmond C, Barker DJ. Pathways of infant and childhood growth that lead to type 2 diabetes. Diabetes Care 2003; 26:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/144\">",
"      Burke JP, Forsgren J, Palumbo PJ, et al. Association of birth weight and type 2 diabetes in Rochester, Minnesota. Diabetes Care 2004; 27:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/145\">",
"      Lawlor DA, Davey Smith G, Clark H, Leon DA. The associations of birthweight, gestational age and childhood BMI with type 2 diabetes: findings from the Aberdeen Children of the 1950s cohort. Diabetologia 2006; 49:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/146\">",
"      Rich-Edwards JW, Colditz GA, Stampfer MJ, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 1999; 130:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/147\">",
"      Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 2008; 300:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/148\">",
"      Dyck RF, Klomp H, Tan L. From \"thrifty genotype\" to \"hefty fetal phenotype\": the relationship between high birthweight and diabetes in Saskatchewan Registered Indians. Can J Public Health 2001; 92:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/149\">",
"      Harder T, Rodekamp E, Schellong K, et al. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007; 165:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/150\">",
"      Sobngwi E, Boudou P, Mauvais-Jarvis F, et al. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet 2003; 361:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/151\">",
"      Hofman PL, Regan F, Jackson WE, et al. Premature birth and later insulin resistance. N Engl J Med 2004; 351:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/152\">",
"      Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. N Engl J Med 2007; 356:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/153\">",
"      Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/154\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/155\">",
"      Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/156\">",
"      Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/157\">",
"      Passmore AP, Whitehead EM, Crawford V, et al. The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med 1991; 81:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/158\">",
"      Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/159\">",
"      Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/160\">",
"      Shafi T, Appel LJ, Miller ER 3rd, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/161\">",
"      Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/162\">",
"      Lipscombe LL, L&eacute;vesque L, Gruneir A, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med 2009; 169:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/163\">",
"      Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/164\">",
"      Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/165\">",
"      Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/31/36346/abstract/166\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1810 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36346=[""].join("\n");
var outline_f35_31_36346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impaired insulin secretion and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Insulin secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Impaired insulin processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of islet amyloid polypeptide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENETIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pancreatic development and beta cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Transcription factor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MODY2 and MODY4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatocyte nuclear factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ROLE OF DIET, OBESITY, AND INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Free fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pattern of fat distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Factors released from adipose tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Leptin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adiponectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Tumor necrosis factor-alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chemokine molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Plasminogen activator inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Resistin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Retinol-binding protein 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Interleukin-1 beta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Uncoupling protein 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Obestatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      ROLE OF INTRAUTERINE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Low birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      High birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      DRUG-INDUCED HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1810|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/44/13006\" title=\"figure 1\">",
"      Obesity and NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/37/33373\" title=\"figure 2\">",
"      Obesity family hx and NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/0/4111\" title=\"figure 3\">",
"      Genetic loci T2 DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/3/29757\" title=\"figure 4\">",
"      Glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/3/7230\" title=\"figure 5\">",
"      Type2 DM weight and exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/37/11870\" title=\"figure 6\">",
"      Fat distribution and NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/56/18318\" title=\"figure 7\">",
"      Birth wt and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/49/38685\" title=\"figure 8\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/3/28733\" title=\"table 1\">",
"      Cand genes function T2 DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/40/10891\" title=\"table 2\">",
"      Drug induced diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15734?source=related_link\">",
"      Amylin analogs for the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17048?source=related_link\">",
"      Determinants of neutrophil movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6522?source=related_link\">",
"      Structure and function of the insulin receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_31_36347="Feature gestational androgenism";
var content_f35_31_36347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the major causes of gestational hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Luteoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Theca-lutein cyst",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sertoli-Leydig tumor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Krukenberg tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incidence",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilaterality",
"       </td>",
"       <td>",
"        ~47 percent",
"       </td>",
"       <td>",
"        ~96 percent",
"       </td>",
"       <td>",
"        ~5 percent",
"       </td>",
"       <td>",
"        &gt;80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal androgen excess",
"       </td>",
"       <td>",
"        ~35 percent",
"       </td>",
"       <td>",
"        ~30 percent",
"       </td>",
"       <td>",
"        69 to 87 percent",
"       </td>",
"       <td>",
"        80 to 100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal virilization",
"       </td>",
"       <td>",
"        High if mother&nbsp;virilized",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        High if mother virilized",
"       </td>",
"       <td>",
"        80 to 100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        ~45 percent",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: McClamrock HD, Adashi EY. Gestational hyperandrogenism.&nbsp;Fertil Steril 1992; 57:257.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36347=[""].join("\n");
var outline_f35_31_36347=null;
var title_f35_31_36348="Risk score CML transplantation";
var content_f35_31_36348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Group for Blood and Marrow Transplantation risk assessment score for allogeneic transplantation in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\">",
"       Item",
"      </td>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Donor",
"      </td>",
"      <td>",
"       HLA Identical sibling donor",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Matched unrelated donor",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage",
"      </td>",
"      <td>",
"       First chronic phase",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Accelerated phase",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blast crisis or &ge;2nd chronic phase",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Age",
"      </td>",
"      <td>",
"       &lt;20 years",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20 to 40 years",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;40 years",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Sex matching (donor/recipient)",
"      </td>",
"      <td>",
"       All other matches",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Female donor, male recipient",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Time to HCT from diagnosis",
"      </td>",
"      <td>",
"       &lt;12 months",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;12 months",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Score",
"      </td>",
"      <td class=\"subtitle1\">",
"       Treatment-related mortality (%)",
"      </td>",
"      <td class=\"subtitle1\">",
"       5-year Overall Survival (%)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       72",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       70",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       62",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       48",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       51",
"      </td>",
"      <td>",
"       40",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       71",
"      </td>",
"      <td>",
"       18",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       73",
"      </td>",
"      <td>",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Scoring: Scoring is from zero to a maximum of seven, with points scored for each of the five risk categories, as shown in the upper table. Treatment-related mortality and five-year overall survivals as a function of the score are shown in the lower table. There were too few patients with a score of seven to adequately assess TRM and OS.",
"    <div class=\"footnotes\">",
"     EGBMT: European Group for Blood and Marrow Transplantation; CML: chronic myelogenous leukemia; HCT: hematopoietic cell transplantation; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gratwohl, A, et al. Lancet 1998; 352:1087.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36348=[""].join("\n");
var outline_f35_31_36348=null;
var title_f35_31_36349="Causes central airway obstruct";
var content_f35_31_36349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with central airway obstruction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Primary endoluminal malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Adenoid cystic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucoepidermoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carcinoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Plasmacytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metastatic carcinoma to the airway",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal cell",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Breast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Colon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Melanoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Laryngeal carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Esophageal carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mediastinal tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thymus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Germ cell",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Lymphadenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Associated with any of the above malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nonmalignant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Lymphadenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infectious (ie, tuberculosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sling",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cartilage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Relapsing polychondritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Granulation tissue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Endotracheal tubes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tracheostomy tubes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Airway stents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Foreign bodies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Surgical anastomosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Pseudotumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hamartomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amyloid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Papillomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hyperdynamic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tracheomalacia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchomalacia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Webs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goiter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucus plug",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vocal cord paralysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epiglottitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blood clot",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278. Copyright &copy; 2004 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36349=[""].join("\n");
var outline_f35_31_36349=null;
var title_f35_31_36350="Resolution bilateral VUR girls";
var content_f35_31_36350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resolution nomogram table for girls with bilateral vesicoureteral reflux",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ureteral anatomy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to resolution (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3 percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 4-5 percent (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         Prenatal hydronephrosis/Sibling VUR",
"        </strong>",
"       </td>",
"       <td rowspan=\"10\">",
"        Single",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        43 (36, 49)",
"       </td>",
"       <td>",
"        35 (31, 39)",
"       </td>",
"       <td>",
"        27 (24, 30)",
"       </td>",
"       <td>",
"        17 (14, 20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        67 (59, 74)",
"       </td>",
"       <td>",
"        58 (52, 63)",
"       </td>",
"       <td>",
"        46 (42, 50)",
"       </td>",
"       <td>",
"        32 (27, 36)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        78 (70, 84)",
"       </td>",
"       <td>",
"        69 (63, 74)",
"       </td>",
"       <td>",
"        57 (52, 62)",
"       </td>",
"       <td>",
"        40 (34, 46)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        85 (78, 90)",
"       </td>",
"       <td>",
"        77 (71, 82)",
"       </td>",
"       <td>",
"        65 (60, 70)",
"       </td>",
"       <td>",
"        48 (41, 54)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        90 (83, 94)",
"       </td>",
"       <td>",
"        83 (77, 87)",
"       </td>",
"       <td>",
"        71 (66, 76)",
"       </td>",
"       <td>",
"        54 (46, 60)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1&nbsp;year&nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        35 (28, 41)",
"       </td>",
"       <td>",
"        28 (24, 32)",
"       </td>",
"       <td>",
"        21 (18.24)",
"       </td>",
"       <td>",
"        14 (11, 16)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        57 (48, 65)",
"       </td>",
"       <td>",
"        48 (42, 54)",
"       </td>",
"       <td>",
"        37 (33, 42)",
"       </td>",
"       <td>",
"        25 (21, 29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        69 (59, 76)",
"       </td>",
"       <td>",
"        59 (52, 65)",
"       </td>",
"       <td>",
"        47 (42, 52)",
"       </td>",
"       <td>",
"        33 (27, 38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        77 (67, 83)",
"       </td>",
"       <td>",
"        67 (60, 73)",
"       </td>",
"       <td>",
"        55 (49, 60)",
"       </td>",
"       <td>",
"        39 (32, 45)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        82 (73, 88)",
"       </td>",
"       <td>",
"        74 (66, 79)",
"       </td>",
"       <td>",
"        61 (55, 67)",
"       </td>",
"       <td>",
"        44 (37, 51)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Duplication",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        31 (23, 37)",
"       </td>",
"       <td>",
"        25 (20, 29)",
"       </td>",
"       <td>",
"        18 (15, 22)",
"       </td>",
"       <td>",
"        12 (9, 14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        52 (41, 61)",
"       </td>",
"       <td>",
"        43 (35, 50)",
"       </td>",
"       <td>",
"        33 (27, 39)",
"       </td>",
"       <td>",
"        22 (17, 27)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        63 (51, 72)",
"       </td>",
"       <td>",
"        54 (45, 61)",
"       </td>",
"       <td>",
"        42 (35, 49)",
"       </td>",
"       <td>",
"        29 (22, 34)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        71 (59, 80)",
"       </td>",
"       <td>",
"        62 (52, 69)",
"       </td>",
"       <td>",
"        50 (41, 57)",
"       </td>",
"       <td>",
"        34 (27, 41)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        77 (65, 85)",
"       </td>",
"       <td>",
"        68 (58, 76)",
"       </td>",
"       <td>",
"        56 (47, 63)",
"       </td>",
"       <td>",
"        39 (31, 47)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1&nbsp;year&nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        24 (18, 30)",
"       </td>",
"       <td>",
"        19 (15, 24)",
"       </td>",
"       <td>",
"        14 (11, 17)",
"       </td>",
"       <td>",
"        9 (7, 11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        43 (33, 51)",
"       </td>",
"       <td>",
"        35 (28, 41)",
"       </td>",
"       <td>",
"        26 (21, 31)",
"       </td>",
"       <td>",
"        17 (13, 21)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        53 (41, 62)",
"       </td>",
"       <td>",
"        44 (35, 52)",
"       </td>",
"       <td>",
"        34 (27, 40)",
"       </td>",
"       <td>",
"        23 (17, 28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        61 (49, 71)",
"       </td>",
"       <td>",
"        52 (42, 60)",
"       </td>",
"       <td>",
"        41 (33, 48)",
"       </td>",
"       <td>",
"        27 (21, 33)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        67 (54, 77)",
"       </td>",
"       <td>",
"        58 (47, 66)",
"       </td>",
"       <td>",
"        46 (37, 54)",
"       </td>",
"       <td>",
"        32 (24, 38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         History of urinary tract infection",
"        </strong>",
"       </td>",
"       <td rowspan=\"10\">",
"        Single",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1&nbsp;year&nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        37 (31, 42)",
"       </td>",
"       <td>",
"        30 (26, 33)",
"       </td>",
"       <td>",
"        22 (20, 25)",
"       </td>",
"       <td>",
"        14 (12, 17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        59 (52, 66)",
"       </td>",
"       <td>",
"        50 (46, 54)",
"       </td>",
"       <td>",
"        39 (36, 43)",
"       </td>",
"       <td>",
"        26 (22, 30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        71 (63, 77)",
"       </td>",
"       <td>",
"        61 (57, 66)",
"       </td>",
"       <td>",
"        49 (45, 53)",
"       </td>",
"       <td>",
"        34 (29, 39)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        79 (71, 84)",
"       </td>",
"       <td>",
"        70 (64, 74)",
"       </td>",
"       <td>",
"        57 (53, 61)",
"       </td>",
"       <td>",
"        41 (34, 46)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        84 (77, 89)",
"       </td>",
"       <td>",
"        76 (71, 80)",
"       </td>",
"       <td>",
"        64 (59, 68)",
"       </td>",
"       <td>",
"        46 (39, 52)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        29 (24, 34)",
"       </td>",
"       <td>",
"        23 (21, 26)",
"       </td>",
"       <td>",
"        17 (16, 19)",
"       </td>",
"       <td>",
"        11 (9, 13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        50 (43, 56)",
"       </td>",
"       <td>",
"        41 (37, 45)",
"       </td>",
"       <td>",
"        32 (29, 34)",
"       </td>",
"       <td>",
"        21 (17, 24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        61 (53, 67)",
"       </td>",
"       <td>",
"        52 (47, 56)",
"       </td>",
"       <td>",
"        40 (37, 44)",
"       </td>",
"       <td>",
"        27 (23, 31)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        69 (61, 75)",
"       </td>",
"       <td>",
"        59 (55, 64)",
"       </td>",
"       <td>",
"        48 (44, 51)",
"       </td>",
"       <td>",
"        33 (27, 38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        75 (67, 81)",
"       </td>",
"       <td>",
"        66 (61, 70)",
"       </td>",
"       <td>",
"        54 (49, 57)",
"       </td>",
"       <td>",
"        38 (32, 43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Duplication",
"       </td>",
"       <td rowspan=\"5\">",
"        &lt;1 year",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        26 (20, 31)",
"       </td>",
"       <td>",
"        20 (16, 24)",
"       </td>",
"       <td>",
"        15 (12, 18)",
"       </td>",
"       <td>",
"        10 (7, 12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        44 (35, 52)",
"       </td>",
"       <td>",
"        36 (30, 42)",
"       </td>",
"       <td>",
"        28 (23, 32)",
"       </td>",
"       <td>",
"        18 (14, 22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        55 (44, 64)",
"       </td>",
"       <td>",
"        46 (38, 53)",
"       </td>",
"       <td>",
"        36 (30, 42)",
"       </td>",
"       <td>",
"        24 (18, 29)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        63 (52, 72)",
"       </td>",
"       <td>",
"        54 (45, 61)",
"       </td>",
"       <td>",
"        42 (35, 49)",
"       </td>",
"       <td>",
"        29 (22, 35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        70 (58, 78)",
"       </td>",
"       <td>",
"        60 (51, 67)",
"       </td>",
"       <td>",
"        48 (40, 55)",
"       </td>",
"       <td>",
"        33 (26, 40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        &ge;1 y",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20 (15, 25)",
"       </td>",
"       <td>",
"        16 (13, 19)",
"       </td>",
"       <td>",
"        12 (9, 14)",
"       </td>",
"       <td>",
"        7 (6, 9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        36 (28, 43)",
"       </td>",
"       <td>",
"        29 (24, 34)",
"       </td>",
"       <td>",
"        22 (18, 26)",
"       </td>",
"       <td>",
"        14 (11, 17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        46 (36, 54)",
"       </td>",
"       <td>",
"        38 (31, 44)",
"       </td>",
"       <td>",
"        29 (23, 34)",
"       </td>",
"       <td>",
"        19 (14, 23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        53 (43, 62)",
"       </td>",
"       <td>",
"        44 (37, 51)",
"       </td>",
"       <td>",
"        34 (28, 40)",
"       </td>",
"       <td>",
"        23 (17, 28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        60 (48, 68)",
"       </td>",
"       <td>",
"        50 (42, 57)",
"       </td>",
"       <td>",
"        39 (32, 45)",
"       </td>",
"       <td>",
"        26 (20, 32)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean predicted rates of cumulative annual spontaneous resolution of primary VUR based upon the age of the patient and the VUR grade expressed as percentage of cases.",
"    <div class=\"footnotes\">",
"     VUR: vesicoureteral reflux; %: percent; CI: confidence interval.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Estrada CR Jr, Passerotti CC, Graham DA, et al. Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2462 children. J Urol 2009; 182:1535. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36350=[""].join("\n");
var outline_f35_31_36350=null;
var title_f35_31_36351="Headlamp for ear foreign body removal";
var content_f35_31_36351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Headlamp for ear foreign body removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use of a head lamp permits the use of both hands are to brace and immobilize the head during removal of an external auditory canal foreign body that is near the tympanic membrane. A metal operating ear speculum is also used to direct light and to protect the lining of the ear canal during the procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_31_36351=[""].join("\n");
var outline_f35_31_36351=null;
